<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients - Hill, P - 2017 | Cochrane Library</title> <meta content="Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients - Hill, P - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004759.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients - Hill, P - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004759.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004759.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients" name="citation_title"/> <meta content="Penny Hill" name="citation_author"/> <meta content="Christchurch Public Hospital" name="citation_author_institution"/> <meta content="pennymorgan@doctors.org.uk" name="citation_author_email"/> <meta content="Nicholas B Cross" name="citation_author"/> <meta content="Christchurch Public Hospital" name="citation_author_institution"/> <meta content="A Nicholas R Barnett" name="citation_author"/> <meta content="Guy's and St Thomas' NHS Foundation Trust" name="citation_author_institution"/> <meta content="Suetonia C Palmer" name="citation_author"/> <meta content="University of Otago Christchurch" name="citation_author_institution"/> <meta content="Angela C Webster" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD004759.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/01/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004759.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004759.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004759.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Alemtuzumab; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [*therapeutic use]; Antilymphocyte Serum [adverse effects, *therapeutic use]; Calcineurin Inhibitors [*therapeutic use]; Cytomegalovirus Infections [etiology]; Graft Rejection [mortality, *prevention &amp; control]; Immunosuppression Therapy [*methods]; Immunosuppressive Agents [adverse effects, *therapeutic use]; *Kidney Transplantation [adverse effects, mortality]; Muromonab-CD3 [therapeutic use]; Randomized Controlled Trials as Topic; Receptors, Interleukin-2 [immunology]; Steroids [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004759.pub2&amp;doi=10.1002/14651858.CD004759.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004759\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004759\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004759.pub2",title:"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients",firstPublishedDate:"Jan 11, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004759.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004759.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004759.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004759.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004759.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004759.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004759.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004759.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004759.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004759.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4019 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004759.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-sec-0069"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-sec-0035"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-sec-0063"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/appendices#CD004759-sec-0074"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/table_n/CD004759StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/table_n/CD004759StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#CD004759-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Penny Hill</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#CD004759-cr-0003">Nicholas B Cross</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#CD004759-cr-0004">A Nicholas R Barnett</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#CD004759-cr-0005">Suetonia C Palmer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information#CD004759-cr-0006">Angela C Webster</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information/en#CD004759-sec-0078">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 January 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004759.pub2">https://doi.org/10.1002/14651858.CD004759.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004759-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004759-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004759-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004759-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004759-abs-0001" lang="en"> <section id="CD004759-sec-0001"> <h3 class="title" id="CD004759-sec-0001">Background</h3> <p>Prolonging kidney transplant survival is an important clinical priority. Induction immunosuppression with antibody therapy is recommended at transplantation and non‐depleting interleukin‐2 receptor monoclonal antibodies (IL2Ra) are considered first line. It is suggested that recipients at high risk of rejection should receive lymphocyte‐depleting antibodies but the relative benefits and harms of the available agents are uncertain. </p> </section> <section id="CD004759-sec-0002"> <h3 class="title" id="CD004759-sec-0002">Objectives</h3> <p>We aimed to: evaluate the relative and absolute effects of different antibody preparations (except IL2Ra) when used as induction therapy in kidney transplant recipients; determine how the benefits and adverse events vary for each antibody preparation; determine how the benefits and harms vary for different formulations of antibody preparation; and determine whether the benefits and harms vary in specific subgroups of recipients (e.g. children and sensitised recipients). </p> </section> <section id="CD004759-sec-0003"> <h3 class="title" id="CD004759-sec-0003">Search methods</h3> <p>We searched the Cochrane Kidney and Transplant's Specialised Register to 29 August 2016 through contact with the Information Specialist using search terms relevant to this review. </p> </section> <section id="CD004759-sec-0004"> <h3 class="title" id="CD004759-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing monoclonal or polyclonal antibodies with placebo, no treatment, or other antibody therapy in adults and children who had received a kidney transplant. </p> </section> <section id="CD004759-sec-0005"> <h3 class="title" id="CD004759-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed risk of bias. Dichotomous outcomes are reported as relative risk (RR) and continuous outcomes as mean difference (MD) together with their 95% confidence intervals (CI). </p> </section> <section id="CD004759-sec-0006"> <h3 class="title" id="CD004759-sec-0006">Main results</h3> <p>We included 99 studies (269 records; 8956 participants; 33 with contemporary agents). Methodology was incompletely reported in most studies leading to lower confidence in the treatment estimates. </p> <p>Antithymocyte globulin (ATG) prevented acute graft rejection (17 studies: RR 0.63, 95% CI 0.51 to 0.78). The benefits of ATG on graft rejection were similar when used with (12 studies: RR 0.61, 0.49 to 0.76) or without (5 studies: RR 0.65, 0.43 to 0.98) calcineurin inhibitor (CNI) treatment. ATG (with CNI therapy) had uncertain effects on death (3 to 6 months, 3 studies: RR 0.41, 0.13 to 1.22; 1 to 2 years, 5 studies: RR 0.75, 0.27 to 2.06; 5 years, 2 studies: RR 0.94, 0.11 to 7.81) and graft loss (3 to 6 months, 4 studies: RR 0.60, 0.34 to 1.05; 1 to 2 years, 3 studies: RR 0.65, 0.36 to 1.19). The effect of ATG on death‐censored graft loss was uncertain at 1 to 2 years and 5 years. In non‐CNI studies, ATG had uncertain effects on death but reduced death‐censored graft loss (6 studies: RR 0.55, 0.38 to 0.78). When CNI and older non‐CNI studies were combined, a benefit was seen with ATG at 1 to 2 years for both all‐cause graft loss (7 studies: RR 0.71, 0.53 to 0.95) and death‐censored graft loss (8 studies: RR 0.55, 0.39 to 0.77) but not sustained longer term. ATG increased cytomegalovirus (CMV) infection (6 studies: RR 1.55, 1.24 to 1.95), leucopenia (4 studies: RR 3.86, 2.79 to 5.34) and thrombocytopenia (4 studies: RR 2.41, 1.61 to 3.61) but had uncertain effects on delayed graft function, malignancy, post‐transplant lymphoproliferative disorder (PTLD), and new onset diabetes after transplantation (NODAT). </p> <p>Alemtuzumab was compared to ATG in six studies (446 patients) with early steroid withdrawal (ESW) or steroid minimisation. Alemtuzumab plus steroid minimisation reduced acute rejection compared to ATG at one year (4 studies: RR 0.57, 0.35 to 0.93). In the two studies with ESW only in the alemtuzumab arm, the effect of alemtuzumab on acute rejection at 1 year was uncertain compared to ATG (RR 1.27, 0.50 to 3.19). Alemtuzumab had uncertain effects on death (1 year, 2 studies: RR 0.39, 0.06 to 2.42; 2 to 3 years, 3 studies: RR 0.67, 95% CI 0.15 to 2.95), graft loss (1 year, 2 studies: RR 0.39, 0.13 to 1.30; 2 to 3 years, 3 studies: RR 0.98, 95% CI 0.47 to 2.06), and death‐censored graft loss (1 year, 2 studies: RR 0.38, 0.08 to 1.81; 2 to 3 years, 3 studies: RR 2.45, 95% CI 0.67 to 8.97) compared to ATG. Creatinine clearance was lower with alemtuzumab plus ESW at 6 months (2 studies: MD ‐13.35 mL/min, ‐23.91 to ‐2.80) and 2 years (2 studies: MD ‐12.86 mL/min, ‐23.73 to ‐2.00) compared to ATG plus triple maintenance. Across all 6 studies, the effect of alemtuzumab versus ATG was uncertain on all‐cause infection, CMV infection, BK virus infection, malignancy, and PTLD. The effect of alemtuzumab with steroid minimisation on NODAT was uncertain, compared to ATG with steroid maintenance. </p> <p>Alemtuzumab plus ESW compared with triple maintenance without induction therapy had uncertain effects on death and all‐cause graft loss at 1 year, acute rejection at 6 months and 1 year. CMV infection was increased (2 studies: RR 2.28, 1.18 to 4.40). Treatment effects were uncertain for NODAT, thrombocytopenia, and malignancy or PTLD. </p> <p>Rituximab had uncertain effects on death, graft loss, acute rejection and all other adverse outcomes compared to placebo. </p> </section> <section id="CD004759-sec-0007"> <h3 class="title" id="CD004759-sec-0007">Authors' conclusions</h3> <p>ATG reduces acute rejection but has uncertain effects on death, graft survival, malignancy and NODAT, and increases CMV infection, thrombocytopenia and leucopenia. Given a 45% acute rejection risk without ATG induction, seven patients would need treatment to prevent one having rejection, while incurring an additional patient experiencing CMV disease for every 12 treated. Excluding non‐CNI studies, the risk of rejection was 37% without induction with six patients needing treatment to prevent one having rejection. </p> <p>In the context of steroid minimisation, alemtuzumab prevents acute rejection at 1 year compared to ATG. Eleven patients would require treatment with alemtuzumab to prevent 1 having rejection, assuming a 21% rejection risk with ATG. </p> <p>Triple maintenance without induction therapy compared to alemtuzumab combined with ESW had similar rates of acute rejection but adverse effects including NODAT were poorly documented. Alemtuzumab plus steroid withdrawal would cause one additional patient experiencing CMV disease for every six patients treated compared to no induction and triple maintenance, in the absence of any clinical benefit. Overall, ATG and alemtuzumab decrease acute rejection at a cost of increased CMV disease while patient‐centred outcomes (reduced death or lower toxicity) do not appear to be improved. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004759-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004759-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004759-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004759-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004759-abs-0003">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004759-abs-0002" lang="en"> <h3>Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients</h3> <p><b>What is the issue?</b> </p> <p>A kidney transplant is the best treatment for many people who have severe kidney disease to allow patients to return to work and feel better. Patients who receive a kidney transplant receive drugs to prevent their own body from rejecting the transplant ‐ the aim of treatment is to prolong the function of the kidney transplant while minimising common long‐term side effects of treatment such as cancer, infection, and diabetes. For some patients who have a much higher risk of rejection, additional treatment is given at the time of the operation (which may lower the body's ability to attack the kidney transplant and increase kidney function but can increase the risk of complications such as infection and cancer). </p> <p><b>What did we do?</b> </p> <p>We searched the Cochrane Kidney and Transplant's Specialised Register to 29 August 2016 for randomised controlled trials (RCTs) comparing monoclonal or polyclonal antibodies with placebo, no treatment, or other antibody therapy in adults and children who had received a kidney transplant. </p> <p><b>What did we find?</b> </p> <p>We identified 99 studies (265 records; 8956 participants; 33 with contemporary agents). From the available studies in this area, an antibody against human immune cells (ATG) reduces the chances of a patient having a kidney rejection by one‐third, but it is uncertain whether this prolongs the function of the kidney transplant or survival for the patient. ATG significantly increases viral infections including cytomegalovirus. In addition, the effects of ATG treatment on cancer are not well understood. Alemtuzumab is another treatment which has been compared to ATG in patients who have received less or no steroid therapy as part of their transplant treatment. Treatment with alemtuzumab with lower steroid doses or no steroid treatment at all may lower a patient's risk of kidney rejection within a year after transplantation when compared to ATG but overall the information about treatment benefits and harms of alemtuzumab in many clinical situations are not certain. This means we are not confident about the effects of alemtuzumab on kidney function, patient survival or treatment side‐effects. </p> <p><b>Conclusions</b> </p> <p>Overall the available research on antibody treatment for kidney transplantation is limited when clinicians and patients make joint decisions about antibody therapy at the time of a kidney transplant because of the uncertain long term benefits and hazards of these treatments. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004759-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004759-sec-0069"></div> <h3 class="title" id="CD004759-sec-0070">Implications for practice</h3> <section id="CD004759-sec-0070"> <p>Given a 45% acute rejection risk with no induction (assumed risk from control group in <a href="./references#CD004759-fig-0007" title="">Analysis 1.4</a>), seven patients would need ATG to prevent one from experiencing acute transplant rejection, while one additional patient would experience CMV disease for every 12 patients treated with ATG. Where only studies including CNI maintenance were assessed, the acute rejection rate was 37% with no induction and six patients would need treatment with ATG to prevent one person having acute rejection. In steroid withdrawal studies, 11 patients would require alemtuzumab to prevent one patient experiencing rejection given a 21% rejection risk with ATG. Alemtuzumab treatment combined with steroid withdrawal would cause one additional patient experiencing CMV disease for every six patients treated when compared with no antibody induction and triple maintenance, and without apparent benefits to patient‐centred outcomes. ATG and alemtuzumab decreased acute rejection at a cost of increased CMV while patient‐centred outcomes including survival or side effects do not appear to be improved. </p> <p>In kidney transplant recipients deemed to be at high risk of rejection, the evidence remains unclear as to whether one particular antibody preparation is better than any other at preventing acute rejection. However, this review does suggest that the perceived benefit of induction immunosuppression in reducing acute rejection may not actually lead to any long‐term benefits or improvements in patient‐centred outcomes. </p> </section> <h3 class="title" id="CD004759-sec-0071">Implications for research</h3> <section id="CD004759-sec-0071"> <p>Longer term follow‐up is always a problem when assessing study data. Although some of the studies in this review have reported fairly long‐term data, the numbers are generally too small to draw conclusions. Longer term follow‐up is needed to really establish whether the benefit of reduced acute rejection with ATG has a significant impact on graft survival or indeed patient survival. In the absence of this information, is it possible to say that decreasing acute rejection is truly a benefit? Reducing the risk of acute rejection becomes less important to an individual patient if this fails to improve long‐term graft or patient survival, especially if the treatment causes potential severe side effects and other harms. We need to find better ways of monitoring long‐term harmful outcomes such as malignancy in any future studies. This may require an ongoing observational cohort study of patients once the initial RCT phase of a study is completed. Another response to this issue is follow up within established registries combined with core patient outcome sets. </p> <p>If ESW or steroid minimisation is planned in an individual patient, the data in this review would support use of alemtuzumab over ATG due to a reduction in acute rejection. Further studies with long‐term follow‐up or ongoing follow‐up of existing studies are needed to show if there is sustained benefit to steroid reduction therapy and indeed if the benefits outweigh risks of increased chronic rejection and potential increased long‐term graft loss. </p> <p>When assessing outcomes in transplantation it is difficult to separate the contribution of induction immunosuppression versus maintenance immunosuppression. The appropriate question for future studies may relate to maintenance rather than induction immunosuppression. Increasing knowledge in the field of transplant immunology has led to continual reassessment of the Banff diagnostic criteria and a much greater understanding of antibody‐mediated rejection over recent years. Future studies comparing different immunosuppression regimens need to assess for not only differences in all cause rejection but also differences in the different subgroups of rejection. Ideally study designs should also include some measure of adherence to maintenance immunosuppression as this is particularly relevant for antibody‐mediated rejection in the presence of de novo donor‐specific antibodies. Adherence can be difficult to measure and is generally poorly reported or not measured at all in studies. However, this may be the area that really needs to be studied if we want to increase long term patient and graft survival in kidney transplantation. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004759-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004759-sec-0008"></div> <div class="table" id="CD004759-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ATG compared with placebo or no induction for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: kidney transplant recipients</b> </p> <p><b>Settings:</b> </p> <p><b>Intervention: ATG</b> </p> <p><b>Comparison: placebo/no treatment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo/no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ATG</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (including CNI)</b> </p> <p>Follow‐up: median 24 months (IQR 12‐24)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.75</b> </p> <p>(0.27 to 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>632 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> <br/> (8 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause graft loss (including CNI)</b> </p> <p>Follow‐up: median 1 year (IQR 12‐24)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.36 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>549 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> <br/> (39 to 129) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Delayed graft function</b> </p> <p>Follow‐up: N/A (immediate)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b> (0.78 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1304 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> <br/> (221 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute rejection (including CNI)</b> </p> <p>Follow‐up: median 1 year (IQR 6‐24)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.61</b> </p> <p>(0.49 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1491 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> <br/> (179 to 277) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection: CMV infection</b> </p> <p>Follow‐up: median 1 year (IQR 4.5‐13.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.55</b> </p> <p>(1.24 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1072 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> <br/> (218 to 343) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Malignancy</b> </p> <p>Follow‐up: median 18 months (IQR 12‐60)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b> </p> <p>(0.30 to 2.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>891 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> <br/> (5 to 44) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval: RR<b>:</b> Risk Ratio; <b>IQR:</b> interquartile range. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> At risk of selection bias as more than 50% of studies rated as allocation concealment and/or random sequence generation unclear or high risk of causing bias. </p> <p><sup>2</sup> Confidence interval includes range of plausible values below clinical significance or including harm. </p> <p><sup>3</sup>Based on few events across all studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004759-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Alemtuzumab plus ESW or steroid minimisation versus ATG for induction therapy for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: kidney transplant recipients</b> </p> <p><b>Settings:</b> </p> <p><b>Intervention: alemtuzumab plus ESW or steroid minimisation</b> </p> <p><b>Comparison: ATG</b> ± <b>ESW or steroid minimisation</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ATG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Alemtuzumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (ESW both arms)</b> </p> <p>Follow‐up: median 1 year (IQR 12‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.27</b> (0.07 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> <br/> (7 to 108) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause graft loss (ESW both arms)</b> </p> <p>Follow‐up: median 18 months (IQR 12‐30)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.34 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (50 to 160) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute rejection (ESW both arms)</b> </p> <p>Follow‐up: median 18 months (IQR 12‐30)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.57</b> </p> <p>(0.35 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> <br/> (73 to 193) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Biopsy‐proven CAN (ESW with alemtuzumab only)</b> </p> <p>Follow‐up: median 30 months (IQR 24‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.45</b> </p> <p>(1.02 to 5.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>284 per 1000</b> <br/> (118 to 689) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CMV infection (all studies)</b> </p> <p>Follow‐up: median 30 months</p> <p>(IQR 24‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.08</b> </p> <p>(0.46 to 2.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> <br/> (37 to 205) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>NODAT (ESW alemtuzumab only)</b> </p> <p>Follow‐up: median 30 months (IQR 24‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> </p> <p>(0.12 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> <br/> (28 to 332) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Malignancy (all studies)</b> </p> <p>Follow‐up: median 36 months (IQR 12‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.93</b> </p> <p>(0.59 to 41.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All reported events from single study (other 2 studies reported 0 events)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> <br/> (6 to 452) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval: RR<b>:</b> Risk Ratio; <b>IQR:</b> interquartile range. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> At risk of selection bias as more than 50% of studies rated as allocation concealment and/or random sequence generation unclear or high risk of causing bias. </p> <p><sup>2</sup> Confidence interval includes range of plausible values below clinical significance or including harm. </p> <p><sup>3</sup>Based on few events across all studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004759-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004759-sec-0009"></div> <section id="CD004759-sec-0010"> <h3 class="title" id="CD004759-sec-0010">Description of the condition</h3> <p>Kidney transplantation is the treatment of choice for many patients with end‐stage kidney disease (ESKD) but demand exceeds supply from organ donors. Increasing this supply and prolonging kidney transplant survival are therefore important for patients and health systems (<a href="./references#CD004759-bbs2-0129" title="TonelliM , WiebeN , KnollG , BelloA , BrowneS , JadhavD , et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. American Journal of Transplantation2011;11(10):2093‐109. [MEDLINE: 21883901] ">Tonelli 2011</a>). </p> </section> <section id="CD004759-sec-0011"> <h3 class="title" id="CD004759-sec-0011">Description of the intervention</h3> <p>Immunosuppressive therapy consists of initial induction and maintenance regimens to prevent rejection. Induction may be defined as treatment with a biologic agent either before, at the time of, or immediately after transplantation to deplete or modulate T cell responses at the time of antigen presentation. Maintenance immunosuppression protocols usually involve three drugs acting on different parts of the T‐cell activation or proliferation cascade: calcineurin inhibitors (CNI) (e.g. cyclosporin (CSA), tacrolimus), antiproliferative agents (e.g. azathioprine, mycophenolate mofetil) and corticosteroids (e.g. prednisolone) (<a href="./references#CD004759-bbs2-0116" title="DentonMD , MageeCC , SayeghMH . Immunosuppressive strategies in transplantation. Lancet1999;353(9158):1083‐91. [MEDLINE: 10199367] ">Denton 1999</a>; <a href="./references#CD004759-bbs2-0120" title="HongJC , KahanBD . Sirolimus‐induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation2000;69(10):2085‐90. [MEDLINE: 10852601] ">Hong 2000</a>). </p> <p>Induction immunosuppression with antibody therapy is now recommended at the time of transplantation for all patients (<a href="./references#CD004759-bbs2-0121" title="Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation2009;9 Suppl 3:S1‐155. [MEDLINE: 19845597] ">KDIGO 2009</a>). Antibody therapies are monoclonal or polyclonal, and depleting or non‐depleting of lymphocytes. Non‐depleting interleukin‐2 receptor monoclonal antibodies (IL2Ra) are considered first line but it is suggested that recipients at high risk of rejection (e.g. children, subsequent transplants, certain racial groups such as African‐Americans, and other sensitised patients) should receive lymphocyte‐depleting antibodies. Depleting antibodies are also used for those at risk of delayed graft function to delay the introduction of full dose CNI, which can prolong the duration of acute tubular necrosis (<a href="./references#CD004759-bbs2-0116" title="DentonMD , MageeCC , SayeghMH . Immunosuppressive strategies in transplantation. Lancet1999;353(9158):1083‐91. [MEDLINE: 10199367] ">Denton 1999</a>). Depleting antibodies include polyclonal antibodies against the human lymphocyte (antilymphocyte globulin (ALG); antithymocyte globulin (ATG)). </p> </section> <section id="CD004759-sec-0012"> <h3 class="title" id="CD004759-sec-0012">How the intervention might work</h3> <p>Depleting antibodies bind to target immune effector cells leading to complement mediated destruction. Non‐depleting antibodies bind to targets on effector cells preventing their interaction with other cells rendering them ineffective, but do not lead to cell destruction. </p> <p>Most antibodies used in transplantation have been directed at T cells. Significant reduction in circulating T‐effector cells is rapidly observed, leading to impaired cell mediated immunity (the desired effect to prevent kidney transplant rejection). A number of different preparations of ATG have been produced over the last few decades. These can be broadly divided into horse ATG (hATG), derived from horse serum after immunisation of horses with human thymocytes, and rabbit ATG (rATG), derived from rabbit serum. There are currently two or three standardised preparations available globally. Historical ATG preparations used in early studies were less standardised compared to the preparations currently available. Even though both hATG and rATG contain antibodies to a wide variety of T‐cell antigens and MHC antigens, it is likely that the effects are not equal given that the two types are prepared differently. One study assessing both efficacy and safety clearly showed differences between these two preparations (<a href="./references#CD004759-bbs2-0012" title="BrennanDC , FlavinK , BurgessS , DolanS , KanoJM , MahonM , et al. A randomized, double‐blinded comparison of thymoglobulin vs ATGAM for induction in adult renal transplant recipients [abstract no: 710]. Transplantation1998;65(12):S180. [CENTRAL: CN‐00602088] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. A randomized, double‐blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. [erratum appears in Transplantation 1999 May 27;67(10):1386.]. Transplantation1999;67(7):1011‐8. [MEDLINE: 10221486] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. Leukocyte response to thymoglobulin or ATGAM for induction immunosuppression in a randomized, double‐blind clinical trial in renal transplant recipients. Transplantation Proceedings1999;31(3B Suppl):16S‐8S. [MEDLINE: 10330962] HardingerKL , RheeS , BuchananP , KochM , MillerB , EnkvetchakulD , et al. A prospective, randomized, double‐blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy: 10‐year results. Transplantation2008;86(7):947‐52. [MEDLINE: 18852661] HardingerKL , SchnitzlerMA , MillerB , LowellJ , ShenoyS , BrennanDC . Long‐term comparison of thymoglobulin versus ATGAM for induction in adult renal transplantation: evidence of improved allograft survival at 5 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):556. [CENTRAL: CN‐00445642] HardingerKL , SchnitzlerMA , MillerB , LowellJA , ShenoyS , KochMJ , et al. Five‐year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation2004;78(1):136‐41. [MEDLINE: 15257052] ">Brennan 1999</a>). </p> <p>Monomurab‐CD3 is a murine monoclonal antibody against the CD3 receptor on activated T cells (Orthoclone OKT3) which became available in the late 1980s. OKT3 removes the functional T‐cell population from circulation, producing immunosuppression useful for both induction therapy and the management of acute rejection. However, this profound immunosuppression is associated with immediate toxicity (cytokine release syndrome) and higher rates of infection and malignancy than standard triple therapy (<a href="./references#CD004759-bbs2-0128" title="SoulillouJP , GiralM . Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation2001;72(12 Suppl):S89‐93. [MEDLINE: 11833147] ">Soulillou 2001</a>). Use of these preparations may also be limited by the development of neutralising antibodies to their xenogeneic components (<a href="./references#CD004759-bbs2-0122" title="KreisH . Antilymphocyte globulins in kidney transplantation. Kidney International ‐ Supplement1992;38:188‐92. [MEDLINE: 1405373] ">Kreis 1992</a>). Use of OKT3 for both induction and treatment of acute rejection has declined in many countries over recent years due to the side effect profile. Janssen‐Cilag discontinued the manufacture of OKT3 in 2010 due to a combination of declining sales and evidence from a Cochrane review on treatment of acute rejection confirming that OKT3 was associated with increased side effects compared to newer biologic agents (<a href="./references#CD004759-bbs2-0132" title="WebsterA , PankhurstT , RinaldiF , ChapmanJR , CraigJC . Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD004756.pub3] ">Webster 2006</a>). </p> <p>More recently, the IL2Ra basiliximab and daclizumab have been used in the induction phase. IL2Ra are IgG monoclonal antibodies to the interleukin‐2 receptor found only on activated T cells. IL2Ra are more specific immunosuppressants, with no immediate toxicity, and are increasingly used as induction agents, but not for treating acute rejection (<a href="./references#CD004759-bbs2-0115" title="CibrikDM , KaplanB , Meier‐KriescheHU . Role of anti‐interleukin‐2 receptor antibodies in kidney transplantation. Biodrugs2001;15(10):655‐66. [MEDLINE: 11604047] ">Cibrik 2001</a>). These agents are investigated in a separate Cochrane review (<a href="./references#CD004759-bbs2-0133" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a>) and so will not be considered here. </p> <p>Other antibodies have also been introduced for kidney transplantation induction such as alemtuzumab. This humanised CD‐52 specific complement fixing monoclonal antibody was first used for induction by <a href="./references#CD004759-bbs2-0114" title="CalneR , MoffattSD , FriendPJ , JamiesonNV , BradleyJA , HaleG , et al. Campath IH allows low‐dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation1999;68(10):613‐6. [MEDLINE: 10589966] ">Calne 1999</a>. Alemtuzumab causes profound depletion of T‐cells from peripheral blood and also less marked depletion of other mononuclear cells. </p> <p>Although the majority of current anti‐rejection therapies are targeted at T‐cell mechanisms, there is increasing evidence that B‐cells may have a role due to their ability to act as antigen presenting cells and T‐cell activators (<a href="./references#CD004759-bbs2-0134" title="ZandMS . Therapeutic antibody agents for B‐cell immunomodulation in renal transplantation. Transplantation2007;84(11 S Suppl):S11‐9. [EMBASE: 350294707] ">Zand 2007</a>). For this reason the B‐cell depleting anti‐CD20 antibody, rituximab is also being used in kidney transplantation. Initially this was used in studies for ABO‐incompatible kidney transplants at induction (<a href="./references#CD004759-bbs2-0130" title="TydenG , KumlienG , FehrmanI . Successful ABO‐incompatible kidney transplantations without splenectomy using antigen specific immunoadsorption and rituximab. Transplantation2003;76(4):730‐1. [MEDLINE: 12973118] ">Tyden 2003</a>) but is now being considered for selected patients in some centres.  </p> </section> <section id="CD004759-sec-0013"> <h3 class="title" id="CD004759-sec-0013">Why it is important to do this review</h3> <p>Favoured antibody preparations and rates of use differ from country to country and among transplant units. In 2007 in the USA, 78% of recipients received an antibody preparation as part of induction immunosuppression. Forty five per cent of kidney recipients received ATG, 1% OKT3, 27% IL2Ra and 10% received alemtuzumab (<a href="./references#CD004759-bbs2-0131" title="United Network for Organ Sharing. OPTN data [direct communication]. www.unos.org (accessed 4 November 2016). ">UNOS 2011</a>). In Australia, 93% of patients received an IL2Ra in 2008 and 5% to 10% received an additional or alternative antibody preparation (<a href="./references#CD004759-bbs2-0113" title="ANZDATA . [direct communication]. Australian and New Zealand Dialysis and Transplant Registry2009. ">ANZDATA 2009</a>). There has clearly been an increase in use of antibody induction therapy over the last decade (<a href="./references#CD004759-bbs2-0113" title="ANZDATA . [direct communication]. Australian and New Zealand Dialysis and Transplant Registry2009. ">ANZDATA 2009</a>; <a href="./references#CD004759-bbs2-0131" title="United Network for Organ Sharing. OPTN data [direct communication]. www.unos.org (accessed 4 November 2016). ">UNOS 2011</a>) but there is still a large amount of variability in the type of antibody preparation used. This reflects local policies to some extent but there is also uncertainty, in particular in patients at high risk of rejection, as to whether one agent is superior to another. In patients at higher risk of rejection, increased risk of side effects may be acceptable if a treatment is more effective at reducing the risk of acute rejection, leading to improved rates of allograft and patient survival.  </p> <p>The aim of this systematic review is to summarise the relative short and long‐term beneficial and adverse effects of different antibody preparations (except IL2Ra) used as induction in kidney transplant recipients. A previous Cochrane review looks at the use of antibodies for treatment of acute rejection episodes (<a href="./references#CD004759-bbs2-0132" title="WebsterA , PankhurstT , RinaldiF , ChapmanJR , CraigJC . Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD004756.pub3] ">Webster 2006</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004759-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004759-sec-0014"></div> <p> <ul id="CD004759-list-0001"> <li> <p>To evaluate the relative and absolute effects of different antibody preparations (except IL2Ra) when used as induction therapy in kidney transplant recipients. </p> </li> <li> <p>To determine how the benefits and adverse events vary for each antibody preparation.</p> </li> <li> <p>To determine how the benefits and harms vary for different formulations of antibody preparation. </p> </li> <li> <p>To determine whether the benefits and harms vary in specific subgroups of recipients (e.g. children and sensitised recipients). </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004759-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004759-sec-0015"></div> <section id="CD004759-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004759-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) and quasi‐RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at different antibody preparations (except IL2Ra) used as induction in kidney transplant recipients. </p> </section> <section id="CD004759-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adults and children who are kidney transplant recipients.</p> <p>Recipients of multi‐organ transplants were excluded from this review.</p> </section> <section id="CD004759-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies using antibody preparations given in combination with any other immunosuppressive agents for induction therapy. </p> <p>Exclusions were IL2Ra, as they are the subject of a separate Cochrane Review (<a href="./references#CD004759-bbs2-0133" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a>). The authors also note that the manufacture of OKT3 was discontinued in January 2010 but have decided to include this agent in the interventions for historical purposes. </p> <p>We examined the following comparisons.</p> <p> <ul id="CD004759-list-0002"> <li> <p>ATG versus placebo/no treatment</p> </li> <li> <p>ATG versus ALG</p> </li> <li> <p>ATG versus a different ATG (e.g. rabbit versus horse)</p> </li> <li> <p>ATG versus monomurab‐CD3</p> </li> <li> <p>ALG versus placebo/no treatment</p> </li> <li> <p>ALG versus monomurab‐CD3</p> </li> <li> <p>Monomurab‐CD3 versus placebo/no treatment</p> </li> <li> <p>Alemtuzumab/anti‐CD52 versus placebo/no treatment</p> </li> <li> <p>Alemtuzumab/anti‐CD52 versus other poly‐ or monoclonal antibody</p> </li> <li> <p>Rituximab/anti‐CD20 versus placebo/no treatment</p> </li> <li> <p>Rituximab/anti‐CD20 versus other poly‐ or monoclonal antibody</p> </li> <li> <p>Other poly‐ or monoclonal antibody versus placebo/no treatment</p> </li> <li> <p>Other poly‐ or monoclonal antibody versus other poly‐ or monoclonal antibody</p> </li> <li> <p>Antibody versus non‐antibody intervention</p> </li> </ul> </p> <p>The 'class effect' of anti‐lymphocyte preparations was initially assumed but differences in formulation were also examined (e.g. rabbit versus horse‐based ATG formulations). All dosage regimens were included and low versus high dose regimens were examined. </p> </section> <section id="CD004759-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Where possible, outcome events were assessed at one, three and six months, and at one, two, three and five years post‐transplantation. </p> <section id="CD004759-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD004759-list-0003"> <li> <p>Death (all cause)</p> </li> <li> <p>Graft loss (defined as dependence on dialysis, graft loss censored for death with a functioning allograft) </p> </li> <li> <p>Graft loss including death with a functioning graft</p> </li> <li> <p>Incidence of acute rejection of kidney (analysed as combined outcome for clinical suspicion, biopsy‐proven and steroid resistant). </p> </li> </ul> </p> </section> <section id="CD004759-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD004759-list-0004"> <li> <p>Kidney allograft function: glomerular filtration rate (GFR), serum creatinine (SCr), creatinine clearance (CrCl), or as defined by authors </p> </li> <li> <p>Incidence of delayed graft function</p> </li> <li> <p>Incidence of bacterial, fungal and viral infectious complications specifically including cytomegalovirus (CMV) (both asymptomatic CMV viraemia and true cases of CMV infection with tissue invasion were analysed as reported by the individual studies) and Polyoma BK virus </p> </li> <li> <p>Incidence of new‐onset diabetes after transplantation (NODAT)</p> </li> <li> <p>Incidence of any malignancy</p> </li> <li> <p>Incidence of post‐transplant lymphoproliferative disorders (PTLD) and lymphoma</p> </li> <li> <p>Incidence of treatment‐related adverse reactions (gastrointestinal, neurological, haematological, biochemical) and recognised syndromes (e.g. serum sickness, cytokine release syndrome). </p> </li> </ul> </p> </section> </section> </section> <section id="CD004759-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004759-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the <a href="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register" target="_blank">Cochrane Kidney and Transplant Specialised Register</a> up to 29 August 2016 through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from the following sources </p> <p> <ol id="CD004759-list-0005"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials CENTRAL</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of kidney‐related journals &amp; the proceedings of major kidney conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected kidney‐journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal &amp; ClinicalTrials.gov</p> </li> </ol> </p> <p>Studies contained in the Specialised register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane kidney and Transplant. Details of these strategies as well as a list of handsearched journals, conference proceedings and current awareness alerts are available in the 'Specialised Register' section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Kidney and Transplant</a>. </p> <p>See <a href="./appendices#CD004759-sec-0075">Appendix 1</a> for search terms used in strategies for this review. </p> </section> </section> <section id="CD004759-sec-0025"> <h3 class="title" id="CD004759-sec-0025">Data collection and analysis</h3> <section id="CD004759-sec-0026"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that might have been relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. However, studies and reviews that might include relevant data or information on studies were retained initially. Two authors independently assessed retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfy the inclusion criteria. </p> </section> <section id="CD004759-sec-0027"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms. Studies reported in non‐English language journals were translated before assessment. Where more than one publication of one study existed, records were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. Any discrepancy between published versions was to be highlighted. Where duplicate publication was suspected authors were contacted for clarification and if duplication was confirmed the initial full publication together with any subsequent publication which adds additional information (e.g. longer term follow‐up data) was included in the review. </p> </section> <section id="CD004759-sec-0028"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD004759-bbs2-0119" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated February 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD004759-sec-0076">Appendix 2</a>). </p> <p> <ul id="CD004759-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study?</p> <ul id="CD004759-list-0007"> <li> <p>Participants and personnel (performance bias)</p> </li> <li> <p>Outcome assessors(detection bias)</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> </section> <section id="CD004759-sec-0029"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes (e.g. rejection) results were expressed as risk ratios (RR) with 95% confidence intervals (95% CI). </p> <p>Where continuous scales of measurement were used to assess the effects of treatment (e.g. CrCl), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales were used. For count data (such as total number of infections/person‐year of follow‐up) the rate ratio was used. Where time‐to‐event data could not be dichotomised, survival analysis methods were used and the results expressed as hazard ratio (HR). </p> <p>Where outcomes were not amenable to meta‐analysis, i.e. if reported idiosyncratically (e.g. drug‐related specific adverse reactions), they were tabulated and assessed with descriptive techniques, and the risk difference (RD) with 95% CI was calculated. Quality of life and economic data was analysed using descriptive techniques. </p> </section> <section id="CD004759-sec-0030"> <h4 class="title">Assessment of heterogeneity</h4> <p>Clinical and methodological heterogeneity was analysed using a Cochran Q test (Chi² with N‐1 degrees of freedom and a P value of 0.05 used for statistical significance) and with the I² test (<a href="./references#CD004759-bbs2-0118" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD004759-sec-0031"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots were used to assess for the potential existence of small study bias (<a href="./references#CD004759-bbs2-0119" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated February 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD004759-sec-0032"> <h4 class="title">Data synthesis</h4> <p>Data was pooled using the random effects model (<a href="./references#CD004759-bbs2-0119" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated February 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD004759-sec-0033"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analysis was used to explore possible clinical sources of heterogeneity.</p> <p> <ul id="CD004759-list-0008"> <li> <p>Baseline maintenance immunosuppression</p> </li> <li> <p>Antibody formulation (e.g. rabbit versus horse ATG)</p> </li> <li> <p>Duration and dose of antibody treatment.</p> </li> </ul> </p> <section id="CD004759-sec-0034"> <h5 class="title">'Summary of findings' tables</h5> <p>We have presented the main results of the review in 'Summary of findings' tables. These tables present key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of the available data for the main outcomes (<a href="./references#CD004759-bbs2-0125" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011a</a>). The 'Summary of findings' tables also include an overall grading of the evidence related to each of the main outcomes using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach (<a href="./references#CD004759-bbs2-0117" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336(7650):924‐6. [MEDLINE: 18436948] ">GRADE 2008</a>). The GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within‐trial risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias (<a href="./references#CD004759-bbs2-0126" title="SchünemannHJ , OxmanAD , HigginsJP , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011b</a>). We presented the following outcomes in the 'Summary of findings' tables. </p> <p> <ul id="CD004759-list-0009"> <li> <p>Death</p> </li> <li> <p>Graft loss</p> </li> <li> <p>Delayed graft function</p> </li> <li> <p>Acute rejection</p> </li> <li> <p>CMV infection</p> </li> <li> <p>Malignancy</p> </li> <li> <p>NODAT</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004759-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004759-sec-0035"></div> <section id="CD004759-sec-0036"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD004759-sec-0080" title="">Characteristics of included studies</a>; <a href="./references#CD004759-sec-0081" title="">Characteristics of excluded studies</a>; <a href="./references#CD004759-sec-0082" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD004759-sec-0083" title="">Characteristics of ongoing studies</a>. </p> <section id="CD004759-sec-0037"> <h4 class="title">Results of the search</h4> <p>After searching the Specialised Register we identified 452 records. After duplicates were removed and titles and abstracts screened we retrieved 285 full‐text articles for further assessment. Of these, 99 studies (268 records) were included and five studies (8 records) were excluded. Three ongoing studies (<a href="./references#CD004759-bbs2-0110" title="HoitsmaAJ . A prospective, randomized, open, multicenter study to evaluate the efficacy and tolerability of induction therapy with a single high‐dose anti‐t‐lymphocyte globulin (ATG) in renal transplant patients with a kidney from a non‐heart‐beating donor and tacrolimus, mycophenolate mofetil, and steroids as basic immunosuppression. www.clinicaltrials.gov/ct2/show/NCT00733733 (accessed 22 August 2016). ">NCT00733733</a>; <a href="./references#CD004759-bbs2-0111" title="FlechnerS . A two part, phase 1/2, safety, PK and PD study of TOL101, an anti‐TCR monoclonal antibody for prophylaxis of acute organ rejection in patients receiving renal transplantation. www.clinicaltrials.gov/ct2/show/NCT01154387 (accessed 22 August 2016). ">NCT01154387</a>; <a href="./references#CD004759-bbs2-0112" title="MamodeM . A randomized trial of rituximab in induction therapy for living donor renal transplantation. www.clinicaltrials.gov/ct2/show/NCT01095172 (accessed 22 August 2016). ">ReMIND Study 2013</a>) were identified, and five studies (<a href="./references#CD004759-bbs2-0105" title="NCT00089947 . Randomized, prospective, phase 2 study comparing thymoglobulin in a rapid discontinuation of corticosteroids protocol with standard corticosteroid therapy in living donor renal transplantation using mycophenolate mofetil and tacrolimus maintenance therapy. clinicaltrials.gov/ct2/show/NCT00089947 (accessed 22 August 2016). ">NCT00089947</a>; <a href="./references#CD004759-bbs2-0106" title="SteigerJ . An open, multicenter, randomised, parallel group pilot study to investigate two different polyclonal rabbit immunoglobulin preparations for safety and efficacy: a comparison of ATG‐fresenius to thymoglobulin in prophylaxis for immunological high risk patients following renal transplantation. www.clinicaltrials gov/ct2/show/NCT00861536 (accessed 22 August 2016). ">NCT00861536</a>; <a href="./references#CD004759-bbs2-0107" title="BurkeGW . Head‐to‐head comparison of thymoglobulin vs. campath‐1h vs. our standard center treatment protocol in living donor renal transplantation ‐ a study to evaluate the avoidance of long‐term nephrotoxic calcineurin inhibitor therapy. www.clinicaltrials.gov/ct2/show/NCT01046955 (accessed 3 November 2016). ">NCT01046955</a>; <a href="./references#CD004759-bbs2-0108" title="TedescoH . Efficacy and safety of induction strategies combined with low tacrolimus exposure in kidney transplant recipients receiving everolimus or sodium mycophenolate. www.clinicaltrials.gov/ct2/show/NCT01354301 (accessed 3 November 2016). ">NCT01354301</a>; <a href="./references#CD004759-bbs2-0109" title="StevensRB , WrenshallLE , MilesCD , FarneyAC , JieT , SandozJP , et al. A double‐blind, double‐dummy, flexible‐design randomized multicenter trial: early safety of single‐ versus divided‐dose rabbit anti‐thymocyte globulin induction in renal transplantation. American Journal of Transplantation2016;16(6):1858‐67. [MEDLINE: 26696251] ">Stevens 2016</a>) were identified prior to publication. These eight studies and will be assessed in a future update of this review (<a href="#CD004759-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD004759-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of included and excluded studies." data-id="CD004759-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of included and excluded studies.</p> </div> </div> </div> </section> <section id="CD004759-sec-0038"> <h4 class="title">Included studies</h4> <p>Of the 99 included studies, 92 had data that could be used for meta‐analysis and these combined studies represented a total of 8802 randomised participants. ATG was used in 41 studies, alemtuzumab in 11, OKT3 in 27, ALG in 26, rituximab in 3 and other antibodies in 5 studies. </p> <p>There were 19 comparisons of an antibody versus placebo or antibody versus other antibody that were studied in a single study only. These are briefly discussed in the text below but have not been meta‐analysed. </p> <section id="CD004759-sec-0039"> <h5 class="title">Interventions</h5> <p><b>Number of studies (participants) in included studies by comparison</b> </p> <p> <div class="table" id="CD004759-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> ATG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> ALG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Alemtuzumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> OKT3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Other<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ATG</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (513)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (446)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (571)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (141)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (2044)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ALG</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (254)<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (644)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (1809)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Alemtuzumab</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (296)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rituximab</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (447)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OKT3</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (55)<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (1184)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other<sup>a</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (20)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (328)</p> </td> </tr> </tbody> </table> </div> </p> <p><sup>a</sup> Includes the following; anti CD2 rat monoclonal antibody, anti CD7 monoclonal antibody, anti‐LFA‐1 monoclonal antibody, anti‐ICAM‐1 monoclonal antibody, rituximab combined with ATG, bortezomib combined with ATG, both rituximab and bortezomib combined with ATG. </p> <p><sup>b</sup> Indicates studies comparing different doses or formulations of same agent. </p> <p><b>ATG versus placebo/no treatment</b> </p> <p>Twelve studies (1491 participants) compared ATG with placebo or no treatment in a CNI‐based regimen (<a href="./references#CD004759-bbs2-0006" title="BanhegyiC , RockenschaubS , MuhlbacherF , KovarikJ , BalckeP , GotzingerP , et al. Preliminary results of a prospective randomized clinical trial comparing cyclosporine A to antithymocyte globulin immunosuppressive induction therapy in kidney transplantation. Transplantation Proceedings1991;23(4):2207‐8. [MEDLINE: 1871846] ">Banhegyi 1991</a>; <a href="./references#CD004759-bbs2-0017" title="CharpentierB , European Tacrolimus vs Microemulsified Cyclosporin Study Group. A three arm study comparing immediate tacrolimus therapy with ATG induction therapy followed by either tacrolimus or cyclosporine in adult renal transplant recipients. Transplantation Proceedings2002;34(5):1625‐6. [MEDLINE: 12176511] CharpentierB , RostaingL , BerthouxF , LangP , CivatiG , TouraineJL , et al. A three‐arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation2003;75(6):844‐51. [MEDLINE: 12660513] RostaingL , Tacrolimus versus Microemulsified Cyclosporin Study Group. Comparison of ATG induction followed by tacrolimus therapy with ATG induction followed by cyclosporine therapy, and immediate tacrolimus‐based triple therapy [abstract]. Journal of the American Society of Nephrology2001;12(Program &amp; Abstracts):916A. [CENTRAL: CN‐00433645] ">Charpentier 2002</a>; <a href="./references#CD004759-bbs2-0048" title="KasiskeBL , GoerdtPJ , Heim‐DuthoyK , RaoKV , DahlDC , NeyAL , et al. Interim results of a randomized controlled trial comparing antithymocyte globulin (ATG) with cyclosporine (CSA) induction [abstract]. Journal of the American Society of Nephrology1995;6(3):1097. [CENTRAL: CN‐00484599] KasiskeBL , JohnsonHJ , GoerdtPJ , Heim‐DuthoyKL , RaoVK , DahlDC , et al. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients. American Journal of Kidney Diseases1997;30(5):639‐45. [MEDLINE: 9370178] ">Kasiske 1997</a>; <a href="./references#CD004759-bbs2-0049" title="KhosroshahiHT , TubbsRS , ShojaMM , GhafariA , NoshadH , ArdalanMR . Effect of prophylaxis with low‐dose anti‐thymocyte globulin on prevention of acute kidney allograft rejection. Transplantation Proceedings2008;40(1):137‐9. [MEDLINE: 18261569] ">Khosroshahi 2008</a>; <a href="./references#CD004759-bbs2-0059" title="MartinsLS , SarmentoAM , DiasL , HenriquesAC , BornerG , CabritaA . Results of safety and efficacy of two ATG bolus‐therapy regimen vs standard therapy in prophylaxis after renal transplantation in end stage renal disease patients [abstract]. Transplantation2004;78(2 Suppl):266. [CENTRAL: CN‐00509341] ">Martins 2004</a>; <a href="./references#CD004759-bbs2-0063" title="Anonymous . Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three‐month results. Transplantation Proceedings1999;31(1‐2):330‐1. [MEDLINE: 10083131] AntoineC , ThakurS , DaugasE , FraouiR , BoudjeltiaS , JuliaP , et al. Vascular microthrombosis in renal transplant recipients treated with tacrolimus. Transplantation Proceedings1998;30(6):2813‐4. [MEDLINE: 9745577] CharpentierB . An induction versus no‐induction protocol in anticalcineurin‐based immunosuppression using very low‐dose steroids. Transplantation Proceedings2001;33(4 Suppl):3S‐10S. [MEDLINE: 11406262] CharpentierB . Induction versus non‐induction protocols in anti‐calcineurin‐based immunosuppression. Transplantation Proceedings2001;33(7‐8):3334‐6. [MEDLINE: 11750425] MouradG , French and Belgian Tacrolimus Renal Transplantation Study Group. ATG‐Induction vs. non‐induction with tacrolimus‐based immunosuppression in renal transplantation [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome, Italy. 2000. [CENTRAL: CN‐00446848] MouradG , GarrigueV , SquiffletJP , BesseT , BerthouxF , AlamartineE , et al. Induction versus noninduction in renal transplant recipients with tacrolimus‐based immunosuppression. Transplantation2001;72(6):1050‐5. [MEDLINE: 11579299] ">Mourad 1998</a>; <a href="./references#CD004759-bbs2-0075" title="SamselR , ChmuraA , Korczak‐KowalskaG , WlodarczykZ , PliszczynskiJ , AdadynskiL , et al. Long term results of single perioperative high dose of ATG as induction in kidney transplantation [abstract]. American Journal of Transplantation2004;4(Suppl 8):351. [CENTRAL: CN‐00509456] SamselR , ChmuraA , WlodarczykZ , WyzgalJ , CieciuraT , LagiewskaB , et al. Perioperative single high dose ATG‐Fresenius S administration as induction immunosuppressive therapy in cadaveric renal transplantation‐‐preliminary results. Annals of Transplantation1999;4(2):37‐9. [MEDLINE: 10850589] SamselR , PliszczynskiJ , ChmuraA , KorczakG , WlodarczykZ , CieciuraT , et al. Safety and efficacy of high dose ATG bolus administration on rewascularization in kidney graft patients‐‐long term results. Annals of Transplantation2008;13(1):32‐9. [MEDLINE: 18344941] SamselR , RowinskiW , ChmuraA , WlodarczykZ , WyzgalJ , CieciuraT , et al. Perioperative administration of single, high‐dose of ATG‐Fresenius‐S as an induction immunosuppressive therapy in cadaveric renal transplantation: preliminary results. Transplantation Proceedings2001;33(6):2952‐4. [MEDLINE: 11543807] ">Samsel 1999</a>; <a href="./references#CD004759-bbs2-0078" title="SheashaaHA , HamdyAF , BakrMA , AbdelbasetSF , GhoneimMA . Long‐term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation. International Urology &amp; Nephrology2008;40(2):515‐20. [MEDLINE: 17978857] ">Sheashaa 2008</a>; <a href="./references#CD004759-bbs2-0087" title="ThibaudinD , AlamartineE , deFilippisJP , DiabN , LaurentB , BerthouxF . Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrology Dialysis Transplantation1998;13(3):711‐5. [MEDLINE: 9550651] ">Thibaudin 1998</a>; <a href="./references#CD004759-bbs2-0091" title="WoodleES , PeddiVR , TomlanovichS , MulgaonkarS , KuoPC , TRIMS Study Investigators. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with thymoglobulin in living‐donor kidney transplantation. Clinical Transplantation2010;24(1):73‐83. [MEDLINE: 19930408] WoodleES , TRIMS Study Group. A randomized, prospective, multicenter comparative study evaluating a thymoglobulin‐based early corticosteroid cessation regime in renal transplantation [abstract no: 673]. American Journal of Transplantation2006;6(Suppl 2):294. [CENTRAL: CN‐00716028] WoodleES , TRIMS Study Group. A randomized, prospective, multicenter study of thymoglobulin in renal transplantation for induction and minimization of steroids (TRIMS) [abstract no: 1632]. American Journal of Transplantation2005;5(Suppl 11):571. [CENTRAL: CN‐00716027] ">TRIMS Study 2010</a>; <a href="./references#CD004759-bbs2-0095" title="van denHoogenMW , KhoMM , AbrahamsAC , vanZuilenAD , SandersJS , vanDijkM , et al. Effect of a single intraoperative high‐dose ATG‐Fresenius on delayed graft function in donation after cardiac‐death donor renal allograft recipients: a randomized study. Experimental &amp; Clinical Transplantation2013;11(2):134‐41. [MEDLINE: 23431996] ">van den Hoogen 2013</a>; <a href="./references#CD004759-bbs2-0099" title="YussimA , ShapiraZ . Single‐bolus high‐dose ATG for prophylaxis of rejection in renal transplantation‐‐a prospective, randomized study. Transplant International2000;13 Suppl 1:S293‐4. [MEDLINE: 11112016] ">Yussim 2000</a>), and a further five studies (553 participants) in a non‐CNI‐based regimen (<a href="./references#CD004759-bbs2-0023" title="CosimiAB . The clinical value of antilymphocyte antibodies. Transplantation Proceedings1981;13(1 Pt 1):462‐8. [MEDLINE: 7022874] CosimiAB , WortisHH , DelmonicoFL , RussellPS . Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery1976;80(2):155‐63. [MEDLINE: 781887] WechterWJ , BrodieJA , MorrellRM , RafiM , SchultzJR . Antithymocyte globulin (ATGAM) in renal allograft recipients. Multicenter trials using a 14‐dose regimen. Transplantation1979;28(4):294‐302. [MEDLINE: 388762] ">Cosimi 1976</a>; <a href="./references#CD004759-bbs2-0026" title="DiethelmAG , BlackstoneE , WhelchelJD , PassRF , ChambersL , PhillipsSJ , et al. The adjunctive value of equine antithymocyte membrane globulin in a randomized study of patients undergoing cadaveric renal transplantation. Transplantation Proceedings1979;11(1):27‐30. [MEDLINE: 377644] ">Diethelm 1979</a>; <a href="./references#CD004759-bbs2-0050" title="ButtKM , ZielinskiCM , ParsaI , ElbergAJ , WechterW , KountzSL . Trends in immunosuppression for kidney transplantation. Kidney International ‐ Supplement1978;13(Suppl 8):S95‐8. [MEDLINE: 357820] KountzSL , ButtKH , RaoTK , ZielinskiCM , RafiM , SchultzJR . Antithymocyte globulin (ATG) dosage and graft survival in renal transplantation. Transplantation Proceedings1977;9(1):1023‐5. [MEDLINE: 325728] ">Kountz 1977</a>; <a href="./references#CD004759-bbs2-0052" title="KreisH , ChkoffN , ChatenoudL . Prolonged administration of a monoclonal anti‐T3 cell antibody (ORTHOCLONE OKT3) to kidney allograft recipients. Transplantation Proceedings1986;18(4):954‐6. [EMBASE: 1986223864] ">Kreis 1986</a>; <a href="./references#CD004759-bbs2-0098" title="WechterWJ , MorrellRM , BerganJ , RosenbergJC , TurcotteJ , SchultzJR . Extended treatment with antithymocyte globulin (ATGAM) in renal allograft recipients. Transplantation1979;28(5):365‐7. [MEDLINE: 392832] ">Wechter 1979</a>). </p> <p><b>Rabbit ATG versus horse ATG</b> </p> <p>Three studies (155 participants) compared rATG with hATG in a CNI‐based regimen (<a href="./references#CD004759-bbs2-0011" title="BockHA , TsinalisD , NickeleitV , MihatschM , ThielG . Randomized prospective study of polyclonal antilymphocyte globulin induction after renal transplantation: ATGAM vs ATG‐Fresenius [abstract no: A3646]. Journal of the American Society of Nephrology1999;10(Program &amp; Abstracts):720A. [CENTRAL: CN‐00583882] ">Bock 1999</a>; <a href="./references#CD004759-bbs2-0012" title="BrennanDC , FlavinK , BurgessS , DolanS , KanoJM , MahonM , et al. A randomized, double‐blinded comparison of thymoglobulin vs ATGAM for induction in adult renal transplant recipients [abstract no: 710]. Transplantation1998;65(12):S180. [CENTRAL: CN‐00602088] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. A randomized, double‐blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. [erratum appears in Transplantation 1999 May 27;67(10):1386.]. Transplantation1999;67(7):1011‐8. [MEDLINE: 10221486] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. Leukocyte response to thymoglobulin or ATGAM for induction immunosuppression in a randomized, double‐blind clinical trial in renal transplant recipients. Transplantation Proceedings1999;31(3B Suppl):16S‐8S. [MEDLINE: 10330962] HardingerKL , RheeS , BuchananP , KochM , MillerB , EnkvetchakulD , et al. A prospective, randomized, double‐blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy: 10‐year results. Transplantation2008;86(7):947‐52. [MEDLINE: 18852661] HardingerKL , SchnitzlerMA , MillerB , LowellJ , ShenoyS , BrennanDC . Long‐term comparison of thymoglobulin versus ATGAM for induction in adult renal transplantation: evidence of improved allograft survival at 5 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):556. [CENTRAL: CN‐00445642] HardingerKL , SchnitzlerMA , MillerB , LowellJA , ShenoyS , KochMJ , et al. Five‐year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation2004;78(1):136‐41. [MEDLINE: 15257052] ">Brennan 1999</a>; <a href="./references#CD004759-bbs2-0073" title="RostaingL , LavayssiereL , KamarN . Hematologic adverse effects of 2 different polyclonal antilymphocyte preparations in de novo kidney transplant patients. Experimental &amp; Clinical Transplantation2010;8(2):178‐80. [MEDLINE: 20565376] ">Rostaing 2010</a>). </p> <p><b>ATG versus alemtuzumab</b> </p> <p>Six studies (446 participants) compared ATG with alemtuzumab. Four studies had early steroid withdrawal (ESW) or steroid minimisation in both arms in a CNI‐based regimen (<a href="./references#CD004759-bbs2-0029" title="DoaresW , AshcraftE , SinghR , HartL , FarneyA , HartmannE , et al. Prospective, randomized, single‐center trial of alemtuzumab vs rabbit anti‐thymocyte globulin induction in renal and pancreas transplant: infectious complications update [abstract no: 315]. American Journal of Transplantation2009;9(Suppl 2):282‐3. [EMBASE: 70010188] FarneyA , RogersJ , DoaresW , IskandarS , OrlandoG , AdamsP , et al. 7 year results of a prospective randomized study of alemtuzumab vs rabbit anti‐thymocyte globulin induction in kidney and kidney pancreas transplantation [abstract]. Transplantation2014;98(Suppl 1):90. [EMBASE: 71543817] FarneyA , RogersJ , HartL , DoaresW , IskandarS , OrlandoG , et al. Long‐term results of a prospective randomized study of alemtuzumab vs rabbit anti‐thymocyte globulin induction in kidney and kidney pancreas transplantation [abstract no: 101]. American Journal of Transplantation2012;12(Suppl S3):56. [EMBASE: 70746048] FarneyA , SinghR , RogersJ , AshcroftE , HartmannE , HartL , et al. A prospective randomized trial of alemtuzumab versus rabbit anti‐thymocyte globulin induction in kidney and pancreas transplantation: minimum 6 months follow up [abstract no: 796]. Transplantation2008;86(2S):278. [CENTRAL: CN‐00740550] FarneyA , SundbergA , MooreP , HartmannE , RogersJ , DoaresW , et al. A randomized trial of alemtuzumab vs. anti‐thymocyte globulin induction in renal and pancreas transplantation. Clinical Transplantation2008;22(1):41‐9. [MEDLINE: 18217904] FarneyAC , DoaresW , RogersJ , SinghR , HartmannE , HartL , et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation2009;88(6):810‐9. [MEDLINE: 19920781] FarneyAC , SinghR , RogersJ , AshcroftE , HartmannE , HartL , et al. A prospective randomized study of alemtuzumab vs rabbit anti‐thymocyte globulin induction in kidney and pancreas transplantation [abstract no: 532]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653719] HartmannEL , DoaresW , Reeves‐DanielA , RogersJ , SinghR , HartL , et al. Safety and efficacy of lymphocyte‐depleting induction therapy in older transplant recipients: should grandpa receive campath? [abstract no: 1755]. American Journal of Transplantation2009;9(Suppl 2):675. [CENTRAL: CN‐00795687] SinghR , FarneyA , RogersJ , DoaresW , HartmannE , Reeves‐DanielA , et al. A randomized, prospective trial of alemtuzumab versus rabbit anti‐thymocyte globulin induction in kidney‐pancreas transplantation: a single center experience [abstract no: 87]. American Journal of Transplantation2009;9(Suppl 2):216. [CENTRAL: CN‐00790946] StrattaR , AshcraftE , HartmannE , RogersJ , DoaresW , HartL , et al. A prospective randomized comparison of alemtuzumab versus rabbit anti‐thymocyte globulin induction in renal and pancreas transplantation [abstract no: P132]. Transplant International2007;20(Suppl 2):127. [CENTRAL: CN‐00740553] StrattaR , RogersJ , OrlandoG , FarooqU , Al‐ShraidehY , DoaresW , et al. 5 year results of a prospective, randomized single center study of alemtuzumab compared to rabbit anti‐thymocyte globulin induction in simultaneous kidney‐pancreas transplantation [abstract]. Transplantation2014;98(Suppl 1):215. [EMBASE: 71544175] StrattaR , SinghR , FarneyA , RogersJ , DoaresW , HartmanE . A randomized, prospective trial of alemtuzumab versus rabbit anti‐thymocyte globulin induction in kidney‐pancrease transplantation: a single center experience [abstract no: O‐289]. Transplant International2009;22(Suppl 2):76‐7. StrattaRJ , RogersJ , HartL , DoaresW , KaczmorskiS , Reeves‐DanielA , et al. 5 year results of a prospective randomized single center study of alemtuzumab compared to rabbit anti‐thymocyte globulin induction in kidney‐pancreas transplantation [abstract]. Transplantation2013;96(Suppl 6):S86. [EMBASE: 71249227] StrattaRJ , RogersJ , OrlandoG , FarooqU , Al‐ShraidehY , DoaresW , et al. Depleting antibody induction in simultaneous pancreas‐kidney transplantation: a prospective single‐center comparison of alemtuzumab versus rabbit anti‐thymocyte globulin. Expert Opinion on Biological Therapy2014;14(12):1723‐30. [MEDLINE: 25156622] StrattaRJ , RogersJ , OrlandoG , FarooqU , Al‐ShraidehY , FarneyAC . 5‐year results of a prospective, randomized, single‐center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney‐pancreas transplantation. Transplantation Proceedings2014;46(6):1928‐31. [MEDLINE: 25131073] ">Farney 2008</a>; <a href="./references#CD004759-bbs2-0042" title="HanawayM , WoodleES , MulgaonkarS , PeddiR , HarrisonG , VandeputteK , et al. 12 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 135]. American Journal of Transplantation2008;8(Suppl 2):215. HanawayMJ , WoodleES , MulgaonkarS , PeddiVR , KaufmanDB , FirstMR , et al. Alemtuzumab induction in renal transplantation. New England Journal of Medicine2011;364(20):1909‐19. [MEDLINE: 21591943] HolmanJ , HarrisonG , VandeputteK , FirstR , FitzsimmonsW . Immune cell activation comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 553]. Transplantation2008;86(2 Suppl):194. [CENTRAL: CN‐00676047] MulgaonkarS , HanawayM , WoodleES , PeddiR , HarrisonG , VandeputteK , et al. Continuing 24 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 312]. American Journal of Transplantation2009;9(Suppl 2):282. [EMBASE: 70010185] PeddiR , HanawayM , WoodleS , MulgaonkarS , HarrisonG , VandeputteK , et al. Final 36 month results of a randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and rapid steroid withdrawal in renal transplantation [abstract no: 35]. American Journal of Transplantation2010;10(Suppl 4):49. [EMBASE: 70463396] WoodleS , HanawayM , MulgaonkarS , PeddiR , HarrisonG , VandeputteK , et al. 12 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 876]. Transplantation2008;86(2 Suppl):306. [CENTRAL: CN‐00653740] ">Hanaway 2011</a>; <a href="./references#CD004759-bbs2-0056" title="LuTM , YangSL , WuWZ , TanJM . Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Chinese Medical Journal2011;124(5):664‐8. [MEDLINE: 21518554] ">Lu 2011</a>; <a href="./references#CD004759-bbs2-0089" title="ThomasPG , WoodsideKJ , LappinJA , VaidyaS , RajaramanS , GugliuzzaKK . Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk Renal transplantation. Transplantation2007;83(11):1509‐12. [MEDLINE: 17565326] ">Thomas 2007</a>) and two studies had ESW in the alemtuzumab arm only (<a href="./references#CD004759-bbs2-0019" title="BaruquiJA , CiancioG , GaynorJ , GuerraG , SageshimaJ , ChenL , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results [abstract no: P‐37]. American Journal of Transplantation2014;14(Suppl 3):80. [EMBASE: 71388259] CarrenoMR , CiancioG , BurkeGW , RosenA , RicordiC , TzakisA , et al. Cellular phenotypes affected by induction therapy with campath‐1h vs thymoglobulin vs zenapax in kidney allograft recipients [abstract]. American Journal of Transplantation2004;4(Suppl 8):405. [CENTRAL: CN‐00509121] CiancioG , BurkeGW , GaynorJJ , CarrenoMR , CiroccoRE , MathewJM , et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune‐monitoring. Transplantation2005;80(4):457‐65. [MEDLINE: 16123718] CiancioG , BurkeGW , GaynorJJ , MattiazziAD , CarrenoMR , RosenA , et al. Randomized trial of three different induction regimens to prevent acute renal allograft rejection: early results [abstract]. American Journal of Transplantation2004;4(Suppl 8):266. [CENTRAL: CN‐00509135] CiancioG , BurkeGW , GaynorJJ , RothD , KupinW , RosenA , et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐up. Clinical Transplantation2008;22(2):200‐10. [MEDLINE: 18339140] CiancioG , BurkeGW , MattiazziAD , IllanesHG , GaynorJJ , CarrenoM , et al. A randomized trial of three different antibody induction regimens in renal transplantation [abstract no: 1625]. American Journal of Transplantation2005;5(Suppl 11):569. [CENTRAL: CN‐00644195] CiancioG , GaynorJJ , GuerraG , SageshimaJ , ChenL , MattiazziA , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results. Transplantation2014;97(11):1128‐38. [MEDLINE: 24477186] CiancioG , GaynorJJ , SageshimaJ , ChenL , RothD , KupinW . Machine perfusion in kidney transplantation: better outcomes in the presence of longer pump time [abstract no: 1011]. American Journal of Transplantation2010;10(Suppl 4):333. [EMBASE: 70464387] CiancioG , GaynorJJ , SageshimaJ , RothD , KupinW , GuerraG , et al. Machine perfusion following static cold storage preservation in kidney transplantation: donor‐matched pair analysis of the prognostic impact of longer pump time. Transplant International2012;25(1):34‐40. [MEDLINE: 21981661] ">Ciancio 2005</a>; <a href="./references#CD004759-bbs2-0020" title="BaruquiJA , CiancioG , GaynorJ , GuerraG , SageshimaJ , ChenL , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results [abstract no: P‐37]. American Journal of Transplantation2014;14(Suppl 3):80. [EMBASE: 71388259] CiancioG , GaynorJJ , GuerraG , SageshimaJ , ChenL , MattiazziA , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results. Transplantation2014;97(11):1128‐38. [MEDLINE: 24477186] CiancioG , GaynorJJ , RothD , KupinW , HansonL , TuerosL , et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplantation Proceedings2010;42(9):3503‐6. [MEDLINE: 21094804] ">Ciancio 2010</a>) and triple maintenance in the ATG groups. </p> <p><b>Alemtuzumab versus placebo/no treatment</b> </p> <p>Four studies (296 participants) compared alemtuzumab with placebo or no treatment. Three of four studies used ESW with either single or double agent maintenance immunosuppression in the alemtuzumab group (<a href="./references#CD004759-bbs2-0015" title="MunozAS , Cabanayan‐CasasolaCB , DanguilanRA , PaduaFB , OnaET . Campath‐1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3‐year follow‐up. Transplantation Proceedings2008;40(7):2230‐3. [MEDLINE: 18790200] VathsalaA , CAMPASIA Study Group. Safety and efficacy of campath‐1h (mabcampath®) with low dose cyclosprorine monotherapy in patients receiving kidney transplants ‐ 6 month analysis of the pilot randomised controlled [abstract]. Transplantation2004;78(2 Suppl):56. [CENTRAL: CN‐00509538] VathsalaA , Campasia Study Group. One year results of a pilot randomised controlled trial of the effectiveness of alemtuzumab as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract no: T‐PO50029]. Nephrology2005;10(Suppl):A215. [CENTRAL: CN‐00583367] VathsalaA , OnaET , TanS , SureshS , ChanY , LouH , et al. Campasia: a pilot randomised controlled trial of the effectiveness of campath‐1h (mabcampath®) as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract]. American Journal of Transplantation2004;4(Suppl 8):406. [CENTRAL: CN‐00509539] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan CasasolaCB , et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation2005;80(6):765‐74. [MEDLINE: 16210963] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Induction therapy with alemtuzumab together with low dose cyclosporine monotherapy permits steroid‐free immunosuppression, mitigates drug‐related, non‐immune toxicities and improves quality of life [abstract no: TH‐PO550]. Journal of the American Society of Nephrology2006;17(Abstracts):224A. [CENTRAL: CN‐00644285] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Lymphocyte recovery after depletion by alemtuzumab in renal transplant recipients: impact on outcome [abstract no: 1015]. American Journal of Transplantation2005;5(Suppl 11):415. [CENTRAL: CN‐00644284] ">CAMPASIA Study 2005</a>; <a href="./references#CD004759-bbs2-0058" title="MargreiterR , KlempnauerJ , NeuhausP , MuehlbacherF . Alemtuzumab (Campath‐1H) induction followed by tacrolimus monotherapy vs tacrolimus based triple drug immunosuppression in cadaveric renal transplantation ‐ results of a multicenter trial [abstract no: 333]. American Journal of Transplantation2007;7(Suppl 2):234. [CENTRAL: CN‐00644175] MargreiterR , KlempnauerJ , NeuhausP , MuehlbacherF , BoesmuellerC , CalneRY . Alemtuzumab (Campath‐1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. American Journal of Transplantation2008;8(7):1480‐5. [MEDLINE: 18510632] ">Margreiter 2008</a>; <a href="./references#CD004759-bbs2-0077" title="Sharaf EI DinUA , Sharaf EI DinBA , EI DamanhouryHA . Alemtuzumab induction as steroid sparing agent in living kidney transplantation: a randomized prospective controlled trial [abstract no: SA‐PO449]. Journal of the American Society of Nephrology2006;17(Abstracts):670A. [CENTRAL: CN‐00644281] ">Sharaf El Din 2006</a>) versus triple therapy maintenance in the control group, and one study (<a href="./references#CD004759-bbs2-0031" title="FriendPJ , CalneRY , HaleG , WaldmannH , EvansDB , RollesK , et al. Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial. Transplantation Proceedings1987;19(1 Pt 3):1898‐900. [MEDLINE: 3079058] FriendPJ , HaleG , WaldmannH , GoreS , ThiruS , JoyseyV , et al. Campath‐1M‐‐prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation1989;48(2):248‐53. [MEDLINE: 2667209] FriendPJ , WaldmannH , HaleG , TigheH , CalneR . The use of anti‐lymphocyte monoclonal antibodies following organ transplantation [abstract]. Nephrology Dialysis Transplantation1988;3(1):97‐8. [CENTRAL: CN‐00796675] ">Friend 1987</a>) used ESW and single agent CSA maintenance in both groups. </p> <p><b>Rituximab versus placebo</b> </p> <p>Three studies (447 participants) compared rituximab with placebo (<a href="./references#CD004759-bbs2-0081" title="JoostenI , BaasMC , KamburovaEG , van denHoogenMW , KoenenHJ , HilbrandsLB . Anti‐B cell therapy with rituximab as induction therapy in renal transplantation. Transplant Immunology2014;31(4):207‐9. [MEDLINE: 25270152] KamburovaE , KoenenH , van denHoogenM , JoostenI , HilbrandsL . A single dose of rituximab results in a long lasting B‐cell depletion in peripheral blood, without affecting the peripheral T‐cell compartment [abstract no: 186]. American Journal of Transplantation2013;13(Suppl S5):87. [EMBASE: 71056762] KamburovaEG , KoenenHJ , van denHoogenMW , BaasMC , JoostenI , HilbrandsLB . Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. PLoS ONE [Electronic Resource]2014;9(11):e112658. [MEDLINE: 25393622] KamburovaEG , van denHoogenMW , KoenenHJ , BaasMC , HilbrandsLB , JoostenI . Cytokine release after treatment with rituximab in renal transplant recipients. Transplantation2015;99(9):1907‐11. [MEDLINE: 25675201] SmeekensSP , van denHoogenMW , KamburovaEG , van deVeerdonkFL , JoostenI , KoenenHJ , et al. The effects of in vivo B‐cell depleting therapy on ex‐vivo cytokine production. Transplant Immunology2013;28(4):183‐8. [MEDLINE: 23651756] van denHoogenM , KamburovaE , BaasM , SteenbergenE , FlorquinS , KoenenH , et al. Type of rejection and biopsy findings after induction therapy with a single dose of rituximab [abstract]. Transplantation2014;98(Suppl 1):463. [EMBASE: 71545077] van denHoogenM , SteenbergenE , HoitsmaA , HilbrandsL . Placebo‐controlled trial [abstract no: 266.1]. American Journal of Transplantation2013;13(Suppl S5):112‐3. [EMBASE: 71056843] van denHoogenMW , KamburovaEG , BaasMC , SteenbergenEJ , FlorquinS , KoenenH , et al. Rituximab as induction therapy after renal transplantation: a randomized, double‐blind, placebo‐controlled study of efficacy and safety. American Journal of Transplantation2015;15(2):407‐16. [MEDLINE: 25612493] ">Smeekens 2013</a>; <a href="./references#CD004759-bbs2-0092" title="TsaiMK , LeeCY , YangCY , YehCC , HuRH , LeePH . Rituximab induction therapy provided additional immunosuppressive effect and functional benefit to non‐sensitized renal transplant recipients: an interim report [abstract no: 997]. American Journal of Transplantation2012;12(Suppl S3):319. [EMBASE: 70746950] ">Tsai 2012</a>; <a href="./references#CD004759-bbs2-0094" title="TydenG , GenbergH , TollemarJ , EkbergH , PerssonNH , TufvesonG , et al. A randomized, doubleblind, placebo‐controlled, study of single‐dose rituximab as induction in renal transplantation. Transplantation2009;87(9):1325‐9. [MEDLINE: 19424032] TydenG , MjornstedtL , EkbergH , TufvesonG . A prospective, randomised, placebo controlled, multicenter study of the efficacy and safety of rituximab as induction therapy together with tacrolimus, mycophenolate mofetil and steroids in renal transplantation [abstract no: 861]. Transplantation2008;86(2S):300. [CENTRAL: CN‐00763744] TydenG , MjornstedtL , EkbergH , TufvesonG . Is rituximab safe to use in kidney transplant patients?. American Journal of Transplantation2010;10(8):1949. [MEDLINE: 20659100] TydénG , EkbergH , TufvesonG , MjörnstedtL . A randomized, double‐blind, placebo‐controlled study of single dose rituximab as induction in renal transplantation: a 3‐year follow‐up. Transplantation.2012;94(3):e21‐2. [MEDLINE: 22872297] ">Tyden 2009</a>). </p> <p><b>ATG versus OKT3</b> </p> <p>Six studies (571 participants) compared ATG with OKT3 (<a href="./references#CD004759-bbs2-0010" title="BockHA , GallatiH , ZurcherRM , BachofenM , MihatschMJ , LandmannJ , et al. A randomized prospective trial of prophylactic immunosuppression with ATG‐Fresenius versus OKT3 after renal transplantation. Transplantation1995;59(6):830‐40. [MEDLINE: 7701577] BockHA , ZurcherR , MihatschM , LandmannJ , ThielG . A randomized prospective trial of prophylactic immunosuppression with OKT3 vs. ATG‐Fresenius (ATG‐F) after renal transplantation [abstract]. 12th International Congress of Nephrology; 1993 June 13‐18; Jerusalem, Israel. 1993:165. [CENTRAL: CN‐00550381] BockHA , ZurcherR , MihatschM , LandmannJ , ThielG . A randomized prospective trial of prophylactic therapy with OKT3 vs ATG‐Fresenius (ATG‐F) after renal transplantation [abstract]. Journal of the American Society of Nephrology1992;3(3):852. [CENTRAL: CN‐00460418] ">Bock 1995</a>; <a href="./references#CD004759-bbs2-0021" title="ColeEH , CattranDC , FarewellVT , AprileM , BearRA , PeiYP , et al. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation1994;57(1):60‐7. [MEDLINE: 8291115] ">Cole 1994</a>; <a href="./references#CD004759-bbs2-0033" title="FukuuchiF , LefrancoisN , BosshardS , ChapuisF , DubernardJM , TouraineJL . Comparison of prophylactic OKT3 versus ATG in immunologic high risk cadaver renal transplant recipients [abstract]. Journal of the American Society of Nephrology1995;6(3):1084. [CENTRAL: CN‐00484030] FukuuchiF , LefrancoisN , ChapuisF , GebuhrerL , BosshardS , DubernardJM , et al. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high‐risk renal transplant recipients. Transplantation Proceedings1996;28(5):2808‐9. [MEDLINE: 8908070] ">Fukuuchi 1996</a>; <a href="./references#CD004759-bbs2-0053" title="KumarMS , CahillK , KumarAM , PanigrahiD , SeirkaD , SingletonR , et al. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. Transplantation Proceedings1998;30(4):1351‐2. [MEDLINE: 9636549] KumarMS , LaskowDA , PanigrahiD , KumarAM , CahillK , PankewyezO , et al. Correlation of CD3 counts and serum IL‐10 levels during induction to incidence of rejections and infections in cadaveric kidney recipients [abstract]. Journal of the American Society of Nephrology1998;9(Program &amp; Abstracts):683A. [CENTRAL: CN‐00446225] ">Kumar 1998a</a>; <a href="./references#CD004759-bbs2-0070" title="Perez‐TamajonL , GonzálezJM , TorresA , RodriguezA , HernandezD , LosadaM , et al. Induction treatment with sequential quadruple therapy in renal transplantation: polyclonal vs. monoclonal AC at low doses [abstract]. Nefrología1996;16:97. [CENTRAL: CN‐00602023] ">Perez‐Tamajon 1996</a>; <a href="./references#CD004759-bbs2-0072" title="RaffaeleP , Pouteil‐NobleC , LefrancoisN , BosshardS , BetuelH , AymardM , et al. Influence of a randomized monoclonal or polyclonal program of therapy on cytomegalovirus infection in kidney transplantation. Transplantation Proceedings1991;23(1 Pt 2):1361‐2. [MEDLINE: 1846465] ">Raffaele 1991</a>). Maintenance immunosuppression was CNI‐based triple therapy and the same in both arms for all six studies. </p> <p><b>OKT3 versus placebo/no treatment</b> </p> <p>Twelve studies (1184 participants) compared OKT3 with placebo or no treatment (<a href="./references#CD004759-bbs2-0002" title="AbramowiczD , GoldmanM , DePauwL , VanherweghemJL , KinnaertP , VereerstraetenP . The long‐term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation‐‐a single‐center, prospective, randomized study. Transplantation1992;54(3):433‐7. [MEDLINE: 1412723] AbramowiczD , NormanDJ , GoldmanM , DePauwL , KinnaertP , KahanaL , et al. OKT3 prophylaxis improves long‐term renal graft survival in high‐risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplantation Proceedings1995;27(1):852‐3. [MEDLINE: 7879204] AbramowiczD , NormanDJ , VereerstraetenP , GoldmanM , DePauwL , VanherweghemJL , et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long‐term survival. Kidney International1996;49(3):768‐72. [MEDLINE: 8648918] GoldmanM , AbramowiczD , DePauwL , MarecauxG , VanderwindenJM , KinnaertP , et al. Beneficial effects of prophylactic OKT3 in cadaver kidney transplantation: comparison with cyclosporin A in a single‐center prospective randomized study. Transplantation Proceedings1991;23(1 Pt 2):1046‐7. [MEDLINE: 1899148] ">Abramowicz 1992</a>; <a href="./references#CD004759-bbs2-0004" title="AckermannJR , LeforWM , KahanaL , WeinsteinS , ShiresDL . Prophylactic use of OKT3 in renal transplantation: Part of a prospective randomized multicenter trial. Transplantation Proceedings1988;20(1 Suppl 1):242‐4. [EMBASE: 1988111881] KahanaL , AckermannJ , LeforW , WeinsteinS , WrightC , DeQuesadaA , et al. Uses of orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation. Transplantation Proceedings1990;22(4):1755‐8. [MEDLINE: 2117799] KahanaL , NarvarteJ , AckermannJ , LeforW , WeinsteinS , WrightC , et al. OKT3 prophylaxis versus conventional drug therapy: single‐center perspective, part of a multicenter trial. American Journal of Kidney Diseases1989;14(5 Suppl 2):5‐9. [MEDLINE: 2510510] ">Ackermann 1988</a>; <a href="./references#CD004759-bbs2-0009" title="BenfieldMR , HerrinJ , FeldL , RoseS , StableinD , TejaniA . Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation1999;67(4):544‐7. [MEDLINE: 10071025] BenfieldMR , SymonsJM , BynonS , EckhoffD , HerrinJ , HarmonW , et al. Mycophenolate mofetil in pediatric renal transplantation. Pediatric Transplantation1999;3(1):33‐7. [MEDLINE: 10359029] BenfieldMR , TejaniA , HarmonWE , McDonaldR , StableinDM , McIntoshM , et al. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation. Pediatric Transplantation2005;9(3):282‐92. [MEDLINE: 15910382] TejaniA . A randomized prospective multicenter trial of T‐cell antibody induction therapy in pediatric renal transplantation [abstract]. XVIII International Congress of the Transplantation Society; 2000 Aug 27‐Sept 1; Rome, Italy. 2000. TejaniA , HarmonW , BenfieldM , ElshihabiI , McDonaldR , StableinD , et al. A randomized prospective multicenter trial of t‐cell antibody induction therapy in pediatric renal transplantation [abstract]. Transplantation2000;69(8 Suppl):S111. [CENTRAL: CN‐00402826] TejaniA , HarmonW , BenfieldM , RoseS , StableinD , StromT , et al. A randomized prospective multicenter trial of t‐cell antibody induction therapy in pediatric renal transplantation [abstract]. Journal of the American Society of Nephrology2000;11(Sept):709A. ">Benfield 1999</a>; <a href="./references#CD004759-bbs2-0024" title="DebureA , ChkoffN , ChatenoudL , LacombeM , CamposH , NoelLH , et al. One‐month prophylactic use of OKT3 in cadaver kidney transplant recipients. Transplantation1988;45(3):546‐53. [MEDLINE: 3279578] DebureA , ChkoffN , ChatenoudL , LacombeM , CamposH , NoelLH , et al. Preventive treatment of rejection by the prolonged administration of OKT3: decrease of the immune response of the host [Traitement prophylactique du rejet par l'administration prolongee d'OKT3: diminution de la reponse immune de l'hote]. Nephrologie1987;8(3):87‐94. [MEDLINE: 3116443] ">Debure 1987</a>; <a href="./references#CD004759-bbs2-0025" title="DePauwL , AbramowiczD , GoldmanM , VereerstraetenP , KinnaertP , ToussaintC . Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation. Transplantation Proceedings1990;22(4):1759‐60. [MEDLINE: 2117800] ">De Pauw 1990</a>; <a href="./references#CD004759-bbs2-0044" title="HenryML , ElkhammasEA , BumgardnerG , DaviesEA , PelletierRP , et al. A prospective randomized trial of neoral and cellcept with and without OKT3 induction [abstract]. Transplantation1998;65(12):S191. [CENTRAL: CN‐00445692] HenryML , PelletierRP , ElkhammasEA , BumgardnerGL , DaviesEA , FergusonRM . A randomized prospective trial of OKT3 induction in the current immunosuppression era. Clinical Transplantation2001;15(6):410‐4. [MEDLINE: 11737118] ">Henry 2001</a>; <a href="./references#CD004759-bbs2-0052" title="KreisH , ChkoffN , ChatenoudL . Prolonged administration of a monoclonal anti‐T3 cell antibody (ORTHOCLONE OKT3) to kidney allograft recipients. Transplantation Proceedings1986;18(4):954‐6. [EMBASE: 1986223864] ">Kreis 1986</a>; <a href="./references#CD004759-bbs2-0062" title="Anonymous . Cyclosporine monotherapy versus OKT3 and cyclosporine versus prednisone and cyclosporine as induction therapy in older renal transplant patients: a multicenter randomized study. Spanish Monotherapy Study Group. Transplantation Proceedings1994;26(5):2522‐4. [MEDLINE: 7940775] MoralesJM , MarcenR , GrinoJM , AriasM , VilardellJ . Comparison of three induction protocols in older renal transplant patients: cyclosporine (CYA) monotherapy (M) vs OKT3 and CYNA vs prednisone (P) and CYA. A multicenter randomized study [abstract]. Journal of the American Society of Nephrology1993;4(Program &amp; Abstracts):950. [CENTRAL: CN‐00485149] ">Morales 1994a</a>; <a href="./references#CD004759-bbs2-0065" title="NormanDJ , ShieldCF3rd , BarryJ , BennettWM , HenellK , KimballJ , et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. American Journal of Kidney Diseases1988;11(2):107‐10. [MEDLINE: 3277400] ">Norman 1988</a>; <a href="./references#CD004759-bbs2-0066" title="AbramowiczD , NormanDJ , GoldmanM , DePauwL , KinnaertP , KahanaL , et al. OKT3 prophylaxis improves long‐term renal graft survival in high‐risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplantation Proceedings1995;27(1):852‐3. [MEDLINE: 7879204] AbramowiczD , NormanDJ , VereerstraetenP , GoldmanM , DePauwL , VanherweghemJL , et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long‐term survival. Kidney International1996;49(3):768‐72. [MEDLINE: 8648918] NormanDJ , KahanaL , StuartFPJr , ThistlethwaiteJRJr , ShieldCF3rd , MonacoA , et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation1993;55(1):44‐50. [MEDLINE: 8420063] ShieldCF3rd , JacobsRJ , WyantS , DasA . A cost‐effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. American Journal of Kidney Diseases1996;27(6):855‐64. [MEDLINE: 8651251] ">Norman 1993</a>; <a href="./references#CD004759-bbs2-0079" title="ShieldCF3rd , BeilmanG . Safety of OKT3 use in the operating room. Transplantation Proceedings1993;25(2 Suppl 1):43‐4. [MEDLINE: 8465423] ">Shield 1993</a>; <a href="./references#CD004759-bbs2-0097" title="VigeralP , ChkoffN , ChatenoudL , CamposH , LacombeM , DrozD , et al. Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent. Transplantation1986;41(6):730‐3. [MEDLINE: 3520988] ">Vigeral 1986</a>). </p> <p><b>ALG versus OKT3</b> </p> <p>Six studies (593 participants) compared ALG with OKT3 (<a href="./references#CD004759-bbs2-0013" title="BroyerM , GagnadouxMF , GuestG , ArsanA , BeurtonD , RevillonY , et al. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts. Transplantation Proceedings1993;25(1 Pt 1):570‐1. [MEDLINE: 8438418] ">Broyer 1993</a>; <a href="./references#CD004759-bbs2-0030" title="FreyDJ , MatasAJ , GillinghamKJ , CanafaxD , PayneWD , DunnDL , et al. MALG vs OKT3 following renal transplantation: a randomized prospective trial. Transplantation Proceedings1991;23(1 Pt 2):1048‐9. [MEDLINE: 1899149] FreyDJ , MatasAJ , GillinghamKJ , CanafaxD , PayneWD , DunnDL , et al. Sequential therapy‐‐a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation1992;54(1):50‐6. [MEDLINE: 1631944] ">Frey 1991</a>; <a href="./references#CD004759-bbs2-0037" title="GonzalezC , GrinoJM , CastelaoAM , SeronD , Gil‐VernetS , AndresE , et al. Pre‐transplant ALG, low dose cyclosporine (CsA) and steroids versus pre‐transplant OKT3, CsA and steroids in kidney cadaveric transplantation [abstract]. Kidney International1990;37(6):1601. [CENTRAL: CN‐00601919] GrinoJM , CastelaoAM , GonzalezC , SeronD , Gil‐VernetS , AndresE , et al. Pre‐transplant ALG, low dose cyclosporine (CYA) and steroids in kidney cadaveric transplantation [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:513A. [CENTRAL: CN‐00601920] GrinoJM , CastelaoAM , SeronD , GonzalezC , GalceranJM , Gil‐VernetS , et al. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. American Journal of Kidney Diseases1992;20(6):603‐10. [MEDLINE: 1462990] GrinoJM , CastelaoAM , SeronD , GonzalezC , GalceranJM , Gil‐VernetS , et al. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation. Transplantation Proceedings1992;24(1):39‐41. [MEDLINE: 1539329] GrinoJM , CastelaoAM , SeronD , GonzalezC , Gil‐VernetS , AndresE , et al. Antilymphocyte serum, cyclosporine and corticoids, versus OKT3, cyclosporine, and corticoids in kidney transplantation [Serum anti‐lymphocyte, ciclosporine et corticoides, versus OKT3, ciclosporine et corticoides en transplantation renale]. Presse Medicale1991;20(40):2039‐42. [MEDLINE: 1837121] MestreM , GonzalezC , GrinoJM , VallsA , BoneteJ , ManeE , et al. Sequential monitoring of immunoregulatory T cell subsets in renal transplantation. Transplantation Proceedings1992;24(1):73‐5. [MEDLINE: 1539351] ">Grino 1991</a>; <a href="./references#CD004759-bbs2-0043" title="HantoDW , JendrisakMD , McCulloughCS , SoSK , MarshJW , RushT , et al. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients. Transplantation Proceedings1991;23(1 Pt 2):1050‐1. [MEDLINE: 1899150] HantoDW , JendrisakMD , SoSK , McCulloughCS , RushTM , MichalskiSM , et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation1994;57(3):377‐84. [MEDLINE: 8108873] ">Hanto 1991</a>; <a href="./references#CD004759-bbs2-0064" title="NiaudetP , MurciaI , JeanG , BroyerM . A comparative trial of OKT3 and antilymphocyte serum in the preventive treatment of rejection after kidney transplantation in children [Essai comparatif de l'OKT3 et du serum antilymphocytaire dans le traitement preventif du rejet apres transplantation renale chez l'enfant]. Annales de Pediatrie1990;37(2):83‐5. [MEDLINE: 2138866] ">Niaudet 1990</a>; <a href="./references#CD004759-bbs2-0096" title="VelaC , CristolJP , ChongG , OkambaA , LorhoR , MionC , et al. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients. Transplant International1994;7 Suppl 1:S259‐62. [MEDLINE: 11271219] ">Vela 1994</a>). </p> <p><b>ALG versus placebo/no treatment</b> </p> <p>Sixteen studies (1809 participants) compared ALG with placebo or no treatment (<a href="./references#CD004759-bbs2-0007" title="BelitskyP , MacDonaldAS , CohenAD , CrockerJ , HirschD , JindalK , et al. Comparison of antilymphocyte globulin and continuous i.v. cyclosporine A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study. Transplantation Proceedings1991;23(1 Pt 2):999‐1000. [MEDLINE: 1989359] GulanikarAC , MacDonaldAS , SungurtekinU , BelitskyP . The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation1992;53(2):323‐8. [MEDLINE: 1738926] GulanikarAC , SungurtekinU , MacDonaldAS , BelitskyP , Bitter‐SuermannH , CohenA , et al. Sequential discontinuation of azathioprine and prednisone in renal transplantation. Transplantation Proceedings1991;23(4):2226‐7. [MEDLINE: 1871856] ">Belitsky 1991</a>; <a href="./references#CD004759-bbs2-0008" title="BellPR , BlameyRW , BriggsJD , CastroJE , HamiltonDN , KnappMS , et al. Medical research council trial of antilymphocyte globulin in renal transplantation. A multicenter randomized double‐blind placebo controlled clinical investigation. Transplantation1983;35(6):539‐45. [MEDLINE: 6346595] ">Bell 1983</a>; <a href="./references#CD004759-bbs2-0016" title="CantarovichM , DurrbachA , HiesseC , BenoitG , CharpentierB . Short and long‐term impact of anti‐thymocyte globulin induction on clinical outcomes in renal transplant patients: 15‐year results of a prospective and randomized trial [abstract no: 1034]. American Journal of Transplantation2002;2(Suppl 3):398. [CENTRAL: CN‐00415382] CantarovichM , DurrbachA , HiesseC , LadouceurM , BenoitG , CharpentierB . 20‐year follow‐up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. Transplantation2008;86(12):1732‐7. [MEDLINE: 19104413] CantarovichM , DurrbachA , LadouceurM , HiesseC , BenoitG , CharpentierB . 20 year follow‐up results of a randomized controlled trial comparing anti‐lymphocyte globulin‐induction to no induction in renal transplant patients [abstract no: 535]. American Journal of Transplantation2008;8(Suppl 2):321. CantarovichM , DurrbachA , LadouceurM , HiesseC , BenoitG , CharpentierB . 20 year follow‐up results of a randomized controlled trial comparing anti‐lymphocyte globulin‐induction to no induction in renal transplant patients [abstract no: 879]. Transplantation2008;86(2S):307. DurrbachA , CantarovichM , HiesseC , BenoirG , CharpentierB . Short and long‐term impact of anti‐lymphocyte globulin induction on clinical outcomes in renal transplant patients: 15‐year results of a prospective and randomized trial [abstract no: 2341]. XIXth International Congress of the Transplantation Society; 2002 Aug 25‐30; Miami, FL. 2002. [CENTRAL: CN‐00420825] ">Cantarovich 2008</a>; <a href="./references#CD004759-bbs2-0022" title="CondieRM , WaskoskyKE , HallBL . Efficacy of Minnesota antilymphoblast globulin in renal transplantation: a multicenter, placebo‐controlled, prospective, randomized, double‐blind study. Transplantation Proceedings1985;17(1 Pt 2):1304‐10. [EMBASE: 1985078723] ">Condie 1985</a>; <a href="./references#CD004759-bbs2-0034" title="GianelloP , SquiffletJP , PirsonY , StoffelM , DeremeT , AlexandreGP . Cyclosporine‐steroids versus conventional therapy in cadaver kidney transplantation: analysis of a randomized trial at two years. Transplantation Proceedings1987;19(1 Pt 3):1867‐72. [MEDLINE: 3547891] ">Gianello 1987</a>; <a href="./references#CD004759-bbs2-0038" title="GrundmannR . Infectious diseases under prophylactic ALG treatment and their prevention in a prospectively randomized trial. Scandinavian Journal of Urology &amp; Nephrology Supplementum1985;92:33‐5. [MEDLINE: 3008314] GrundmannR , WienandP , HesseU . Improvement in cyclosporine handling by anti‐lymphocyte globulin in the early post‐operative period. Proceedings of the European Dialysis &amp; Transplant Association ‐ European Renal Association1985;21:987‐91. [MEDLINE: 3887394] GrundmannR , WienandP , HesseU . Improvement of the cyclosporin A handling by ALG in the early postoperative period [abstract]. Kidney International1984;26(4):637. [CENTRAL: CN‐00601926] GrundmannR , WienandP , MeiderG , VlahoV , PichlmaierH . Use and limits of preventive antilymphocyte globulin therapy following kidney transplantation. A prospective randomized study [Nutzen und grenzen einer prophylaktischen antilymphozytenglobulin‐therapie nach nierentransplantation. Eine prospektiv randomisierte studie]. Klinische Wochenschrift1984;62(20):979‐85. [MEDLINE: 6389973] ">Grundmann 1984</a>; <a href="./references#CD004759-bbs2-0041" title="HalloranP , LudwinD , AprileM . Randomized comparison between cyclosporine and conventional therapy plus Minnesota antilymphocyte globulin in cadaveric renal transplantation. Transplantation Proceedings1983;15(4 Suppl 1‐2):2513‐6. [EMBASE: 1984089086] HalloranPF , LienJ , AprileM , WhiteN . Preliminary results of a randomized comparison of cyclosporine and Minnesota antilymphoblast globulin. Transplantation Proceedings1982;14(4):627‐30. [MEDLINE: 6301117] ">Halloran 1982</a>; <a href="./references#CD004759-bbs2-0047" title="JakobsenA , FlatmarkA , LundgrenG , SolheimB , GrothCG . A controlled trial with AHLG Behring: lack of effect on cadaveric renal graft survival. Scandinavian Journal of Urology &amp; Nephrology Supplementum1981;64:205‐12. [MEDLINE: 6755682] ">Jakobsen 1981</a>; <a href="./references#CD004759-bbs2-0036" title="GrinoJM , AlsinaJ , SabaterR , CastelaoAM , Gil‐VernetS , AndresE , et al. Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation. Transplantation1990;49(6):1114‐7. [2360253] KogaA , MoresoFJ , SeronD , Gil‐VernetS , CruzadoJM , CastelaoAM , et al. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long‐term renal allograft outcome. Transplantation Proceedings2004;36(5):1305‐7. [MEDLINE: 15251318] ">Grino 1990</a>; <a href="./references#CD004759-bbs2-0054" title="LaunoisB , CampionJP , FauchetR , KerbaolM , CartierF . Prospective randomized clinical trial in patients with cadaver‐kidney transplants. Transplantation Proceedings1977;9(1):1027‐30. [MEDLINE: 325729] ">Launois 1977</a>; <a href="./references#CD004759-bbs2-0057" title="MaiorcaR , CristinelliL , ScolariS , SandriniS , BrunoriG , ToniniG , et al. Prospective controlled trial with antilynfocytic globulin (A.L.G.), in first cadaveric renal transplants treated with low‐dose steroids both in prophylaxis and rejection therapy [abstract]. Kidney International1984;26(4):644. [CENTRAL: CN‐00775915] ">Maiorca 1984</a>; <a href="./references#CD004759-bbs2-0061" title="BoudreauxJP , McHughL , CanafaxDM , AscherN , SutherlandDE , PayneW , et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation1987;44(3):376‐81. [MEDLINE: 3307061] CanafaxDM , MinDI , GruberSA , MatasAJ , PayneWD , DunnDL , et al. Immunosuppression for cadaveric renal allograft recipients: a risk‐factor matched comparison of the Minnesota randomized trial with an antilymphoblast globulin, azathioprine, cyclosporine, and prednisone protocol. Clinical Transplantation1989;3(2):110‐9. [EMBASE: 1989138098] CanafaxDM , SimmonsRL , SutherlandDE , FrydDS , StrandMH , AscherNL , et al. Early and late effects of two immunosuppressive drug protocols on recipients of renal allografts: results of the Minnesota randomized trial comparing cyclosporine versus antilymphocyte globulin‐azathioprine. Transplantation Proceedings1986;18(2 Suppl 1):192‐6. [MEDLINE: 3515687] CanafaxDM , TorresA , FrydDS , HeilJE , StrandMH , AscherNL , et al. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG‐azathioprine. Transplantation1986;41(2):177‐81. [MEDLINE: 3511581] FergusonRM , RynasiewiczJJ , SutherlandDE , SimmonsRL , NajarianJS . Cyclosporin A in renal transplantation: a prospective randomized trial. Surgery1982;92(2):175‐82. [MEDLINE: 6285533] FrickT , FrydDS , GoodaleRL , SimmonsRL , SutherlandDE , NajarianJS . Incidence and treatment of candida esophagitis in patients undergoing renal transplantation. Data from the Minnesota prospective randomized trial of cyclosporine versus antilymphocyte globulin‐azathioprine. American Journal of Surgery1988;155(2):311‐3. [MEDLINE: 3277475] FrickTW , FrydDS , GoodaleRL , SimmonsRL , SutherlandDE , NajarianJS . Lack of association between azathioprine and acute pancreatitis in renal transplantation patients. Lancet1991;337(8735):251‐2. [MEDLINE: 1670892] FrickTW , FrydDS , SutherlandDE , GoodaleRL , SimmonsRL , NajarianJS . Hypercalcemia associated with pancreatitis and hyperamylasemia in renal transplant recipients. Data from the Minnesota randomized trial of cyclosporine versus antilymphoblast azathioprine. American Journal of Surgery1987;154(5):487‐9. [MEDLINE: 2445214] GoresPF , FrydDS , SutherlandDE , NajarianJS , SimmonsRL . Hyperuricemia after renal transplantation. American Journal of Surgery1988;156(5):397‐400. [MEDLINE: 3056057] GruberS , PescovitzM , SimmonsR , FrydD . Cyclosporine use lowers risk of thromboembolism in diabetic renal allograft recipients [abstract]. Kidney International1987;31(1):458. [CENTRAL: CN‐00550666] GruberSA , ChaversB , PayneWD , FrydDS , CanafaxDM , SimmonsRL , et al. Allograft renal vascular thrombosis‐‐lack of increase with cyclosporine immunosuppression. Transplantation1989;47(3):475‐8. [MEDLINE: 2646779] GruberSA , ChaversB , PayneWD , FrydDS , CanafaxDM , SimmonsRL , et al. Frequency of allograft renal vascular thrombosis under three immunosuppressive regimens at a single institution. Transplantation Proceedings1989;21(1 Pt 2):2139‐40. [MEDLINE: 2652690] GruberSA , PescovitzM , SimmonsRL , NajarianJS , AscherNL , PayneWD , et al. Thromboembolic complications after renal transplantation: results from the randomized trial of cyclosporine v azathioprine‐antilymphocyte globulin. Transplantation Proceedings1987;19(1 Pt 2):1815‐6. [MEDLINE: 3079041] GruberSA , PescovitzMD , SimmonsRL , NajarianJS , AscherNL , PayneWD , et al. Thromboembolic complications in renal allograft recipients. A report from the prospective randomized study of cyclosporine versus azathioprine‐antilymphocyte globulin. Transplantation1987;44(6):775‐8. [MEDLINE: 3321586] GruberSA , SimmonsRL , NajarianJS , VercellottiG , AscherNL , DunnDL , et al. Erythrocytosis and thromboembolic complications after renal transplantation: results from a randomized trial of cyclosporine versus azathioprine‐antilymphocyte globulin. Transplantation Proceedings1988;20(3 Suppl 3):948‐50. [MEDLINE: 3291331] HesseUJ , FrydDS , ChatterjeeSN , SimmonsRL , SutherlandDE , NajarianJS . Pulmonary infections. The Minnesota randomized prospective trial of cyclosporine vs azathioprine‐antilymphocyte globulin for immunosuppression in renal allograft recipients. Archives of Surgery1986;121(9):1056‐60. [MEDLINE: 3527111] JohnsonCP , SimmonsRL , SutherlandDE , CanafaxDM , AscherNL , PayneWD , et al. A randomized trial comparing cyclosporine with antilymphoblast‐globulin‐azathioprine for renal allograft recipients. Results at 2 1/2‐6 years. Transplantation1988;45(2):380‐5. [MEDLINE: 3278431] NajarianJS , FergusonRM , SutherlandDE . A prospective trial of the efficacy of cyclosporine in renal transplantation at the University of Minnesota. Transplantation Proceedings1983;15(1):438‐41. [EMBASE: 1983156214] NajarianJS , FrydDS , StrandM , CanafaxDM , AscherNL , PayneWD , et al. A single institution, randomized, prospective trial of cyclosporin versus azathioprine‐antilymphocyte globulin for immunosuppression in renal allograft recipients. Annals of Surgery1985;201(2):142‐57. [MEDLINE: 3882063] PescovitzMD , GruberSA , AscherNL , KruseLV , NajarianJS , PayneWD , et al. Frequency of diabetes‐related complications in renal allograft recipients prospectively randomized to cyclosporine or azathioprine. Transplantation Proceedings1987;19(1 Pt 2):1537‐8. [MEDLINE: 3274376] RynasiewiczJJ , SutherlandDE , FergusonRM , SquiffletJP , MorrowCE , GoetzFC , et al. Cyclosporin A for immunosuppression: observations in rat heart, pancreas, and islet allograft models and in human renal and pancreas transplantation. Diabetes1982;31 Suppl 4:92‐108. [MEDLINE: 6819969] SimmonsRL , CanafaxDM , StrandM , AscherNL , PayneWD , SutherlandDE , et al. Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prednisone. Transplantation Proceedings1985;17(4 Suppl 1):266‐75. [MEDLINE: 3895665] SutherlandDE , FrydDS , StrandM , AscherN , SimmonsRL , NajarianJS . Results of renal transplantation in diabetics at the University of Minnesota since 1979, including a comparison of outcome in diabetic and nondiabetic recipients randomized to cyclosporine versus azathioprine for immunosuppression. Transplantation Proceedings1984;16(3):629‐32. [MEDLINE: 6375030] SutherlandDE , FrydDS , StrandMH , CanafaxDM , AscherNL , PayneWD , et al. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine‐antilymphocyte globulin for immunosuppression in renal allograft recipients. American Journal of Kidney Diseases1985;5(6):318‐27. [MEDLINE: 3893106] SutherlandDE , PayneWD , FrydDS . Comparison of cyclosporine and azathioprine for immunosuppression in diabetic and nondiabetic renal allograft recipients. Transplantation Proceedings1985;17(1 Pt 2):1204‐11. [EMBASE: 1985079661] SutherlandDE , StrandM , FydDS , FergusonRM , SimmonsRL , AscherNL , et al. Comparison of azathioprine‐antilymphocyte globulin versus cyclosporine in renal transplantation. American Journal of Kidney Diseases1984;3(6):456‐61. [MEDLINE: 6372449] ">Minnesota Study 1982</a>; <a href="./references#CD004759-bbs2-0069" title="NovickAC , BraunWE , SteinmullerD , BusztaC , GreenstreetR , KiserW . A controlled randomized double‐blind study of antilymphoblast globulin in cadaver renal transplantation. Transplantation1983;35(2):175‐9. [MEDLINE: 6338636] ">Novick 1983</a>; <a href="./references#CD004759-bbs2-0076" title="SansomJR , BarnesAD , HallCL . A randomized prospective clinical trial of antilymphocyte globulin in 100 cadaveric renal transplants. Postgraduate Medical Journal1976;52(5 Suppl):75‐8. [MEDLINE: 792851] ">Sansom 1976</a>; <a href="./references#CD004759-bbs2-0080" title="JohnsonCP , SlakeyDP , CallaluceRD , BrowneBJ , RozaAM , AdamsMB . Prospective randomized comparison of quadruple vs triple therapy for first cadaver transplants with immediate function. Transplantation Proceedings1993;25(1 Pt 1):585‐6. [MEDLINE: 8438425] SlakeyDP , JohnsonCP , CallaluceRD , BrowneBJ , ZhuYR , RozaAM , et al. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function. Transplantation1993;56(4):827‐31. [MEDLINE: 8212201] ">Slakey 1993</a>; <a href="./references#CD004759-bbs2-0086" title="AckmanCF , TaylorHE , SchualRS . Long‐term follow up of Canadian clinical trial of antilymphocyte globulin in renal transplantation [abstract]. Kidney International1979;15(6):709. [CENTRAL: CN‐00444100] MacDonaldAS , BelitskyP , LannonSG , CohenA , WhiteJ . Antithymocyte globulin in cadaver renal grafts: prophylaxis and antirejection therapy with three different preparations. Transplantation Proceedings1982;14(4):631‐4. [MEDLINE: 6762719] TaylorHE , AckmanCF , HorowitzI . Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation. Canadian Medical Association Journal1976;115(12):1205‐8. [MEDLINE: 793705] ">Taylor 1976</a>). </p> <p><b>Other antibodies</b> </p> <p>Five studies looked at single antibody comparisons each: anti‐CD2 rat monoclonal antibody versus placebo (40 participants, <a href="./references#CD004759-bbs2-0083" title="SquiffletJP , BesseT , MalaiseJ , MouradM , DelcordeC , HopeJA , et al. BTI‐322 for induction therapy after renal transplantation: a randomized study. Transplantation Proceedings1997;29(1‐2):317‐9. [MEDLINE: 9123018] SquiffletJP , BesseT , MouradM , MalaiseJ , DelcordeC , PirsonY , et al. A randomized study of BTI‐322 for the prevention of renal allograft rejection: one year follow up [abstract]. 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10‐14; Chicago (ILL). 1997:258. [CENTRAL: CN‐00509490] ">Squifflet 1997</a>), anti‐CD7 monoclonal antibody versus OKT3 (20 participants, <a href="./references#CD004759-bbs2-0055" title="LazarovitsAI , RochonJ , BanksL , HollombyDJ , MuirheadN , JevnikarAM , et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. Journal of Immunology1993;150(11):5163‐74. [MEDLINE: 7684422] LazarovitsAI , RochonJ , BanksL , HollombyDJ , MuirheadN , JevnikarAM , et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. Transplantation Proceedings1993;25(1 Pt 1):820‐2. [MEDLINE: 7679844] SharmaL , MuirheadN , LazarovitsAI . Human mouse chimeric Cd7 monoclonal antibody (SCZCHH380) for the prophylaxis of kidney transplant rejection: no transplant losses and absence of chronic rejection at 4 years [abstract]. 15th Annual Meeting American Society of Transplant Physicians (ASTP); 1996 May 10‐14; Chicago Ill. 1996. ">Lazarovits 1993</a>), anti‐LFA‐1 monoclonal antibody versus placebo (22 participants, <a href="./references#CD004759-bbs2-0082" title="SpillnerJ , KohnleM , AlbrechtKH , HeemannU . Anti‐LFA‐1 monoclonal antibody in renal transplantation: renal function, infections, and other complications. Transplantation Proceedings1998;30(5):2163. [MEDLINE: 9723427] ">Spillner 1998</a>), anti‐LFA‐1 monoclonal antibody versus ATG (101 participants, <a href="./references#CD004759-bbs2-0046" title="HourmantM . Multicenter comparative study of an anti‐lfa1 adhesion molecule monoclonal antibody and thymoglobulin in prophylaxis of acute rejection in kidney transplantation. [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:336. [CENTRAL: CN‐00509239] HourmantM , BedrossianJ , DurandD , KesslerM , LeBranchuY , CaudrelierP , et al. Multicenter comparative study of an anti‐LFA‐1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Transplantation Proceedings1995;27(1):864. [MEDLINE: 7879209] HourmantM , BedrossianJ , DurandD , KesslerM , LebranchuY , CaudrelierP , et al. Multicenter study of an anti‐LFA1 adhesion molecule monoclonal antibody (Moab) and anti‐thymocyte globulin (ATG) in prophylaxis of acute rejection (AR) in kidney transplantation (KT) [abstract]. 14th Annual Meeting. American Society of Transplant Physicians (ASTP); 1995 May 14‐17; Chicago (ILL). 1995. HourmantM , BedrossianJ , DurandD , LebranchuY , RenoultE , CaudrelierP , et al. A randomized multicenter trial comparing leukocyte function‐associated antigen‐1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation1996;62(11):1565‐70. [MEDLINE: 8970608] ">Hourmant 1996</a>), and anti‐ICAM‐1 monoclonal antibody versus placebo (266 participants, <a href="./references#CD004759-bbs2-0027" title="SalmelaK , WramnerL , EkbergH , HauserI , BentdalO , LinsLE , et al. A randomized multicenter trial of the anti‐ICAM‐1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti‐ICAM‐1 Renal Transplant Study Group. Transplantation1999;67(5):729‐36. [MEDLINE: 10096530] ">EARTS Study 1999</a>). One small pilot study compared ATG with 3 other combination induction regimens; ATG + rituximab, ATG + bortezomib; ATG + rituximab + bortezomib (40 participants, <a href="./references#CD004759-bbs2-0028" title="EjazN , ShieldsA , AllowayR , SadakaB , GirnitaA , MogilishettyG , et al. A prospective, randomized pilot study of B‐cell targeted induction therapy in sensitized kidney transplant recipients: final report [abstract no: 175]. American Journal of Transplantation2013;13(Suppl S5):84. [EMBASE: 71056751] EjazNS , ShieldsAR , AllowayRR , SadakaB , GirnitaAL , MogilishettyG , et al. Randomized controlled pilot study of B cell‐targeted induction therapy in HLA sensitized kidney transplant recipients. American Journal of Transplantation2013;13(12):3142‐54. [MEDLINE: 24266968] SchmidtN , ShieldsAR , AllowayRR , SadakaB , MogilishettyG , KremerJ , et al. Randomized controlled trial of B‐cell targeted induction therapy in HLA sensitized kidney transplant recipients: preliminary results [abstract no: 100]. American Journal of Transplantation2012;12(Suppl S3):56. [EMBASE: 70746047] ">Ejaz 2013</a>). </p> <p><b>Other comparisons</b> </p> <p>A further thirteen studies looked at other ATG, OKT3 or ALG comparisons but each of these had only a single study for each comparison. The ATG studies were: </p> <p> <ul id="CD004759-list-0010"> <li> <p>Single versus divided dose ATG (142 participants, <a href="./references#CD004759-bbs2-0085" title="StevensR , FosterK , MilesC , RigleyT , KalilA , WrenshallL . A randomized 2X2 factorial trial: Part 1, single‐dose rATG induction improves long‐term renal transplant outcomes [abstract]. Transplantation2014;98(Suppl 1):91. [EMBASE: 71543822] StevensR , FosterK , MilesC , RigleyT , WrenshallL . A randomized trial of renal transplantation: Steroid and calcineurin‐inhibitor withdrawal after rabbit anti‐thymocyte globulin induction [abstract]. Transplantation2014;98(Suppl 1):476. [EMBASE: 71545124] StevensRB . Modern approaches to combining sirolimus with calcineurin inhibitors. Transplantation Proceedings2008;40(10 Suppl):S21‐4. [MEDLINE: 19100901] StevensRB , FosterKW , MilesCD , KalilAC , FlorescuDF , SandozJP , et al. A randomized 2x2 factorial clinical trial of renal transplantation: steroid‐free maintenance immunosuppression with calcineurin inhibitor withdrawal after six months associates with improved renal function and reduced chronic histopathology. PLoS ONE [Electronic Resource]2015;10(10):e0139247. [MEDLINE: 26465152] StevensRB , FosterKW , MilesCD , LaneJT , KalilAC , FlorescuDF , et al. A randomized 2x2 factorial trial, part 1: single‐dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation2015;99(1):197‐209. [MEDLINE: 25083614] StevensRB , KalilAC , MilesCD , FlorescuDF , LaneJT , SkorupaAJ , et al. Reduced patient mortality and infectious complications, and superior graft function, in renal transplant patients after single‐dose RATG induction; 5‐year data from a prospective, randomized trial [abstract no: 38]. American Journal of Transplantation2010;10(Suppl 4):49‐50. [EMBASE: 70463399] StevensRB , LaneJT , BoernerBP , MilesCD , RigleyTH , SandozJP , et al. Single‐dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clinical Transplantation2012;26(1):123‐32. [MEDLINE: 21401720] StevensRB , LaneJT , BoernerBP , MilesCD , RigleyTH , SandozJP , et al. Single‐dose rabbit anti‐thymocyte globulin (rATG) induction reduces tubular injury after renal transplantation, resulting in superior renal function, serum Mg++ retention, and glucose regulation [abstract no: 1703]. American Journal of Transplantation2010;10(Suppl 4):522. [EMBASE: 70465078] StevensRB , MercerD , RigleyT , NielsenK , HenningM , SkorupaA , et al. Single‐dose induction with rabbit anti‐thymocyte globulin (rATG) safely improves renal allograft function and reduces chronic allograft nephropathy [abstract no: 538]. American Journal of Transplantation2008;8(Suppl 2):322. [CENTRAL: CN‐00653788] StevensRB , MercerDF , GrantWJ , FreifeldAG , LaneJT , GroggelGC , et al. Randomized trial of single‐dose versus divided‐dose rabbit anti‐thymocyte globulin induction in renal transplantation: an interim report. Transplantation2008;85(10):1391‐9. [MEDLINE: 18497677] StevensRB , RigleyT , SkorupaJ , NielsenK , WrenshallL . Successful calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients: reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 2123]. Transplantation2008;86(2S):695. StevensRB , RigleyTH , NielsenKJ , SkorupaA , SandozJ , KelloggA , et al. Single‐dose induction with rabbit anti‐thymocyte globulin (rATG; 6 mg/kg over 24 hours) is safer and improves immediate and long‐term renal allograft function [abstract no: 616]. American Journal of Transplantation2009;9(Suppl 2):369. StevensRB , RigleyTH , NielsenKJ , SkorupaJY , SkorupaA , SandozJ , et al. Calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients without increase rejection or graft loss [abstract no: 1100]. American Journal of Transplantation2009;9(Suppl 2):501. StevensRB , SkorupaJY , RigleyTH , SandozJP , KelloggA , MillerN , et al. Calcineurin‐inhibitor withdrawal vs minimization after kidney transplantation is safe but does not improve renal function; 5‐year results of a prospective, randomized trial [abstract no: 1643]. American Journal of Transplantation2010;10(Suppl 4):505. StevensRB , WrenshallL , MercerD , RigleyT , NielsenK , HenningM , et al. Successful calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients; reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 289]. American Journal of Transplantation2008;8(Suppl 2):255. [CENTRAL: CN‐00653790] ">Stevens 2008</a>) </p> </li> <li> <p>Two versus four doses (same total) of ATG (17 participants, <a href="./references#CD004759-bbs2-0014" title="BuchlerM , LonguetH , LemoineR , HerrF , GataultP , ThibaultG , et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transplant Immunology2013;28(2‐3):120‐6. [MEDLINE: 23507258] LonguetH , BuchlerM , LemoineR , HerrF , GataultP , ThibaultG , et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte antiglobulin dosing regimens [abstract no: O069]. Transplant International2013;26(Suppl 2):44‐5. [EMBASE: 71359107] ">Buchler 2013</a>) </p> </li> <li> <p>rATG Fresenius versus rATG Merieux (90 participants, <a href="./references#CD004759-bbs2-0068" title="NorrbyJ , OlaussonM . A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplantation Proceedings1997;29(7):3135‐6. [MEDLINE: 9365697] ">Norrby 1997</a>) </p> </li> <li> <p>ATG adjusted for CD3 count versus fixed dose (45 participants, <a href="./references#CD004759-bbs2-0001" title="AbounaGM , KumarMS , al‐AbdullahIH , LooseJ , SullivanDK , PhillipsK , et al. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells. Transplantation Proceedings1995;27(5):2676‐8. [MEDLINE: 7482872] AbounaGM , al‐AbdullahIH , Kelly‐SullivanD , KumarMS , LooseJ , PhillipsK , et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation1995;59(11):1564‐8. [MEDLINE: 7778170] ">Abouna 1995</a>) </p> </li> <li> <p>ATG adjusted for CD3 count versus adjusted for total lymphocyte count (21 participants, <a href="./references#CD004759-bbs2-0005" title="AtaP , KaraM , OzdemirE , CanbakanM , GokceAM , BayraktarFA , et al. Monitoring of CD3(+) T‐cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation. Transplantation Proceedings2013;45(3):929‐31. [MEDLINE: 23622590] ">Ata 2013</a>) </p> </li> <li> <p>standard versus low dose ATG (43 participants, <a href="./references#CD004759-bbs2-0035" title="GrafalsM , SimpsonM , GilliganH , PomposelliJ , AkoadM , KwajaK , et al. Prospective randomized study of low dose antithymocyte globulin as induction in non sensitized adult renal transplant recipients [abstract no: C1351]. American Journal of Transplantation2013;13(Suppl 5):430. [EMBASE: 71057927] GrafalsM , SmithB , MurakamiN , TrabuccoA , HamillK , MarangosE , et al. Immunophenotyping and efficacy of low dose ATG in non‐sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS ONE [Electronic Resource]2014;9(8):e104408. [MEDLINE: 25111080] SmithB , GrafalsM , MurakamiN , TrabuccoA , HamillK , MarangosE , et al. Immune phenotyping and efficacy of low dose ATG in non‐sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study [abstract]. Transplantation2014;98(Suppl 1):580. [EMBASE: 71545491] ">Grafals 2014</a>) </p> </li> <li> <p>ATG versus ALG (50 participants, <a href="./references#CD004759-bbs2-0090" title="Toledo‐PereyraLH , BergrenC , MittalVK , WhittenJI , BaskinS , McNicholL . A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaver kidney transplantation. Transplantation1985;40(4):448‐50. [MEDLINE: 3901446] Toledo‐PereyraLH , BergrenC , WhittenJ . Comparison of ALG and ATG for renal transplantation [abstract]. Kidney International1985;28(2):388. [CENTRAL: CN‐00583280] ">Toledo‐Pereyra 1985</a>). </p> </li> </ul> </p> <p>The OKT3 studies were:</p> <p> <ul id="CD004759-list-0011"> <li> <p>Standard versus low dose (26 participants, <a href="./references#CD004759-bbs2-0067" title="NormanDJ , KimballJA , BarryJM . Cytokine‐release syndrome: differences between high and low doses of OKT3. Transplantation Proceedings1993;25(2 Suppl 1):35‐8. [MEDLINE: 8465420] NormanDJ , KimballJA , BennettWM , ShihabF , BatiukTD , MeyerMM , et al. A prospective, double‐blind, randomized study of high‐versus low‐dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transplant International1994;7(5):356‐61. [MEDLINE: 7993573] ">Norman 1993a</a>) </p> </li> <li> <p>Standard versus high dose (29 participants, <a href="./references#CD004759-bbs2-0003" title="AbramowiczD , GoldmanM , MatO , EstermansG , CrusiauxA , VanherweghemJL , et al. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transplant International1994;7(4):258‐63. [MEDLINE: 7916925] ">Abramowicz 1994</a>) </p> </li> <li> <p>OKT3 versus ALG given only for delayed graft function (51 participants, <a href="./references#CD004759-bbs2-0084" title="SteinmullerDR , HayesJ , NovickAC , StreemSB , HodgeE , SlavisS , et al. Comparison of OKT3 to ALG for prophylaxis for patients with acute renal failure after cadaver renal transplantation [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:512A. [CENTRAL: CN‐00716029] SteinmullerDR , HayesJM , NovickAC , StreemSB , HodgeE , SlavisS , et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation1991;52(1):67‐71. [MEDLINE: 1677502] ">Steinmuller 1991</a>). </p> </li> </ul> </p> <p>The remaining ALG studies were:</p> <p> <ul id="CD004759-list-0012"> <li> <p>Low versus high dose (83 participants, <a href="./references#CD004759-bbs2-0074" title="SakhraniL , AswadS , ObispoE , MendezRG , KhetanU , AsaiP , et al. Optimal dose of Minnesota antilymphocyte globulin for induction immunosuppression in cadaveric renal transplants. Transplantation Proceedings1992;24(5):1730‐1. [MEDLINE: 1412814] ">Sakhrani 1992</a>) </p> </li> <li> <p>Low potency versus high potency ALG (71 participants, <a href="./references#CD004759-bbs2-0088" title="ThomasF , Mendez‐PiconG , ThomasJ , PeaceK , FloraR , LeeHM . Effect of antilyphocyte‐globulin potency on survival of cadaver renal transplants. Prospective randomised double‐blind trial. Lancet1977;2(8040):671‐4. [MEDLINE: 71492] ">Thomas 1977</a>) </p> </li> <li> <p>Fourteen versus 7 days induction (100 participants, <a href="./references#CD004759-bbs2-0039" title="GrundmannR , HesseU , WienandP , BaldamusC , ArnsW . Graft survival and long‐term renal function after sequential conventional cyclosporin A therapy in cadaver kidney transplantation‐‐a prospective randomized trial. Klinische Wochenschrift1987;65(18):879‐84. [MEDLINE: 3312789] GrundmannR , WienandP , HesseU . Sequential conventional and cyclosporine therapy in cadaver renal transplantation‐‐a prospective randomized trial. Transplantation Proceedings1987;19(5):4033‐4. [MEDLINE: 3313993] ">Grundmann 1987</a>). </p> </li> </ul> </p> </section> <section id="CD004759-sec-0040"> <h5 class="title">Reported outcome measures</h5> <p>The reporting of outcome measures was variable across studies: 83 reported patient death, 70 reported all‐cause graft loss and 24 death‐censored graft loss while 84 reported acute rejection and 42 reported delayed graft function (see <a href="#CD004759-fig-0001">Figure 1</a>). Acute rejection was reported in a further seven studies but could not be used in meta‐analysis as rejection was either reported without actual figures or reported as total number of episodes rather than number of participants. Graft function was reported at a variety of time points in 33 studies. Some studies reporting graft function could not be included in meta‐analysis as there was no SD or SE reported. Reporting of harms was more limited and inconsistent among studies. Participants with any serious infection were reported in 61 (66%) studies, however a further 7 studies also assessed infection, but expressed their results as ‘infectious episodes’, or reported no actual figures and so this data could not be easily meaningfully combined. CMV infection was reported in 35 studies and BKV infection in only 7 studies. Malignancy and PTLD were reported in only 30 studies and NODAT in 12. Haematological effects were reported in very few studies; 16 reported leucopenia and 12 thrombocytopenia. Very small numbers of studies reported other adverse outcomes including serum sickness, tremor, headache, chronic allograft nephropathy (on biopsy) and failure to complete induction therapy. </p> </section> </section> <section id="CD004759-sec-0041"> <h4 class="title">Excluded studies</h4> <p>Five studies were excluded (<a href="./references#CD004759-bbs2-0100" title="AllowayR , KotbM , HathawayD , OhmanM , StrainS , GaberAO . The pharmacokinetic profile of standard and low‐dose OKT3 induction immunosuppression in renal transplant recipients. Transplantation1994;58(2):249‐53. [MEDLINE: 8042244] AllowayR , KotbM , HathawayDK , GaberLW , VeraSR , GaberAO . Randomized double‐blind study of standard versus low‐dose OKT3 induction therapy in renal allograft recipients. American Journal of Kidney Diseases1993;22(1):36‐43. [MEDLINE: 8322791] AllowayR , KotbM , HathawayDK , GaberLW , VeraSR , GaberAO . Results of a prospective, randomized double‐blind study comparing standard vs low‐dose OKT3 induction therapy. Transplantation Proceedings1993;25(1 Pt 1):550‐2. [MEDLINE: 8438410] ChaballaM , AllowayRR , KotbM , HathawayDK , GaberL , VeraSR , et al. Five year follow up of prospective, randomized double‐blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients [abstract]. 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10‐14; Chicago (ILL). 1997:259. [CENTRAL: CN‐00509127] ">Alloway 1993</a>; <a href="./references#CD004759-bbs2-0101" title="KirschBM , HaidingerM , ZeydaM , BohmigGA , TombinskyJ , MuhlbacherF , et al. Alemtuzumab (Campath‐1H) induction therapy and dendritic cells: impact on peripheral dendritic cell repertoire in renal allograft recipients. Transplant Immunology2006;16(3‐4):254‐7. [MEDLINE: 17138063] ">Kirsch 2006</a>; <a href="./references#CD004759-bbs2-0102" title="KumarA , ZamanW , ChaurasiaD , GuptaA , SharmaRK , GulatiS . Prospective randomized trial to evaluate the efficacy of single low dose ATG induction in renal transplant recipient with spousal kidney. Indian Journal of Urology2002;19(1):58‐62. [EMBASE: 36347895] ">Kumar 2002b</a>; <a href="./references#CD004759-bbs2-0103" title="Blechman‐KromI . Controlled trial of induction therapy in renal transplantation. www.clinicaltrials.gov/ct2/show/NCT00000936 (accessed 3 November 2016). ">NCT00000936</a>; <a href="./references#CD004759-bbs2-0104" title="TsaiMK . Clinical outcome of de novo everolimus‐based immunosuppressive therapy for renal transplantation using rituximab induction. www.clinicaltrials.gov/ct2/show/NCT01312064 (accessed 22 August 2016). ">NCT01312064</a>). The reasons for exclusion were: </p> <p> <ul id="CD004759-list-0013"> <li> <p>Mixed population and data could not be separated (<a href="./references#CD004759-bbs2-0100" title="AllowayR , KotbM , HathawayD , OhmanM , StrainS , GaberAO . The pharmacokinetic profile of standard and low‐dose OKT3 induction immunosuppression in renal transplant recipients. Transplantation1994;58(2):249‐53. [MEDLINE: 8042244] AllowayR , KotbM , HathawayDK , GaberLW , VeraSR , GaberAO . Randomized double‐blind study of standard versus low‐dose OKT3 induction therapy in renal allograft recipients. American Journal of Kidney Diseases1993;22(1):36‐43. [MEDLINE: 8322791] AllowayR , KotbM , HathawayDK , GaberLW , VeraSR , GaberAO . Results of a prospective, randomized double‐blind study comparing standard vs low‐dose OKT3 induction therapy. Transplantation Proceedings1993;25(1 Pt 1):550‐2. [MEDLINE: 8438410] ChaballaM , AllowayRR , KotbM , HathawayDK , GaberL , VeraSR , et al. Five year follow up of prospective, randomized double‐blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients [abstract]. 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10‐14; Chicago (ILL). 1997:259. [CENTRAL: CN‐00509127] ">Alloway 1993</a>) </p> </li> <li> <p>No outcomes of interest were reported (<a href="./references#CD004759-bbs2-0101" title="KirschBM , HaidingerM , ZeydaM , BohmigGA , TombinskyJ , MuhlbacherF , et al. Alemtuzumab (Campath‐1H) induction therapy and dendritic cells: impact on peripheral dendritic cell repertoire in renal allograft recipients. Transplant Immunology2006;16(3‐4):254‐7. [MEDLINE: 17138063] ">Kirsch 2006</a>) </p> </li> <li> <p>Not a true randomisation (<a href="./references#CD004759-bbs2-0102" title="KumarA , ZamanW , ChaurasiaD , GuptaA , SharmaRK , GulatiS . Prospective randomized trial to evaluate the efficacy of single low dose ATG induction in renal transplant recipient with spousal kidney. Indian Journal of Urology2002;19(1):58‐62. [EMBASE: 36347895] ">Kumar 2002b</a>) </p> </li> <li> <p>Study terminated and no results published (<a href="./references#CD004759-bbs2-0103" title="Blechman‐KromI . Controlled trial of induction therapy in renal transplantation. www.clinicaltrials.gov/ct2/show/NCT00000936 (accessed 3 November 2016). ">NCT00000936</a>; <a href="./references#CD004759-bbs2-0104" title="TsaiMK . Clinical outcome of de novo everolimus‐based immunosuppressive therapy for renal transplantation using rituximab induction. www.clinicaltrials.gov/ct2/show/NCT01312064 (accessed 22 August 2016). ">NCT01312064</a>). </p> </li> </ul> </p> </section> </section> <section id="CD004759-sec-0042"> <h3 class="title">Risk of bias in included studies</h3> <p>Reporting of details of study methodology was incomplete for the majority of studies. Details are summarised in <a href="#CD004759-fig-0002">Figure 2</a> and <a href="#CD004759-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD004759-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004759-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD004759-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004759-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD004759-sec-0043"> <h4 class="title">Allocation</h4> <p>Twenty studies reported adequate sequence generation, and 27 reported adequate allocation concealment. Five studies used inadequate methods of sequence generation and four used inadequate allocation concealment. The remainder (74 studies for sequence generation and 68 for allocation concealment) used unclear methodology. </p> </section> <section id="CD004759-sec-0044"> <h4 class="title">Blinding</h4> <p>Seventy‐six studies adequately reported blinding of participants and personnel, and 54 studies adequately reported blinding of outcome assessment. Two studies had inadequate blinding of participants and personnel and six studies had inadequate blinding of outcome assessment. The remainder had unclear methods. </p> </section> <section id="CD004759-sec-0045"> <h4 class="title">Incomplete outcome data</h4> <p>Incomplete outcome data was adequately addressed in 68 studies, and inadequately in eight studies. The remainder were unclear. </p> </section> <section id="CD004759-sec-0046"> <h4 class="title">Selective reporting</h4> <p>Forty‐five studies were free of selective reporting, 43 studies were inadequate, while the remainder of studies were unclear. </p> </section> <section id="CD004759-sec-0047"> <h4 class="title">Other potential sources of bias</h4> <p>Thirteen studies declared their funding source to be independent or academic funding body, and so were judged free of other potential biases. Twenty‐eight studies were deemed to be high risk of other bias due to funding from a pharmaceutical company or author links to industry or other reasons not covered by above bias assessments. Others did not disclose the funding source of the study or gave limited information about funding and were judged unclear. </p> </section> </section> <section id="CD004759-sec-0048"> <h3 class="title" id="CD004759-sec-0048">Effects of interventions</h3> <p>See: <a href="./full#CD004759-tbl-0001"><b>Summary of findings for the main comparison</b> </a>; <a href="./full#CD004759-tbl-0002"><b>Summary of findings 2</b> </a> </p> <section id="CD004759-sec-0049"> <h4 class="title">ATG versus placebo/no induction treatment</h4> <p>ATG had little or no effect on death at 1 to 2 years compared to placebo or no treatment in older studies without CNI maintenance (<a href="./references#CD004759-fig-0004" title="">Analysis 1.1</a>.3 (6 studies, 621 participants): RR 1.03, 95% CI 0.86 to 1.22; I<sup>2</sup> = 0%) and uncertain effect in more contemporary studies including CNI maintenance (<a href="./references#CD004759-fig-0004" title="">Analysis 1.1</a>.2 (5 studies, 632 participants): RR 0.75, 95% CI 0.27 to 2.06; I<sup>2</sup> = 0%). In the CNI studies, there was also uncertain effect on death at 3 to 6 months (<a href="./references#CD004759-fig-0004" title="">Analysis 1.1</a>.1 (3 studies, 523 participants): RR 0.41, 95% CI 0.13 to 1.22; I<sup>2</sup> = 0%) and at 5 years (<a href="./references#CD004759-fig-0004" title="">Analysis 1.1</a>.4 (2 studies, 159 participants): RR 0.94, 95% CI 0.11 to 7.81; I<sup>2</sup> = 48%). </p> <p>Treatment with ATG had uncertain effect on all‐cause graft loss in CNI studies at 3 to 6 months (<a href="./references#CD004759-fig-0005" title="">Analysis 1.2</a>.1 (4 studies, 638 participants): RR 0.60, 95% CI 0.34 to 1.05; I<sup>2</sup> = 0%), at 1 to 2 years (<a href="./references#CD004759-fig-0005" title="">Analysis 1.2</a>.2 (3 studies, 549 participants): RR 0.65, 95% CI 0.36 to 1.19; I<sup>2</sup> = 6%) and at 5 years (<a href="./references#CD004759-fig-0005" title="">Analysis 1.2</a>.4 (2 studies, 159 participants): RR 1.13, 95% CI 0.62 to 2.05; I<sup>2</sup> = 0%). However, ATG reduced graft loss in the non‐CNI studies at 1 to 2 years (<a href="./references#CD004759-fig-0005" title="">Analysis 1.2</a>.3 (4 studies, 500 participants): RR 0.70, 95% CI 0.49 to 1.01; I<sup>2</sup> = 50%). When CNI and non‐CNI studies were combined, ATG reduced all‐cause graft loss at 1 to 2 years (<a href="./references#CD004759-fig-0005" title="">Analysis 1.2</a>.5 (7 studies, 1049 participants): RR 0.71, 95% CI 0.53 to 0.95; I<sup>2</sup> = 35%). </p> <p>Death‐censored graft loss was reduced at 1 to 2 years in non‐CNI studies (<a href="./references#CD004759-fig-0006" title="">Analysis 1.3</a>.2 (6 studies, 299 participants): RR 0.55, 95% CI 0.38 to 0.78; I<sup>2</sup> = 0%) but there was uncertain effect in CNI studies at 2 years (<a href="./references#CD004759-fig-0006" title="">Analysis 1.3</a>.1 (2 studies, 82 participants): RR 0.57, 95% CI 0.19 to 1.75; I<sup>2</sup> = 0%) and at 5 years (<a href="./references#CD004759-fig-0006" title="">Analysis 1.3</a>.3 (2 studies, 148 participants): RR 1.64, 95% CI 0.20 to 13.18; I<sup>2</sup> = 71%). Again, if CNI and non‐CNI studies were combined then death censored graft loss was significantly reduced with ATG at 1 to 2 years (<a href="./references#CD004759-fig-0006" title="">Analysis 1.3</a>.4 (8 studies, 381 participants): RR 0.55, 95% CI 0.39 to 0.77; I<sup>2</sup> = 0%). </p> <p>ATG prevented acute rejection (<a href="./references#CD004759-fig-0007" title="">Analysis 1.4</a> (17 studies, 2044 participants): RR 0.63, 95% CI 0.51 to 0.78; I<sup>2</sup> = 65%). The relative reduction in risk of rejection was similar in studies including CNI maintenance (<a href="./references#CD004759-fig-0007" title="">Analysis 1.4</a>.1 (12 studies, 1491 participants): RR 0.61, 95% CI 0.49 to 0.76; I<sup>2</sup> = 35%) compared to non‐CNI studies (<a href="./references#CD004759-fig-0007" title="">Analysis 1.4</a>.2 (5 studies, 553 participants): RR 0.65, 95% CI 0.43 to 0.98; I<sup>2</sup> = 73%) (P = 0.79; I<sup>2</sup> = 0% for subgroup analysis). </p> <p>ATG had little or no effect on delayed graft function (<a href="./references#CD004759-fig-0008" title="">Analysis 1.5</a> (9 studies, 1304 participants): RR 0.93, 95% CI 0.78 to 1.10; I<sup>2</sup> = 0%). </p> <p>ATG increased CMV infection (<a href="./references#CD004759-fig-0009" title="">Analysis 1.6</a>.2 (6 studies, 1072 participants): RR 1.55, CI 1.24 to 1.95; I<sup>2</sup> = 0%) but had uncertain effects on all‐cause viral infection (<a href="./references#CD004759-fig-0009" title="">Analysis 1.6</a>.4 (3 studies, 197 participants): RR 1.38, 95% CI 0.56 to 3.39; I<sup>2</sup> = 46%) and bacterial infection (<a href="./references#CD004759-fig-0009" title="">Analysis 1.6</a>.5 (5 studies, 775 participants): RR 1.15, 95% CI 0.96 to 1.37; I<sup>2</sup> = 0%). </p> <p>Leucopenia (<a href="./references#CD004759-fig-0010" title="">Analysis 1.7</a> (4 studies, 920 participants): RR 3.86, 95% CI 2.79 to 5.34; I<sup>2</sup> = 0%) and thrombocytopenia (<a href="./references#CD004759-fig-0011" title="">Analysis 1.8</a> (4 studies, 848 participants): RR 2.41, 95% CI 1.61 to 3.61; I<sup>2</sup> = 0%) were both increased by ATG. </p> <p>ATG had uncertain effects on both early malignancy at 1 to 2 years (<a href="./references#CD004759-fig-0012" title="">Analysis 1.9</a>.1 (3 studies, 611 participants): RR 0.94, 95% CI 0.22 to 3.94; I<sup>2</sup> = 0%) and on late malignancy at 5 years (<a href="./references#CD004759-fig-0012" title="">Analysis 1.9</a>.2 (2 studies, 159 participants): RR 0.94, 95% CI 0.14 to 6.23; I<sup>2</sup> = 0%). The single study (151 participants) that reported PTLD had no events at 1 year in either arm (<a href="./references#CD004759-fig-0012" title="">Analysis 1.9</a>). </p> <p>ATG had uncertain effect on development of NODAT (<a href="./references#CD004759-fig-0013" title="">Analysis 1.10</a>.1 (6 studies, 935 participants): RR 1.01, 95% CI 0.56 to 1.84; I<sup>2</sup> = 39%). </p> <p>There was no difference in SCr at 6 months (<a href="./references#CD004759-fig-0014" title="">Analysis 1.11</a>.1 (2 studies, 503 participants): MD ‐5.34 µmol/L, 95% CI ‐13.44 to 2.75; I<sup>2</sup> = 0%), 1 year (<a href="./references#CD004759-fig-0014" title="">Analysis 1.11</a>.2 (2 studies, 222 participants): MD ‐10.56 µmol/L, 95% CI ‐21.81 to 0.69) or 5 years (<a href="./references#CD004759-fig-0014" title="">Analysis 1.11</a>.5 (1 study, 55 participants): MD ‐32.70 µmol/L, 95% CI ‐68.98 to 3.58) following ATG therapy in studies including CNI maintenance. There was also no difference in SCr at 1 year in the single non CNI study that assessed graft function (<a href="./references#CD004759-bbs2-0093" title="TurcotteJG , FeduskaNJ , HainesRF , FreierDT , GikasPW , McDonaldFD , et al. Antithymocyte globulin in renal transplant recipients. A clinical trial. Archives of Surgery1973;106(4):484‐8. [MEDLINE: 4572345] ">Turcotte 1973</a>). Graft function measured by eGFR was only assessed in one study (<a href="./references#CD004759-bbs2-0078" title="SheashaaHA , HamdyAF , BakrMA , AbdelbasetSF , GhoneimMA . Long‐term evaluation of single bolus high dose ATG induction therapy for prophylaxis of rejection in live donor kidney transplantation. International Urology &amp; Nephrology2008;40(2):515‐20. [MEDLINE: 17978857] ">Sheashaa 2008</a>) and was similar between treatment groups at 5 years (1 study, 71 participants: MD 4.80 mL/min, 95% CI ‐2.57 to 12.17). </p> </section> <section id="CD004759-sec-0050"> <h4 class="title">Rabbit ATG versus horse ATG</h4> <p>There was sparse data for meta‐analyses comparing rATG versus hATG. rATG had uncertain effects on death at 1 year (<a href="./references#CD004759-fig-0015" title="">Analysis 2.1</a>.1 (2 studies, 139 participants): RR 0.41, 95% CI 0.07 to 2.30; I<sup>2</sup> = 0%) and on long‐term death at 10 years (<a href="./references#CD004759-fig-0016" title="">Analysis 2.2</a>.2 (1 study, 72 participants): RR 0.75, 95% CI 0.35 to 1.59) compared to hATG. The effect on all‐cause graft loss was also uncertain at both 1 year (<a href="./references#CD004759-fig-0015" title="">Analysis 2.1</a>.3 (2 studies, 139 participants: RR 0.31, 95% CI 0.08 to 1.27; I<sup>2</sup> = 14%) and at 10 years (<a href="./references#CD004759-fig-0015" title="">Analysis 2.1</a>.4 (1 study, 72 participants: RR 0.96, 95% CI 0.58 to 1.58). </p> <p>rATG prevented acute rejection (2 studies, 88 participants: RR 0.17, 95% CI 0.04 to 0.76) compared to hATG although one study reported no events (<a href="./references#CD004759-bbs2-0073" title="RostaingL , LavayssiereL , KamarN . Hematologic adverse effects of 2 different polyclonal antilymphocyte preparations in de novo kidney transplant patients. Experimental &amp; Clinical Transplantation2010;8(2):178‐80. [MEDLINE: 20565376] ">Rostaing 2010</a>). </p> <p>Single studies reported uncertain effects of rATG compared to hATG with respect to delayed graft function (<a href="./references#CD004759-bbs2-0073" title="RostaingL , LavayssiereL , KamarN . Hematologic adverse effects of 2 different polyclonal antilymphocyte preparations in de novo kidney transplant patients. Experimental &amp; Clinical Transplantation2010;8(2):178‐80. [MEDLINE: 20565376] ">Rostaing 2010</a>) (<a href="./references#CD004759-fig-0015" title="">Analysis 2.1</a>.7, 16 participants: RR 0.50, 95% CI 0.06 to 4.47), all‐cause infection (<a href="./references#CD004759-bbs2-0073" title="RostaingL , LavayssiereL , KamarN . Hematologic adverse effects of 2 different polyclonal antilymphocyte preparations in de novo kidney transplant patients. Experimental &amp; Clinical Transplantation2010;8(2):178‐80. [MEDLINE: 20565376] ">Rostaing 2010</a>) (<a href="./references#CD004759-fig-0016" title="">Analysis 2.2</a>.1, 16 participants: RR 1.67, 95% CI 0.59 to 4.73), and malignancy (<a href="./references#CD004759-bbs2-0012" title="BrennanDC , FlavinK , BurgessS , DolanS , KanoJM , MahonM , et al. A randomized, double‐blinded comparison of thymoglobulin vs ATGAM for induction in adult renal transplant recipients [abstract no: 710]. Transplantation1998;65(12):S180. [CENTRAL: CN‐00602088] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. A randomized, double‐blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. [erratum appears in Transplantation 1999 May 27;67(10):1386.]. Transplantation1999;67(7):1011‐8. [MEDLINE: 10221486] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. Leukocyte response to thymoglobulin or ATGAM for induction immunosuppression in a randomized, double‐blind clinical trial in renal transplant recipients. Transplantation Proceedings1999;31(3B Suppl):16S‐8S. [MEDLINE: 10330962] HardingerKL , RheeS , BuchananP , KochM , MillerB , EnkvetchakulD , et al. A prospective, randomized, double‐blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy: 10‐year results. Transplantation2008;86(7):947‐52. [MEDLINE: 18852661] HardingerKL , SchnitzlerMA , MillerB , LowellJ , ShenoyS , BrennanDC . Long‐term comparison of thymoglobulin versus ATGAM for induction in adult renal transplantation: evidence of improved allograft survival at 5 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):556. [CENTRAL: CN‐00445642] HardingerKL , SchnitzlerMA , MillerB , LowellJA , ShenoyS , KochMJ , et al. Five‐year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation2004;78(1):136‐41. [MEDLINE: 15257052] ">Brennan 1999</a>) (<a href="./references#CD004759-fig-0016" title="">Analysis 2.2</a>.4, 72 participants: RR 0.40, 95% CI 0.12 to 1.35). </p> <p><a href="./references#CD004759-bbs2-0012" title="BrennanDC , FlavinK , BurgessS , DolanS , KanoJM , MahonM , et al. A randomized, double‐blinded comparison of thymoglobulin vs ATGAM for induction in adult renal transplant recipients [abstract no: 710]. Transplantation1998;65(12):S180. [CENTRAL: CN‐00602088] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. A randomized, double‐blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. [erratum appears in Transplantation 1999 May 27;67(10):1386.]. Transplantation1999;67(7):1011‐8. [MEDLINE: 10221486] BrennanDC , FlavinK , LowellJA , HowardTK , ShenoyS , BurgessS , et al. Leukocyte response to thymoglobulin or ATGAM for induction immunosuppression in a randomized, double‐blind clinical trial in renal transplant recipients. Transplantation Proceedings1999;31(3B Suppl):16S‐8S. [MEDLINE: 10330962] HardingerKL , RheeS , BuchananP , KochM , MillerB , EnkvetchakulD , et al. A prospective, randomized, double‐blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy: 10‐year results. Transplantation2008;86(7):947‐52. [MEDLINE: 18852661] HardingerKL , SchnitzlerMA , MillerB , LowellJ , ShenoyS , BrennanDC . Long‐term comparison of thymoglobulin versus ATGAM for induction in adult renal transplantation: evidence of improved allograft survival at 5 years [abstract]. American Journal of Transplantation2003;3(Suppl 5):556. [CENTRAL: CN‐00445642] HardingerKL , SchnitzlerMA , MillerB , LowellJA , ShenoyS , KochMJ , et al. Five‐year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation2004;78(1):136‐41. [MEDLINE: 15257052] ">Brennan 1999</a> reported CMV disease was reduced with rATG at 1 year (<a href="./references#CD004759-fig-0016" title="">Analysis 2.2</a>.2, 72 participants: RR 0.38, 95% CI 0.15 to 0.96), more leucopenia with rATG compared to hATG (analysis 2.2.3, 72 participants: RR 13.50, 95% CI 1.95 to 93.46), and graft function was better at 10 years with a lower SCr in the hATG group (<a href="./references#CD004759-fig-0017" title="">Analysis 2.3</a>, 35 participants: MD 44.0 µmol/L, 95% CI 20.41 to 67.59). </p> </section> <section id="CD004759-sec-0051"> <h4 class="title">Alemtuzumab versus ATG</h4> <p>The effects of alemtuzumab (with ESW or minimisation) compared to ATG on death were uncertain both at 1 year (<a href="./references#CD004759-fig-0018" title="">Analysis 3.1</a>.1 (2 studies, 41 participants): RR 0.39, 95% CI 0.06 to 2.42; I<sup>2</sup> = 0%) and at 2 to 3 years (<a href="./references#CD004759-fig-0018" title="">Analysis 3.1</a>.2 (3 studies, 225 participants): RR 0.67, 95% CI 0.15 to 2.95; I<sup>2</sup> = 33%). Similarly, alemtuzumab had uncertain effect on all‐cause graft loss at 1 year (<a href="./references#CD004759-fig-0018" title="">Analysis 3.1</a>.3 (2 studies, 41 participants): RR 0.39, 95% CI 0.12 to 1.30; I<sup>2</sup> = 0%) and at 2 to 3 years (<a href="./references#CD004759-fig-0018" title="">Analysis 3.1</a>.4 (3 studies, 379 participants): RR 0.98, 95% CI 0.47 to 2.06; I<sup>2</sup> = 42%) and on death‐censored graft loss at 1 year (<a href="./references#CD004759-fig-0018" title="">Analysis 3.1</a>.5 (2 studies, 37 participants): RR 0.38, 95% CI 0.08 to 1.81; I<sup>2</sup> = 0%) and at 2 to 3 years (<a href="./references#CD004759-fig-0018" title="">Analysis 3.1</a>.6 (2 studies, 186 participants): RR 2.45, 95% CI 0.67 to 8.97; I<sup>2</sup> = 17%) compared to ATG. There was also uncertain effect of alemtuzumab versus ATG on delayed graft function (<a href="./references#CD004759-fig-0018" title="">Analysis 3.1</a>.7 (2 studies, 86 participants): RR 0.62, 95% CI 0.13 to 3.07; I<sup>2</sup> = 0%). </p> <p>Alemtuzumab had uncertain effect on acute rejection in the first 6 months (<a href="./references#CD004759-fig-0019" title="">Analysis 3.2</a>.1 (3 studies, 341 participants): RR 0.47, 95% CI 0.17 to 1.30; I<sup>2</sup> = 32%) and at 1 year or more (<a href="./references#CD004759-fig-0019" title="">Analysis 3.2</a>.2 (6 studies, 446 participants: RR 0.68, 95% CI 0.44 to 1.05; I<sup>2</sup> = 0%). Two of these 6 studies favoured ATG (<a href="./references#CD004759-bbs2-0019" title="BaruquiJA , CiancioG , GaynorJ , GuerraG , SageshimaJ , ChenL , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results [abstract no: P‐37]. American Journal of Transplantation2014;14(Suppl 3):80. [EMBASE: 71388259] CarrenoMR , CiancioG , BurkeGW , RosenA , RicordiC , TzakisA , et al. Cellular phenotypes affected by induction therapy with campath‐1h vs thymoglobulin vs zenapax in kidney allograft recipients [abstract]. American Journal of Transplantation2004;4(Suppl 8):405. [CENTRAL: CN‐00509121] CiancioG , BurkeGW , GaynorJJ , CarrenoMR , CiroccoRE , MathewJM , et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune‐monitoring. Transplantation2005;80(4):457‐65. [MEDLINE: 16123718] CiancioG , BurkeGW , GaynorJJ , MattiazziAD , CarrenoMR , RosenA , et al. Randomized trial of three different induction regimens to prevent acute renal allograft rejection: early results [abstract]. American Journal of Transplantation2004;4(Suppl 8):266. [CENTRAL: CN‐00509135] CiancioG , BurkeGW , GaynorJJ , RothD , KupinW , RosenA , et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐up. Clinical Transplantation2008;22(2):200‐10. [MEDLINE: 18339140] CiancioG , BurkeGW , MattiazziAD , IllanesHG , GaynorJJ , CarrenoM , et al. A randomized trial of three different antibody induction regimens in renal transplantation [abstract no: 1625]. American Journal of Transplantation2005;5(Suppl 11):569. [CENTRAL: CN‐00644195] CiancioG , GaynorJJ , GuerraG , SageshimaJ , ChenL , MattiazziA , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results. Transplantation2014;97(11):1128‐38. [MEDLINE: 24477186] CiancioG , GaynorJJ , SageshimaJ , ChenL , RothD , KupinW . Machine perfusion in kidney transplantation: better outcomes in the presence of longer pump time [abstract no: 1011]. American Journal of Transplantation2010;10(Suppl 4):333. [EMBASE: 70464387] CiancioG , GaynorJJ , SageshimaJ , RothD , KupinW , GuerraG , et al. Machine perfusion following static cold storage preservation in kidney transplantation: donor‐matched pair analysis of the prognostic impact of longer pump time. Transplant International2012;25(1):34‐40. [MEDLINE: 21981661] ">Ciancio 2005</a>; <a href="./references#CD004759-bbs2-0020" title="BaruquiJA , CiancioG , GaynorJ , GuerraG , SageshimaJ , ChenL , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results [abstract no: P‐37]. American Journal of Transplantation2014;14(Suppl 3):80. [EMBASE: 71388259] CiancioG , GaynorJJ , GuerraG , SageshimaJ , ChenL , MattiazziA , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results. Transplantation2014;97(11):1128‐38. [MEDLINE: 24477186] CiancioG , GaynorJJ , RothD , KupinW , HansonL , TuerosL , et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplantation Proceedings2010;42(9):3503‐6. [MEDLINE: 21094804] ">Ciancio 2010</a>) while the other four favoured alemtuzumab (<a href="./references#CD004759-bbs2-0029" title="DoaresW , AshcraftE , SinghR , HartL , FarneyA , HartmannE , et al. Prospective, randomized, single‐center trial of alemtuzumab vs rabbit anti‐thymocyte globulin induction in renal and pancreas transplant: infectious complications update [abstract no: 315]. American Journal of Transplantation2009;9(Suppl 2):282‐3. [EMBASE: 70010188] FarneyA , RogersJ , DoaresW , IskandarS , OrlandoG , AdamsP , et al. 7 year results of a prospective randomized study of alemtuzumab vs rabbit anti‐thymocyte globulin induction in kidney and kidney pancreas transplantation [abstract]. Transplantation2014;98(Suppl 1):90. [EMBASE: 71543817] FarneyA , RogersJ , HartL , DoaresW , IskandarS , OrlandoG , et al. Long‐term results of a prospective randomized study of alemtuzumab vs rabbit anti‐thymocyte globulin induction in kidney and kidney pancreas transplantation [abstract no: 101]. American Journal of Transplantation2012;12(Suppl S3):56. [EMBASE: 70746048] FarneyA , SinghR , RogersJ , AshcroftE , HartmannE , HartL , et al. A prospective randomized trial of alemtuzumab versus rabbit anti‐thymocyte globulin induction in kidney and pancreas transplantation: minimum 6 months follow up [abstract no: 796]. Transplantation2008;86(2S):278. [CENTRAL: CN‐00740550] FarneyA , SundbergA , MooreP , HartmannE , RogersJ , DoaresW , et al. A randomized trial of alemtuzumab vs. anti‐thymocyte globulin induction in renal and pancreas transplantation. Clinical Transplantation2008;22(1):41‐9. [MEDLINE: 18217904] FarneyAC , DoaresW , RogersJ , SinghR , HartmannE , HartL , et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation2009;88(6):810‐9. [MEDLINE: 19920781] FarneyAC , SinghR , RogersJ , AshcroftE , HartmannE , HartL , et al. A prospective randomized study of alemtuzumab vs rabbit anti‐thymocyte globulin induction in kidney and pancreas transplantation [abstract no: 532]. American Journal of Transplantation2008;8(Suppl 2):320. [CENTRAL: CN‐00653719] HartmannEL , DoaresW , Reeves‐DanielA , RogersJ , SinghR , HartL , et al. Safety and efficacy of lymphocyte‐depleting induction therapy in older transplant recipients: should grandpa receive campath? [abstract no: 1755]. American Journal of Transplantation2009;9(Suppl 2):675. [CENTRAL: CN‐00795687] SinghR , FarneyA , RogersJ , DoaresW , HartmannE , Reeves‐DanielA , et al. A randomized, prospective trial of alemtuzumab versus rabbit anti‐thymocyte globulin induction in kidney‐pancreas transplantation: a single center experience [abstract no: 87]. American Journal of Transplantation2009;9(Suppl 2):216. [CENTRAL: CN‐00790946] StrattaR , AshcraftE , HartmannE , RogersJ , DoaresW , HartL , et al. A prospective randomized comparison of alemtuzumab versus rabbit anti‐thymocyte globulin induction in renal and pancreas transplantation [abstract no: P132]. Transplant International2007;20(Suppl 2):127. [CENTRAL: CN‐00740553] StrattaR , RogersJ , OrlandoG , FarooqU , Al‐ShraidehY , DoaresW , et al. 5 year results of a prospective, randomized single center study of alemtuzumab compared to rabbit anti‐thymocyte globulin induction in simultaneous kidney‐pancreas transplantation [abstract]. Transplantation2014;98(Suppl 1):215. [EMBASE: 71544175] StrattaR , SinghR , FarneyA , RogersJ , DoaresW , HartmanE . A randomized, prospective trial of alemtuzumab versus rabbit anti‐thymocyte globulin induction in kidney‐pancrease transplantation: a single center experience [abstract no: O‐289]. Transplant International2009;22(Suppl 2):76‐7. StrattaRJ , RogersJ , HartL , DoaresW , KaczmorskiS , Reeves‐DanielA , et al. 5 year results of a prospective randomized single center study of alemtuzumab compared to rabbit anti‐thymocyte globulin induction in kidney‐pancreas transplantation [abstract]. Transplantation2013;96(Suppl 6):S86. [EMBASE: 71249227] StrattaRJ , RogersJ , OrlandoG , FarooqU , Al‐ShraidehY , DoaresW , et al. Depleting antibody induction in simultaneous pancreas‐kidney transplantation: a prospective single‐center comparison of alemtuzumab versus rabbit anti‐thymocyte globulin. Expert Opinion on Biological Therapy2014;14(12):1723‐30. [MEDLINE: 25156622] StrattaRJ , RogersJ , OrlandoG , FarooqU , Al‐ShraidehY , FarneyAC . 5‐year results of a prospective, randomized, single‐center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney‐pancreas transplantation. Transplantation Proceedings2014;46(6):1928‐31. [MEDLINE: 25131073] ">Farney 2008</a>; <a href="./references#CD004759-bbs2-0042" title="HanawayM , WoodleES , MulgaonkarS , PeddiR , HarrisonG , VandeputteK , et al. 12 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 135]. American Journal of Transplantation2008;8(Suppl 2):215. HanawayMJ , WoodleES , MulgaonkarS , PeddiVR , KaufmanDB , FirstMR , et al. Alemtuzumab induction in renal transplantation. New England Journal of Medicine2011;364(20):1909‐19. [MEDLINE: 21591943] HolmanJ , HarrisonG , VandeputteK , FirstR , FitzsimmonsW . Immune cell activation comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 553]. Transplantation2008;86(2 Suppl):194. [CENTRAL: CN‐00676047] MulgaonkarS , HanawayM , WoodleES , PeddiR , HarrisonG , VandeputteK , et al. Continuing 24 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 312]. American Journal of Transplantation2009;9(Suppl 2):282. [EMBASE: 70010185] PeddiR , HanawayM , WoodleS , MulgaonkarS , HarrisonG , VandeputteK , et al. Final 36 month results of a randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and rapid steroid withdrawal in renal transplantation [abstract no: 35]. American Journal of Transplantation2010;10(Suppl 4):49. [EMBASE: 70463396] WoodleS , HanawayM , MulgaonkarS , PeddiR , HarrisonG , VandeputteK , et al. 12 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract no: 876]. Transplantation2008;86(2 Suppl):306. [CENTRAL: CN‐00653740] ">Hanaway 2011</a>; <a href="./references#CD004759-bbs2-0056" title="LuTM , YangSL , WuWZ , TanJM . Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Chinese Medical Journal2011;124(5):664‐8. [MEDLINE: 21518554] ">Lu 2011</a>; <a href="./references#CD004759-bbs2-0089" title="ThomasPG , WoodsideKJ , LappinJA , VaidyaS , RajaramanS , GugliuzzaKK . Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk Renal transplantation. Transplantation2007;83(11):1509‐12. [MEDLINE: 17565326] ">Thomas 2007</a>). This difference may be explained by ESW in the alemtuzumab group but not the ATG group in two studies (<a href="./references#CD004759-bbs2-0019" title="BaruquiJA , CiancioG , GaynorJ , GuerraG , SageshimaJ , ChenL , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results [abstract no: P‐37]. American Journal of Transplantation2014;14(Suppl 3):80. [EMBASE: 71388259] CarrenoMR , CiancioG , BurkeGW , RosenA , RicordiC , TzakisA , et al. Cellular phenotypes affected by induction therapy with campath‐1h vs thymoglobulin vs zenapax in kidney allograft recipients [abstract]. American Journal of Transplantation2004;4(Suppl 8):405. [CENTRAL: CN‐00509121] CiancioG , BurkeGW , GaynorJJ , CarrenoMR , CiroccoRE , MathewJM , et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune‐monitoring. Transplantation2005;80(4):457‐65. [MEDLINE: 16123718] CiancioG , BurkeGW , GaynorJJ , MattiazziAD , CarrenoMR , RosenA , et al. Randomized trial of three different induction regimens to prevent acute renal allograft rejection: early results [abstract]. American Journal of Transplantation2004;4(Suppl 8):266. [CENTRAL: CN‐00509135] CiancioG , BurkeGW , GaynorJJ , RothD , KupinW , RosenA , et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐up. Clinical Transplantation2008;22(2):200‐10. [MEDLINE: 18339140] CiancioG , BurkeGW , MattiazziAD , IllanesHG , GaynorJJ , CarrenoM , et al. A randomized trial of three different antibody induction regimens in renal transplantation [abstract no: 1625]. American Journal of Transplantation2005;5(Suppl 11):569. [CENTRAL: CN‐00644195] CiancioG , GaynorJJ , GuerraG , SageshimaJ , ChenL , MattiazziA , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results. Transplantation2014;97(11):1128‐38. [MEDLINE: 24477186] CiancioG , GaynorJJ , SageshimaJ , ChenL , RothD , KupinW . Machine perfusion in kidney transplantation: better outcomes in the presence of longer pump time [abstract no: 1011]. American Journal of Transplantation2010;10(Suppl 4):333. [EMBASE: 70464387] CiancioG , GaynorJJ , SageshimaJ , RothD , KupinW , GuerraG , et al. Machine perfusion following static cold storage preservation in kidney transplantation: donor‐matched pair analysis of the prognostic impact of longer pump time. Transplant International2012;25(1):34‐40. [MEDLINE: 21981661] ">Ciancio 2005</a>; <a href="./references#CD004759-bbs2-0020" title="BaruquiJA , CiancioG , GaynorJ , GuerraG , SageshimaJ , ChenL , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results [abstract no: P‐37]. American Journal of Transplantation2014;14(Suppl 3):80. [EMBASE: 71388259] CiancioG , GaynorJJ , GuerraG , SageshimaJ , ChenL , MattiazziA , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results. Transplantation2014;97(11):1128‐38. [MEDLINE: 24477186] CiancioG , GaynorJJ , RothD , KupinW , HansonL , TuerosL , et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplantation Proceedings2010;42(9):3503‐6. [MEDLINE: 21094804] ">Ciancio 2010</a>), compared to ESW in both arms in the other four studies. Subgroup analysis of these four studies showed acute rejection was reduced at 1 year and beyond by alemtuzumab compared to ATG in studies with ESW in both arms (<a href="./references#CD004759-fig-0019" title="">Analysis 3.2</a>.3 (4 studies, 360 participants: RR 0.57, 95% CI 0.35 to 0.93; I<sup>2</sup> = 0%) (test for subgroup differences, P = 0.13). Subgroup analysis of the two studies with alemtuzumab plus ESW versus ATG and steroid continuation showed the effect of alemtuzumab and ESW on acute rejection at 1 year was uncertain (<a href="./references#CD004759-fig-0019" title="">Analysis 3.2</a>.4 (2 studies, 86 participants): RR 1.27, 95% CI 0.50 to 3.19; I<sup>2</sup> = 0%). The results of all outcomes other than acute rejection were not significantly altered when subgroup analysis was done including only studies with steroid avoidance in both the alemtuzumab and ATG arms. </p> <p>There was an increased rate of chronic allograft nephropathy (CAN) on biopsy with alemtuzumab plus ESW but this was only assessed in the 2 studies that had triple maintenance immunosuppression in the ATG arms (<a href="./references#CD004759-fig-0019" title="">Analysis 3.2</a>.5 (2 studies, 86 participants): RR 2.64, 95% CI 1.09 to 6.36; I<sup>2</sup> = 0%). The classification of CAN is a historical one, present in the original Banff 1997 diagnostic categories (<a href="./references#CD004759-bbs2-0124" title="RacusenLC , SolezK , ColvinRB , BonsibSM , CastroMC , CavalloT , et al. The Banff 97 working classification of renal allograft pathology. Kidney international1999;55(2):713‐23. [MEDLINE: 9987096] ">Racusen 1999</a>) but removed in the 2005 update (<a href="./references#CD004759-bbs2-0127" title="SolezK , ColvinRB , RacusenLC , SisB , HalloranPF , BirkPE , et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). American Journal of Transplantation2007; Vol. 7, issue 3:518‐26. [MEDLINE: 17352710] ">Solez 2007</a>). </p> <p>Alemtuzumab had uncertain effect on all‐cause infection (<a href="./references#CD004759-fig-0020" title="">Analysis 3.3</a>.1 (4 studies, 247 participants): RR 0.94, 95% CI 0.63 to 1.41; I<sup>2</sup> = 0%), CMV infection (<a href="./references#CD004759-fig-0020" title="">Analysis 3.3</a>.2 (3 studies, 225 participants): RR 1.08, 95% CI 0.46 to 2.56; I<sup>2</sup> = 0%), and BKV infection (<a href="./references#CD004759-fig-0020" title="">Analysis 3.3</a>.3 (2 studies, 86 participants: RR 3.00 95% CI 0.13 to 70.83; I<sup>2</sup> = 0%), when compared to ATG. </p> <p>Risk of leucopenia was assessed in one study (<a href="./references#CD004759-bbs2-0019" title="BaruquiJA , CiancioG , GaynorJ , GuerraG , SageshimaJ , ChenL , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results [abstract no: P‐37]. American Journal of Transplantation2014;14(Suppl 3):80. [EMBASE: 71388259] CarrenoMR , CiancioG , BurkeGW , RosenA , RicordiC , TzakisA , et al. Cellular phenotypes affected by induction therapy with campath‐1h vs thymoglobulin vs zenapax in kidney allograft recipients [abstract]. American Journal of Transplantation2004;4(Suppl 8):405. [CENTRAL: CN‐00509121] CiancioG , BurkeGW , GaynorJJ , CarrenoMR , CiroccoRE , MathewJM , et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune‐monitoring. Transplantation2005;80(4):457‐65. [MEDLINE: 16123718] CiancioG , BurkeGW , GaynorJJ , MattiazziAD , CarrenoMR , RosenA , et al. Randomized trial of three different induction regimens to prevent acute renal allograft rejection: early results [abstract]. American Journal of Transplantation2004;4(Suppl 8):266. [CENTRAL: CN‐00509135] CiancioG , BurkeGW , GaynorJJ , RothD , KupinW , RosenA , et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow‐up. Clinical Transplantation2008;22(2):200‐10. [MEDLINE: 18339140] CiancioG , BurkeGW , MattiazziAD , IllanesHG , GaynorJJ , CarrenoM , et al. A randomized trial of three different antibody induction regimens in renal transplantation [abstract no: 1625]. American Journal of Transplantation2005;5(Suppl 11):569. [CENTRAL: CN‐00644195] CiancioG , GaynorJJ , GuerraG , SageshimaJ , ChenL , MattiazziA , et al. Randomized trial of three induction antibodies in kidney transplantation: long‐term results. Transplantation2014;97(11):1128‐38. [MEDLINE: 24477186] CiancioG , GaynorJJ , SageshimaJ , ChenL , RothD , KupinW . Machine perfusion in kidney transplantation: better outcomes in the presence of longer pump time [abstract no: 1011]. American Journal of Transplantation2010;10(Suppl 4):333. [EMBASE: 70464387] CiancioG , GaynorJJ , SageshimaJ , RothD , KupinW , GuerraG , et al. Machine perfusion following static cold storage preservation in kidney transplantation: donor‐matched pair analysis of the prognostic impact of longer pump time. Transplant International2012;25(1):34‐40. [MEDLINE: 21981661] ">Ciancio 2005</a>) and was increased at one month with alemtuzumab compared to ATG (<a href="./references#CD004759-fig-0021" title="">Analysis 3.4</a>.1 (60 participants): RR 21.00, 95% CI 1.29 to 342.93) but not at two years (<a href="./references#CD004759-fig-0021" title="">Analysis 3.4</a>.2 (53 participants): RR 3.12, 95% CI 0.13 to 70.83). </p> <p>The effect of alemtuzumab plus ESW and dual maintenance (tacrolimus and mycophenolate) versus ATG and triple maintenance (CNI, steroid and either azathioprine or mycophenolate) on NODAT was uncertain (<a href="./references#CD004759-fig-0021" title="">Analysis 3.4</a>.3 (2 studies, 69 participants): RR 0.41, 95% CI 0.12 to 1.40; I<sup>2</sup> = 0%). </p> <p>There was uncertain effect of alemtuzumab compared to ATG for other harms including malignancy (<a href="./references#CD004759-fig-0021" title="">Analysis 3.4</a>.4 (3 studies, 187 participants): RR 4.93, 95% CI 0.59 to 41.11), PTLD (<a href="./references#CD004759-fig-0021" title="">Analysis 3.4</a>.5 (2 studies, 165 participants): no events), cytokine release syndrome (<a href="./references#CD004759-fig-0021" title="">Analysis 3.4</a>.6 (1 study, 22 participants): RR 0.20, 95% CI 0.01 to 3.74), or occurrence of any serious adverse event (<a href="./references#CD004759-fig-0021" title="">Analysis 3.4</a>.7 (1 study, 139 participants): RR 0.81, 95% CI 0.59 to 1.12). </p> <p>Graft function measured by CrCl was lower with alemtuzumab plus ESW and dual maintenance at six months (<a href="./references#CD004759-fig-0022" title="">Analysis 3.5</a>.1 (2 studies, 83 participants): MD ‐13.35 mL/min, 95% CI ‐23.91 to ‐2.80; I<sup>2</sup> = 0%) and two years (<a href="./references#CD004759-fig-0022" title="">Analysis 3.5</a>.2 (2 studies, 77 participants): MD ‐12.86 mL/min, 95% CI ‐23.73 to ‐2.00; I<sup>2</sup> = 0%) compared to ATG plus triple maintenance. </p> </section> <section id="CD004759-sec-0052"> <h4 class="title">Alemtuzumab (and ESW) versus no induction</h4> <p>Three of the four studies used triple maintenance immunosuppression including steroids in the control group (<a href="./references#CD004759-bbs2-0015" title="MunozAS , Cabanayan‐CasasolaCB , DanguilanRA , PaduaFB , OnaET . Campath‐1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3‐year follow‐up. Transplantation Proceedings2008;40(7):2230‐3. [MEDLINE: 18790200] VathsalaA , CAMPASIA Study Group. Safety and efficacy of campath‐1h (mabcampath®) with low dose cyclosprorine monotherapy in patients receiving kidney transplants ‐ 6 month analysis of the pilot randomised controlled [abstract]. Transplantation2004;78(2 Suppl):56. [CENTRAL: CN‐00509538] VathsalaA , Campasia Study Group. One year results of a pilot randomised controlled trial of the effectiveness of alemtuzumab as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract no: T‐PO50029]. Nephrology2005;10(Suppl):A215. [CENTRAL: CN‐00583367] VathsalaA , OnaET , TanS , SureshS , ChanY , LouH , et al. Campasia: a pilot randomised controlled trial of the effectiveness of campath‐1h (mabcampath®) as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract]. American Journal of Transplantation2004;4(Suppl 8):406. [CENTRAL: CN‐00509539] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan CasasolaCB , et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation2005;80(6):765‐74. [MEDLINE: 16210963] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Induction therapy with alemtuzumab together with low dose cyclosporine monotherapy permits steroid‐free immunosuppression, mitigates drug‐related, non‐immune toxicities and improves quality of life [abstract no: TH‐PO550]. Journal of the American Society of Nephrology2006;17(Abstracts):224A. [CENTRAL: CN‐00644285] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Lymphocyte recovery after depletion by alemtuzumab in renal transplant recipients: impact on outcome [abstract no: 1015]. American Journal of Transplantation2005;5(Suppl 11):415. [CENTRAL: CN‐00644284] ">CAMPASIA Study 2005</a>; <a href="./references#CD004759-bbs2-0058" title="MargreiterR , KlempnauerJ , NeuhausP , MuehlbacherF . Alemtuzumab (Campath‐1H) induction followed by tacrolimus monotherapy vs tacrolimus based triple drug immunosuppression in cadaveric renal transplantation ‐ results of a multicenter trial [abstract no: 333]. American Journal of Transplantation2007;7(Suppl 2):234. [CENTRAL: CN‐00644175] MargreiterR , KlempnauerJ , NeuhausP , MuehlbacherF , BoesmuellerC , CalneRY . Alemtuzumab (Campath‐1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. American Journal of Transplantation2008;8(7):1480‐5. [MEDLINE: 18510632] ">Margreiter 2008</a>; <a href="./references#CD004759-bbs2-0077" title="Sharaf EI DinUA , Sharaf EI DinBA , EI DamanhouryHA . Alemtuzumab induction as steroid sparing agent in living kidney transplantation: a randomized prospective controlled trial [abstract no: SA‐PO449]. Journal of the American Society of Nephrology2006;17(Abstracts):670A. [CENTRAL: CN‐00644281] ">Sharaf El Din 2006</a>), <a href="./references#CD004759-bbs2-0031" title="FriendPJ , CalneRY , HaleG , WaldmannH , EvansDB , RollesK , et al. Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial. Transplantation Proceedings1987;19(1 Pt 3):1898‐900. [MEDLINE: 3079058] FriendPJ , HaleG , WaldmannH , GoreS , ThiruS , JoyseyV , et al. Campath‐1M‐‐prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation1989;48(2):248‐53. [MEDLINE: 2667209] FriendPJ , WaldmannH , HaleG , TigheH , CalneR . The use of anti‐lymphocyte monoclonal antibodies following organ transplantation [abstract]. Nephrology Dialysis Transplantation1988;3(1):97‐8. [CENTRAL: CN‐00796675] ">Friend 1987</a> used only CSA. Sensitivity analyses excluding <a href="./references#CD004759-bbs2-0031" title="FriendPJ , CalneRY , HaleG , WaldmannH , EvansDB , RollesK , et al. Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial. Transplantation Proceedings1987;19(1 Pt 3):1898‐900. [MEDLINE: 3079058] FriendPJ , HaleG , WaldmannH , GoreS , ThiruS , JoyseyV , et al. Campath‐1M‐‐prophylactic use after kidney transplantation. A randomized controlled clinical trial. Transplantation1989;48(2):248‐53. [MEDLINE: 2667209] FriendPJ , WaldmannH , HaleG , TigheH , CalneR . The use of anti‐lymphocyte monoclonal antibodies following organ transplantation [abstract]. Nephrology Dialysis Transplantation1988;3(1):97‐8. [CENTRAL: CN‐00796675] ">Friend 1987</a> did not significantly alter the summary risk ratio for any outcomes for the remaining studies. Results are therefore reported including all four studies. </p> <p>Alemtuzumab and ESW had uncertain effect on death (<a href="./references#CD004759-fig-0023" title="">Analysis 4.1</a>.1 (4 studies, 296 participants): RR 1.54, 95% CI 0.60 to 4.00; I<sup>2</sup> = 0%) and all‐cause graft loss (<a href="./references#CD004759-fig-0023" title="">Analysis 4.1</a>.2 (4 studies, 296 participants): RR 0.86, 95% CI 0.47 to 1.59; I<sup>2</sup> = 0%) at 6 to 12 months compared to no induction. </p> <p>Alemtuzumab and ESW had little or no effect on acute rejection within 6 months compared with no induction (<a href="./references#CD004759-fig-0023" title="">Analysis 4.1</a>.3 (3 studies, 213 participants): RR 0.72, 95% CI 0.48 to 1.08; I<sup>2</sup> = 0%) and had uncertain effect at 1 year or later (<a href="./references#CD004759-fig-0023" title="">Analysis 4.1</a>.4 (4 studies, 244 participants): RR 0.89, 95% CI 0.42 to 1.87; I<sup>2</sup> = 32%). </p> <p><a href="./references#CD004759-bbs2-0015" title="MunozAS , Cabanayan‐CasasolaCB , DanguilanRA , PaduaFB , OnaET . Campath‐1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3‐year follow‐up. Transplantation Proceedings2008;40(7):2230‐3. [MEDLINE: 18790200] VathsalaA , CAMPASIA Study Group. Safety and efficacy of campath‐1h (mabcampath®) with low dose cyclosprorine monotherapy in patients receiving kidney transplants ‐ 6 month analysis of the pilot randomised controlled [abstract]. Transplantation2004;78(2 Suppl):56. [CENTRAL: CN‐00509538] VathsalaA , Campasia Study Group. One year results of a pilot randomised controlled trial of the effectiveness of alemtuzumab as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract no: T‐PO50029]. Nephrology2005;10(Suppl):A215. [CENTRAL: CN‐00583367] VathsalaA , OnaET , TanS , SureshS , ChanY , LouH , et al. Campasia: a pilot randomised controlled trial of the effectiveness of campath‐1h (mabcampath®) as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract]. American Journal of Transplantation2004;4(Suppl 8):406. [CENTRAL: CN‐00509539] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan CasasolaCB , et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation2005;80(6):765‐74. [MEDLINE: 16210963] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Induction therapy with alemtuzumab together with low dose cyclosporine monotherapy permits steroid‐free immunosuppression, mitigates drug‐related, non‐immune toxicities and improves quality of life [abstract no: TH‐PO550]. Journal of the American Society of Nephrology2006;17(Abstracts):224A. [CENTRAL: CN‐00644285] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Lymphocyte recovery after depletion by alemtuzumab in renal transplant recipients: impact on outcome [abstract no: 1015]. American Journal of Transplantation2005;5(Suppl 11):415. [CENTRAL: CN‐00644284] ">CAMPASIA Study 2005</a> showed uncertain effects of alemtuzumab on delayed graft function (<a href="./references#CD004759-fig-0023" title="">Analysis 4.1</a>.5 (30 participants): RR 2.00, 95% CI 0.26 to 15.62) </p> <p>The risk of CMV infection was increased with alemtuzumab (<a href="./references#CD004759-fig-0024" title="">Analysis 4.2</a>.1 (2 studies, 161 participants): RR 2.28, 95% CI 1.18 to 4.40; I<sup>2</sup> = 0%) compared with control. </p> <p>The effect of alemtuzumab was imprecise for all‐cause infection (<a href="./references#CD004759-fig-0024" title="">Analysis 4.2</a>.2 (3 studies, 213 participants): RR 1.15, 95% CI 0.46 to 2.89; I<sup>2</sup> = 71%), NODAT (<a href="./references#CD004759-fig-0024" title="">Analysis 4.2</a>.3 (2 studies, 161 participants): RR 0.57, 95% CI 0.13 to 2.46; I<sup>2</sup> = 0%), and thrombocytopenia (<a href="./references#CD004759-fig-0024" title="">Analysis 4.2</a>.4 (1 study, 30 participants): RR 1.33, 95% CI 0.45 to 3.96). Malignancy and PTLD were assessed in <a href="./references#CD004759-bbs2-0015" title="MunozAS , Cabanayan‐CasasolaCB , DanguilanRA , PaduaFB , OnaET . Campath‐1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3‐year follow‐up. Transplantation Proceedings2008;40(7):2230‐3. [MEDLINE: 18790200] VathsalaA , CAMPASIA Study Group. Safety and efficacy of campath‐1h (mabcampath®) with low dose cyclosprorine monotherapy in patients receiving kidney transplants ‐ 6 month analysis of the pilot randomised controlled [abstract]. Transplantation2004;78(2 Suppl):56. [CENTRAL: CN‐00509538] VathsalaA , Campasia Study Group. One year results of a pilot randomised controlled trial of the effectiveness of alemtuzumab as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract no: T‐PO50029]. Nephrology2005;10(Suppl):A215. [CENTRAL: CN‐00583367] VathsalaA , OnaET , TanS , SureshS , ChanY , LouH , et al. Campasia: a pilot randomised controlled trial of the effectiveness of campath‐1h (mabcampath®) as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants [abstract]. American Journal of Transplantation2004;4(Suppl 8):406. [CENTRAL: CN‐00509539] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan CasasolaCB , et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation2005;80(6):765‐74. [MEDLINE: 16210963] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Induction therapy with alemtuzumab together with low dose cyclosporine monotherapy permits steroid‐free immunosuppression, mitigates drug‐related, non‐immune toxicities and improves quality of life [abstract no: TH‐PO550]. Journal of the American Society of Nephrology2006;17(Abstracts):224A. [CENTRAL: CN‐00644285] VathsalaA , OnaET , TanSY , SureshS , LouHX , Cabanayan‐CasasolaCB , et al. Lymphocyte recovery after depletion by alemtuzumab in renal transplant recipients: impact on outcome [abstract no: 1015]. American Journal of Transplantation2005;5(Suppl 11):415. [CENTRAL: CN‐00644284] ">CAMPASIA Study 2005</a> and there were no events reported in either group. </p> <p>There was little or no effect on graft function measured by SCr with alemtuzumab and ESW compared to no induction both at 6 months (<a href="./references#CD004759-fig-0025" title="">Analysis 4.3</a>.1 (1 study, 27 participants): MD ‐5.00 µmol/L, 95% CI ‐28.90 to 18.90) and 1 year (<a href="./references#CD004759-fig-0025" title="">Analysis 4.3</a>.2 (2 studies, 108 participants): MD ‐2.89 µmol/L, 95% CI ‐43.29 to 37.52; I<sup>2</sup> = 0%). </p> </section> <section id="CD004759-sec-0053"> <h4 class="title">Rituximab versus placebo</h4> <p>Only death and acute rejection were reported in all three studies comparing rituximab versus placebo. </p> <p>Rituximab had uncertain effect on death both at 6 months (<a href="./references#CD004759-fig-0026" title="">Analysis 5.1</a>.1 (3 studies, 447 participants): RR 0.55, 95% CI 0.18 to 1.71; I<sup>2</sup> = 0%) and at 3 to 4 years (<a href="./references#CD004759-fig-0026" title="">Analysis 5.1</a>.2 (2 studies, 381 participants): RR 2.06, 95% CI 0.27 to 15.64; I<sup>2</sup> = 74%) when compared to placebo. </p> <p>There was uncertain effects of rituximab on all‐cause graft loss (<a href="./references#CD004759-fig-0026" title="">Analysis 5.1</a>.3 (2 studies, 416 participants): RR 0.58, 95% CI 0.26 to 1.28; I<sup>2</sup> = 0%) and death‐censored graft loss (<a href="./references#CD004759-fig-0026" title="">Analysis 5.1</a>.4 (2 studies, 405 participants): RR 0.55, 95% CI 0.21 to 1.46; I<sup>2</sup> = 0%) at 6 months. </p> <p>Acute rejection was not reduced at 6 months with rituximab compared to placebo (<a href="./references#CD004759-fig-0026" title="">Analysis 5.1</a>.5 (3 studies, 447 participants): RR 0.73, 95% CI 0.48 to 1.10; I<sup>2</sup> = 0%). </p> <p>Leucopenia at 6 months was increased (<a href="./references#CD004759-fig-0027" title="">Analysis 5.2</a>.4 (2 studies, 416 participants): RR 8.15, 95% CI 2.00 to 33.15; I<sup>2</sup> = 21%) with rituximab compared to placebo. </p> <p>The effect of rituximab on CMV infection, BKV infection, fungal infection and malignancy was also uncertain (<a href="./references#CD004759-fig-0027" title="">Analysis 5.2</a>). </p> <p>There was little or no effect of rituximab on graft function (eGFR) at 6 months (<a href="./references#CD004759-fig-0028" title="">Analysis 5.3</a> (2 studies, 388 participants): MD 0.32 mL/min, 95% CI ‐3.34 to 3.97; I<sup>2</sup> = 0%). </p> </section> <section id="CD004759-sec-0054"> <h4 class="title">ATG versus OKT3</h4> <p>ATG had uncertain effect on death at 6 to 12 months compared with OKT3 (<a href="./references#CD004759-fig-0029" title="">Analysis 6.1</a>.1 (5 studies, 451 participants): RR 1.29, 95% CI 0.64 to 2.60; I<sup>2</sup> = 0%) and no effect on death‐censored graft loss at 6 to 12 months (<a href="./references#CD004759-fig-0029" title="">Analysis 6.1</a>.2 (5 studies, 439 participants): RR 1.00, 95% CI 0.64 to 1.57; I<sup>2</sup> = 0%). </p> <p>There was little or no effect on acute rejection with ATG compared to OKT3 at 1 year (<a href="./references#CD004759-fig-0029" title="">Analysis 6.1</a>.3 (4 studies, 450 participants): RR 0.76, 95% CI 0.53 to 1.09; I<sup>2</sup> = 67%) and on delayed graft function (<a href="./references#CD004759-fig-0029" title="">Analysis 6.1</a>.4 (3 studies, 235 participants): RR 0.80, 95% CI 0.52 to 1.24; I<sup>2</sup> = 0%). </p> <p>ATG had no effect compared to OKT3 on CMV infection (<a href="./references#CD004759-fig-0030" title="">Analysis 6.2</a>.1 (3 studies, 274 participants): RR 1.13, 95% CI 0.88 to 1.46; I<sup>2</sup> = 4%) and uncertain effects on bacterial infection (<a href="./references#CD004759-fig-0030" title="">Analysis 6.2</a>.2 (1 study, 50 participants): RR 0.51, 95% CI 0.20 to 1.32), leucopenia (<a href="./references#CD004759-fig-0030" title="">Analysis 6.2</a>.3 (1 study, 104 participants): RR 1.92, 95% CI 0.78 to 4.74), thrombocytopenia (<a href="./references#CD004759-fig-0030" title="">Analysis 6.2</a>.4 (1 study, 104 participants): RR 4.81, 95% CI 0.24 to 97.91), and the inability to complete induction due to side effects (<a href="./references#CD004759-fig-0030" title="">Analysis 6.2</a>.6 (2 studies, 131 participants): RR 1.96, 95% CI 0.10 to 39.72; I<sup>2</sup> = 50%). Malignancy was only reported in <a href="./references#CD004759-bbs2-0010" title="BockHA , GallatiH , ZurcherRM , BachofenM , MihatschMJ , LandmannJ , et al. A randomized prospective trial of prophylactic immunosuppression with ATG‐Fresenius versus OKT3 after renal transplantation. Transplantation1995;59(6):830‐40. [MEDLINE: 7701577] BockHA , ZurcherR , MihatschM , LandmannJ , ThielG . A randomized prospective trial of prophylactic immunosuppression with OKT3 vs. ATG‐Fresenius (ATG‐F) after renal transplantation [abstract]. 12th International Congress of Nephrology; 1993 June 13‐18; Jerusalem, Israel. 1993:165. [CENTRAL: CN‐00550381] BockHA , ZurcherR , MihatschM , LandmannJ , ThielG . A randomized prospective trial of prophylactic therapy with OKT3 vs ATG‐Fresenius (ATG‐F) after renal transplantation [abstract]. Journal of the American Society of Nephrology1992;3(3):852. [CENTRAL: CN‐00460418] ">Bock 1995</a> and there were no events reported in either group (<a href="./references#CD004759-fig-0030" title="">Analysis 6.2</a>.5). </p> <p><a href="./references#CD004759-bbs2-0010" title="BockHA , GallatiH , ZurcherRM , BachofenM , MihatschMJ , LandmannJ , et al. A randomized prospective trial of prophylactic immunosuppression with ATG‐Fresenius versus OKT3 after renal transplantation. Transplantation1995;59(6):830‐40. [MEDLINE: 7701577] BockHA , ZurcherR , MihatschM , LandmannJ , ThielG . A randomized prospective trial of prophylactic immunosuppression with OKT3 vs. ATG‐Fresenius (ATG‐F) after renal transplantation [abstract]. 12th International Congress of Nephrology; 1993 June 13‐18; Jerusalem, Israel. 1993:165. [CENTRAL: CN‐00550381] BockHA , ZurcherR , MihatschM , LandmannJ , ThielG . A randomized prospective trial of prophylactic therapy with OKT3 vs ATG‐Fresenius (ATG‐F) after renal transplantation [abstract]. Journal of the American Society of Nephrology1992;3(3):852. [CENTRAL: CN‐00460418] ">Bock 1995</a> reported ATG had uncertain effects compared to OKT3 on graft function at 1 year (SCr) (<a href="./references#CD004759-fig-0031" title="">Analysis 6.3</a> (88 participants): MD 0.00 µmol/L, 95% CI ‐3.56 to 3.56). </p> </section> <section id="CD004759-sec-0055"> <h4 class="title">OKT3 versus placebo/no treatment</h4> <p>A reduction in death was seen with OKT3 compared to no induction at 1 to 2 years (<a href="./references#CD004759-fig-0032" title="">Analysis 7.1</a>.1 (6 studies, 491 participants): RR 0.41, 95% CI 0.18 to 0.97; I<sup>2</sup> = 0%) but the benefit was uncertain at 3 to 5 years (<a href="./references#CD004759-fig-0032" title="">Analysis 7.1</a>.2 (5 studies, 768 participants): RR 0.72, 95% CI 0.37 to 1.44; I<sup>2</sup> = 38%). </p> <p>The effect of OKT3 compared to no induction on graft loss was uncertain both at 1 to 2 years (<a href="./references#CD004759-fig-0032" title="">Analysis 7.1</a>.3 (7 studies, 416 participants): RR 0.55, 95% CI 0.30 to 1.02; I<sup>2</sup> = 0%) and at 3 to 5 years (<a href="./references#CD004759-fig-0032" title="">Analysis 7.1</a>.4 (5 studies, 768 participants): RR 0.73, 95% CI 0.47 to 1.14; I<sup>2</sup> = 65%). </p> <p>Acute rejection was decreased with OKT3 compared to no induction for CNI studies (<a href="./references#CD004759-fig-0032" title="">Analysis 7.1</a>.5 (8 studies, 968 participants): RR 0.60, 95% CI 0.43 to 0.83; I<sup>2</sup> = 79%) but the effect was uncertain in non CNI studies (<a href="./references#CD004759-fig-0032" title="">Analysis 7.1</a>.6 (3 studies, 85 participants): RR 0.70, 95% CI 0.33 to 1.46; I<sup>2</sup> = 86%). </p> <p>The effect of OKT3 compared to placebo on delayed graft function was uncertain (<a href="./references#CD004759-fig-0032" title="">Analysis 7.1</a>.7 (6 studies, 494 participants): RR 1.08, 95% CI 0.70 to 1.65; I<sup>2</sup> = 63%) </p> <p><a href="./references#CD004759-bbs2-0002" title="AbramowiczD , GoldmanM , DePauwL , VanherweghemJL , KinnaertP , VereerstraetenP . The long‐term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation‐‐a single‐center, prospective, randomized study. Transplantation1992;54(3):433‐7. [MEDLINE: 1412723] AbramowiczD , NormanDJ , GoldmanM , DePauwL , KinnaertP , KahanaL , et al. OKT3 prophylaxis improves long‐term renal graft survival in high‐risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplantation Proceedings1995;27(1):852‐3. [MEDLINE: 7879204] AbramowiczD , NormanDJ , VereerstraetenP , GoldmanM , DePauwL , VanherweghemJL , et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long‐term survival. Kidney International1996;49(3):768‐72. [MEDLINE: 8648918] GoldmanM , AbramowiczD , DePauwL , MarecauxG , VanderwindenJM , KinnaertP , et al. Beneficial effects of prophylactic OKT3 in cadaver kidney transplantation: comparison with cyclosporin A in a single‐center prospective randomized study. Transplantation Proceedings1991;23(1 Pt 2):1046‐7. [MEDLINE: 1899148] ">Abramowicz 1992</a> showed an increased risk of all‐cause infection with OKT3 (<a href="./references#CD004759-fig-0033" title="">Analysis 7.2</a>.1 (108 participants): RR 1.38, 95% CI 1.04 to 1.82). OKT3 had uncertain effects on all other infection subtypes including bacterial infection (<a href="./references#CD004759-fig-0033" title="">Analysis 7.2</a>.2 (3 studies, 366 participants): RR 1.01, 95% CI 0.76 to 1.34; I<sup>2</sup> = 0%), all‐cause viral infection (<a href="./references#CD004759-fig-0033" title="">Analysis 7.2</a>.3 (2 studies, 353 participants: RR 0.99, 95% CI 0.72 to 1.37; I<sup>2</sup> = 0%), CMV infection (<a href="./references#CD004759-fig-0033" title="">Analysis 7.2</a>.4 (3 studies, 332 participants): RR 1.52, 95% CI 0.82 to 2.84; I<sup>2</sup> = 0%), Herpes Simplex virus infection (<a href="./references#CD004759-fig-0033" title="">Analysis 7.2</a>.5 (1 study, 215 participants): RR 1.45, 95% CI 0.89 to 2.38), and fungal infection (<a href="./references#CD004759-fig-0033" title="">Analysis 7.2</a>.6 (3 studies, 568 participants): RR 1.26, 95% CI 0.33 to 4.89; I<sup>2</sup> = 68%). </p> <p>The effect of OKT3 compared to placebo on malignancy and PTLD was uncertain (<a href="./references#CD004759-fig-0033" title="">Analysis 7.2</a>.7 (3 studies, 610 participants): RR 1.34, 95% CI 0.52 to 3.50; I<sup>2</sup> = 0%). </p> <p>There was no difference in graft function measured by SCr with OKT3 compared to placebo both at 3 months (<a href="./references#CD004759-fig-0034" title="">Analysis 7.3</a>.1 (3 studies, 226 participants): MD ‐0.93 µmol/L, 95% CI ‐15.78 to 13.93; I<sup>2</sup> = 0%) and at 1 year (<a href="./references#CD004759-fig-0034" title="">Analysis 7.3</a>.2 (2 studies, 261 participants): MD ‐6.22 µmol/L, 95% CI ‐18.21 to 5.76; I<sup>2</sup> = 0%). The effect on graft function at 3 to 4 years was uncertain with only 2 studies reporting for a total of 38 participants at this time point (<a href="./references#CD004759-fig-0034" title="">Analysis 7.3</a>.3 (2 studies, 38 participants): ‐21.10 µmol/L, 95% CI ‐49.81 to 7.61; I<sup>2</sup> = 60%). </p> </section> <section id="CD004759-sec-0056"> <h4 class="title">ALG versus OKT3</h4> <p>ALG had uncertain effects on death at 1 to 2 years (<a href="./references#CD004759-fig-0035" title="">Analysis 8.1</a>.1 (3 studies, 300 participants): RR 2.00, 95% CI 0.62 to 6.47; I<sup>2</sup> = 0%) and 3 years (<a href="./references#CD004759-fig-0035" title="">Analysis 8.1</a>.2 (2 studies, 265 participants): RR 1.03, 95% CI 0.13 to 8.09; I<sup>2</sup> = 41%) and also uncertain effect on all‐cause graft loss at 1 to 2 years (<a href="./references#CD004759-fig-0035" title="">Analysis 8.1</a>.3 (3 studies, 300 participants): RR 1.01, 95% CI 0.57 to 1.80; I<sup>2</sup> = 18%) and 3 years (<a href="./references#CD004759-fig-0035" title="">Analysis 8.1</a>.4 (2 studies, 265 participants): RR 1.08, 95% CI 0.68 to 1.70 ; I<sup>2</sup> = 0%) compared with OKT3. </p> <p>There was little or no effect on acute rejection with ALG compared to OKT3 (<a href="./references#CD004759-fig-0035" title="">Analysis 8.1</a>.5 (6 studies, 593 participants): RR 0.97, 95% CI 0.83 to 1.13; I<sup>2</sup> = 0%). </p> <p>Delayed graft function was less with ALG compared to OKT3 (<a href="./references#CD004759-fig-0035" title="">Analysis 8.1</a>.6 (3 studies, 310 participants): RR 0.78, 95% CI 0.61 to 0.99; I<sup>2</sup> = 0%) </p> <p>ALG had uncertain effect on CMV infection (<a href="./references#CD004759-fig-0036" title="">Analysis 8.2</a>.1 (4 studies, 431 participants): RR 1.53, 95% CI 0.82 to 2.85; I<sup>2</sup> = 57%) and all other infection outcomes (<a href="./references#CD004759-fig-0036" title="">Analysis 8.2</a>). </p> <p>ALG treatment was associated with lower SCr values at 1 year (<a href="./references#CD004759-fig-0037" title="">Analysis 8.3</a>.1 (2 studies, 245 participants): MD ‐15.85 µmol/L, 95% CI ‐28.55 to ‐3.15; I<sup>2</sup> = 0%) but this was not sustained at 2 years (<a href="./references#CD004759-fig-0037" title="">Analysis 8.3</a>.2 (2 studies, 223 participants): MD 12.50 µmol/L, 95% CI ‐13.52 to 38.52; I<sup>2</sup> = 59%). </p> </section> <section id="CD004759-sec-0057"> <h4 class="title">ALG versus placebo/no treatment</h4> <p>ALG had little or no effect on all‐cause death or all‐cause graft loss at any time point after transplantation compared to placebo or no induction (<a href="./references#CD004759-fig-0038" title="">Analysis 9.1</a>). </p> <p>Acute rejection was prevented with ALG compared to placebo or no induction (<a href="./references#CD004759-fig-0038" title="">Analysis 9.1</a>.7 (13 studies, 1575 participants): RR 0.69, 95% CI 0.53 to 0.92; I<sup>2</sup> = 87%) and ALG reduced delayed graft function (<a href="./references#CD004759-fig-0038" title="">Analysis 9.1</a>.8 (5 studies, 615 participants): RR 0.55, 95% CI 0.31 to 0.97; I<sup>2</sup> = 73%). </p> <p>ALG markedly increased both CMV infection (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.1 (3 studies, 289 participants): RR 2.45, 95% CI 1.23 to 4.85; I<sup>2</sup> = 0%) and all‐cause viral infections (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.2 (2 studies, 324 participants): RR 2.71, 95% CI 1.86 to 3.95; I<sup>2</sup> = 0%), and may increase bacterial infection rates (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.3 (4 studies, 742 participants): RR 1.18, 95% CI 0.92 to 1.52; I<sup>2</sup> = 43%). The treatment effect on fungal infection rates was uncertain (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.4 (1 study, 230 participants): RR 1.11, 95% CI 0.63 to 1.95). </p> <p>ALG markedly increased thrombocytopenia (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.5 (1 study, 67 participants): RR 12.19, 95% CI 3.10 to 47.92) and leucopenia (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.6 (2 studies, 297 participants): RR 20.31, 95% CI 0.61 to 676.54; I<sup>2</sup> = 83%). ALG had uncertain effects on malignancy or PTLD (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.7 (4 studies, 623 participants): RR 0.60, 95% CI 0.27 to 1.31; I<sup>2</sup> = 0%) and NODAT (<a href="./references#CD004759-fig-0039" title="">Analysis 9.2</a>.8 (1 study, 105 participants): RR 0.93, 95% CI 0.22 to 3.93). </p> <p>ALG had uncertain effect on both early graft function at 1‐2 years and long term graft function at 10‐20 years compared to placebo or no induction (<a href="./references#CD004759-fig-0040" title="">Analysis 9.3</a>). </p> </section> <section id="CD004759-sec-0058"> <h4 class="title">Other studies</h4> <p>The remainder of comparisons (<a href="#CD004759-fig-0001">Figure 1</a>) involved only a single study and therefore could not be used for meta‐analysis. The results are summarised briefly below. </p> <section id="CD004759-sec-0059"> <h5 class="title">Dose comparisons</h5> <p><a href="./references#CD004759-bbs2-0085" title="StevensR , FosterK , MilesC , RigleyT , KalilA , WrenshallL . A randomized 2X2 factorial trial: Part 1, single‐dose rATG induction improves long‐term renal transplant outcomes [abstract]. Transplantation2014;98(Suppl 1):91. [EMBASE: 71543822] StevensR , FosterK , MilesC , RigleyT , WrenshallL . A randomized trial of renal transplantation: Steroid and calcineurin‐inhibitor withdrawal after rabbit anti‐thymocyte globulin induction [abstract]. Transplantation2014;98(Suppl 1):476. [EMBASE: 71545124] StevensRB . Modern approaches to combining sirolimus with calcineurin inhibitors. Transplantation Proceedings2008;40(10 Suppl):S21‐4. [MEDLINE: 19100901] StevensRB , FosterKW , MilesCD , KalilAC , FlorescuDF , SandozJP , et al. A randomized 2x2 factorial clinical trial of renal transplantation: steroid‐free maintenance immunosuppression with calcineurin inhibitor withdrawal after six months associates with improved renal function and reduced chronic histopathology. PLoS ONE [Electronic Resource]2015;10(10):e0139247. [MEDLINE: 26465152] StevensRB , FosterKW , MilesCD , LaneJT , KalilAC , FlorescuDF , et al. A randomized 2x2 factorial trial, part 1: single‐dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation2015;99(1):197‐209. [MEDLINE: 25083614] StevensRB , KalilAC , MilesCD , FlorescuDF , LaneJT , SkorupaAJ , et al. Reduced patient mortality and infectious complications, and superior graft function, in renal transplant patients after single‐dose RATG induction; 5‐year data from a prospective, randomized trial [abstract no: 38]. American Journal of Transplantation2010;10(Suppl 4):49‐50. [EMBASE: 70463399] StevensRB , LaneJT , BoernerBP , MilesCD , RigleyTH , SandozJP , et al. Single‐dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clinical Transplantation2012;26(1):123‐32. [MEDLINE: 21401720] StevensRB , LaneJT , BoernerBP , MilesCD , RigleyTH , SandozJP , et al. Single‐dose rabbit anti‐thymocyte globulin (rATG) induction reduces tubular injury after renal transplantation, resulting in superior renal function, serum Mg++ retention, and glucose regulation [abstract no: 1703]. American Journal of Transplantation2010;10(Suppl 4):522. [EMBASE: 70465078] StevensRB , MercerD , RigleyT , NielsenK , HenningM , SkorupaA , et al. Single‐dose induction with rabbit anti‐thymocyte globulin (rATG) safely improves renal allograft function and reduces chronic allograft nephropathy [abstract no: 538]. American Journal of Transplantation2008;8(Suppl 2):322. [CENTRAL: CN‐00653788] StevensRB , MercerDF , GrantWJ , FreifeldAG , LaneJT , GroggelGC , et al. Randomized trial of single‐dose versus divided‐dose rabbit anti‐thymocyte globulin induction in renal transplantation: an interim report. Transplantation2008;85(10):1391‐9. [MEDLINE: 18497677] StevensRB , RigleyT , SkorupaJ , NielsenK , WrenshallL . Successful calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients: reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 2123]. Transplantation2008;86(2S):695. StevensRB , RigleyTH , NielsenKJ , SkorupaA , SandozJ , KelloggA , et al. Single‐dose induction with rabbit anti‐thymocyte globulin (rATG; 6 mg/kg over 24 hours) is safer and improves immediate and long‐term renal allograft function [abstract no: 616]. American Journal of Transplantation2009;9(Suppl 2):369. StevensRB , RigleyTH , NielsenKJ , SkorupaJY , SkorupaA , SandozJ , et al. Calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients without increase rejection or graft loss [abstract no: 1100]. American Journal of Transplantation2009;9(Suppl 2):501. StevensRB , SkorupaJY , RigleyTH , SandozJP , KelloggA , MillerN , et al. Calcineurin‐inhibitor withdrawal vs minimization after kidney transplantation is safe but does not improve renal function; 5‐year results of a prospective, randomized trial [abstract no: 1643]. American Journal of Transplantation2010;10(Suppl 4):505. StevensRB , WrenshallL , MercerD , RigleyT , NielsenK , HenningM , et al. Successful calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients; reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 289]. American Journal of Transplantation2008;8(Suppl 2):255. [CENTRAL: CN‐00653790] ">Stevens 2008</a> assessed single versus divided dose ATG. There were no differences in any reported outcomes. <a href="./references#CD004759-bbs2-0001" title="AbounaGM , KumarMS , al‐AbdullahIH , LooseJ , SullivanDK , PhillipsK , et al. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells. Transplantation Proceedings1995;27(5):2676‐8. [MEDLINE: 7482872] AbounaGM , al‐AbdullahIH , Kelly‐SullivanD , KumarMS , LooseJ , PhillipsK , et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation1995;59(11):1564‐8. [MEDLINE: 7778170] ">Abouna 1995</a> compared ATG adjusted for the CD3 count with fixed dose ATG and again there was no difference in outcomes. One very small study by <a href="./references#CD004759-bbs2-0005" title="AtaP , KaraM , OzdemirE , CanbakanM , GokceAM , BayraktarFA , et al. Monitoring of CD3(+) T‐cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation. Transplantation Proceedings2013;45(3):929‐31. [MEDLINE: 23622590] ">Ata 2013</a> compared ATG with dose adjusted by CD3 count compared to dose adjusted for total lymphocyte count and there was no difference in outcomes. <a href="./references#CD004759-bbs2-0035" title="GrafalsM , SimpsonM , GilliganH , PomposelliJ , AkoadM , KwajaK , et al. Prospective randomized study of low dose antithymocyte globulin as induction in non sensitized adult renal transplant recipients [abstract no: C1351]. American Journal of Transplantation2013;13(Suppl 5):430. [EMBASE: 71057927] GrafalsM , SmithB , MurakamiN , TrabuccoA , HamillK , MarangosE , et al. Immunophenotyping and efficacy of low dose ATG in non‐sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS ONE [Electronic Resource]2014;9(8):e104408. [MEDLINE: 25111080] SmithB , GrafalsM , MurakamiN , TrabuccoA , HamillK , MarangosE , et al. Immune phenotyping and efficacy of low dose ATG in non‐sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study [abstract]. Transplantation2014;98(Suppl 1):580. [EMBASE: 71545491] ">Grafals 2014</a> compared 'standard' dose ATG (3.75 mg/kg total) with low dose ATG (2.25 mg/kg total) and found no significant difference in outcomes. Another very small study by <a href="./references#CD004759-bbs2-0014" title="BuchlerM , LonguetH , LemoineR , HerrF , GataultP , ThibaultG , et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transplant Immunology2013;28(2‐3):120‐6. [MEDLINE: 23507258] LonguetH , BuchlerM , LemoineR , HerrF , GataultP , ThibaultG , et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte antiglobulin dosing regimens [abstract no: O069]. Transplant International2013;26(Suppl 2):44‐5. [EMBASE: 71359107] ">Buchler 2013</a> compared a split of four versus two doses of ATG (same total dose of 6 mg/kg) and found no difference in outcomes. Two studies compared different OKT3 dose regimens: standard versus low dose (<a href="./references#CD004759-bbs2-0067" title="NormanDJ , KimballJA , BarryJM . Cytokine‐release syndrome: differences between high and low doses of OKT3. Transplantation Proceedings1993;25(2 Suppl 1):35‐8. [MEDLINE: 8465420] NormanDJ , KimballJA , BennettWM , ShihabF , BatiukTD , MeyerMM , et al. A prospective, double‐blind, randomized study of high‐versus low‐dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transplant International1994;7(5):356‐61. [MEDLINE: 7993573] ">Norman 1993a</a>) and standard versus high dose (<a href="./references#CD004759-bbs2-0003" title="AbramowiczD , GoldmanM , MatO , EstermansG , CrusiauxA , VanherweghemJL , et al. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transplant International1994;7(4):258‐63. [MEDLINE: 7916925] ">Abramowicz 1994</a>). There were no significant differences in either of these small studies. Low versus high dose ALG was also assessed in <a href="./references#CD004759-bbs2-0074" title="SakhraniL , AswadS , ObispoE , MendezRG , KhetanU , AsaiP , et al. Optimal dose of Minnesota antilymphocyte globulin for induction immunosuppression in cadaveric renal transplants. Transplantation Proceedings1992;24(5):1730‐1. [MEDLINE: 1412814] ">Sakhrani 1992</a> and seven days versus 14 days ALG was addressed in <a href="./references#CD004759-bbs2-0039" title="GrundmannR , HesseU , WienandP , BaldamusC , ArnsW . Graft survival and long‐term renal function after sequential conventional cyclosporin A therapy in cadaver kidney transplantation‐‐a prospective randomized trial. Klinische Wochenschrift1987;65(18):879‐84. [MEDLINE: 3312789] GrundmannR , WienandP , HesseU . Sequential conventional and cyclosporine therapy in cadaver renal transplantation‐‐a prospective randomized trial. Transplantation Proceedings1987;19(5):4033‐4. [MEDLINE: 3313993] ">Grundmann 1987</a>. There were no differences in the low versus high dose study. Treatment was frequently stopped early in the 14 day group but there were no other differences in outcomes. One older study by <a href="./references#CD004759-bbs2-0088" title="ThomasF , Mendez‐PiconG , ThomasJ , PeaceK , FloraR , LeeHM . Effect of antilyphocyte‐globulin potency on survival of cadaver renal transplants. Prospective randomised double‐blind trial. Lancet1977;2(8040):671‐4. [MEDLINE: 71492] ">Thomas 1977</a> comparing low potency ALG with high potency ALG found increased acute rejection at three months (RR 4.14, 95% CI 1.55 to 11.00) and increased graft loss at 1 year (RR 2.53, 95% CI 1.30 to 4.90) with the low potency ALG. </p> <section id="CD004759-sec-0060"> <h6 class="title">Table summarising single studies of different dose comparisons</h6> <p> <div class="table" id="CD004759-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison / Study ID (number of participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> 95% CI </b> </p> <p><b> lower limit</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> 95% CI </b> </p> <p><b> upper limit</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>rATG: single 6 mg/kg versus 4 x 1.5 mg/kg doses (same total dose)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><a href="./references#CD004759-bbs2-0085" title="StevensR , FosterK , MilesC , RigleyT , KalilA , WrenshallL . A randomized 2X2 factorial trial: Part 1, single‐dose rATG induction improves long‐term renal transplant outcomes [abstract]. Transplantation2014;98(Suppl 1):91. [EMBASE: 71543822] StevensR , FosterK , MilesC , RigleyT , WrenshallL . A randomized trial of renal transplantation: Steroid and calcineurin‐inhibitor withdrawal after rabbit anti‐thymocyte globulin induction [abstract]. Transplantation2014;98(Suppl 1):476. [EMBASE: 71545124] StevensRB . Modern approaches to combining sirolimus with calcineurin inhibitors. Transplantation Proceedings2008;40(10 Suppl):S21‐4. [MEDLINE: 19100901] StevensRB , FosterKW , MilesCD , KalilAC , FlorescuDF , SandozJP , et al. A randomized 2x2 factorial clinical trial of renal transplantation: steroid‐free maintenance immunosuppression with calcineurin inhibitor withdrawal after six months associates with improved renal function and reduced chronic histopathology. PLoS ONE [Electronic Resource]2015;10(10):e0139247. [MEDLINE: 26465152] StevensRB , FosterKW , MilesCD , LaneJT , KalilAC , FlorescuDF , et al. A randomized 2x2 factorial trial, part 1: single‐dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes. Transplantation2015;99(1):197‐209. [MEDLINE: 25083614] StevensRB , KalilAC , MilesCD , FlorescuDF , LaneJT , SkorupaAJ , et al. Reduced patient mortality and infectious complications, and superior graft function, in renal transplant patients after single‐dose RATG induction; 5‐year data from a prospective, randomized trial [abstract no: 38]. American Journal of Transplantation2010;10(Suppl 4):49‐50. [EMBASE: 70463399] StevensRB , LaneJT , BoernerBP , MilesCD , RigleyTH , SandozJP , et al. Single‐dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clinical Transplantation2012;26(1):123‐32. [MEDLINE: 21401720] StevensRB , LaneJT , BoernerBP , MilesCD , RigleyTH , SandozJP , et al. Single‐dose rabbit anti‐thymocyte globulin (rATG) induction reduces tubular injury after renal transplantation, resulting in superior renal function, serum Mg++ retention, and glucose regulation [abstract no: 1703]. American Journal of Transplantation2010;10(Suppl 4):522. [EMBASE: 70465078] StevensRB , MercerD , RigleyT , NielsenK , HenningM , SkorupaA , et al. Single‐dose induction with rabbit anti‐thymocyte globulin (rATG) safely improves renal allograft function and reduces chronic allograft nephropathy [abstract no: 538]. American Journal of Transplantation2008;8(Suppl 2):322. [CENTRAL: CN‐00653788] StevensRB , MercerDF , GrantWJ , FreifeldAG , LaneJT , GroggelGC , et al. Randomized trial of single‐dose versus divided‐dose rabbit anti‐thymocyte globulin induction in renal transplantation: an interim report. Transplantation2008;85(10):1391‐9. [MEDLINE: 18497677] StevensRB , RigleyT , SkorupaJ , NielsenK , WrenshallL . Successful calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients: reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 2123]. Transplantation2008;86(2S):695. StevensRB , RigleyTH , NielsenKJ , SkorupaA , SandozJ , KelloggA , et al. Single‐dose induction with rabbit anti‐thymocyte globulin (rATG; 6 mg/kg over 24 hours) is safer and improves immediate and long‐term renal allograft function [abstract no: 616]. American Journal of Transplantation2009;9(Suppl 2):369. StevensRB , RigleyTH , NielsenKJ , SkorupaJY , SkorupaA , SandozJ , et al. Calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients without increase rejection or graft loss [abstract no: 1100]. American Journal of Transplantation2009;9(Suppl 2):501. StevensRB , SkorupaJY , RigleyTH , SandozJP , KelloggA , MillerN , et al. Calcineurin‐inhibitor withdrawal vs minimization after kidney transplantation is safe but does not improve renal function; 5‐year results of a prospective, randomized trial [abstract no: 1643]. American Journal of Transplantation2010;10(Suppl 4):505. StevensRB , WrenshallL , MercerD , RigleyT , NielsenK , HenningM , et al. Successful calcineurin‐inhibitor (CI) discontinuation following early steroid withdrawal (ESW) in renal allograft recipients; reduced chronic allograft nephropathy (CAN) and improved renal function without increased rejection or graft loss [abstract no: 289]. American Journal of Transplantation2008;8(Suppl 2):255. [CENTRAL: CN‐00653790] ">Stevens 2008</a> (142) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 6 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss (all cause) at 6 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.40</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malignancy/PTLD</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BKV</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe febrile reaction (anaphylaxis requiring ICU)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum sickness</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NODAT</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ATG: 2 x3 mg/kg versus 4 x 1.5 mg/kg doses (same total)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004759-bbs2-0014" title="BuchlerM , LonguetH , LemoineR , HerrF , GataultP , ThibaultG , et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transplant Immunology2013;28(2‐3):120‐6. [MEDLINE: 23507258] LonguetH , BuchlerM , LemoineR , HerrF , GataultP , ThibaultG , et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte antiglobulin dosing regimens [abstract no: O069]. Transplant International2013;26(Suppl 2):44‐5. [EMBASE: 71359107] ">Buchler 2013</a> (17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>**</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> ATG: adjusted for CD3 count versus fixed dose of 15 mg/kg/d</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p><a href="./references#CD004759-bbs2-0001" title="AbounaGM , KumarMS , al‐AbdullahIH , LooseJ , SullivanDK , PhillipsK , et al. Induction immunosuppression with antithymocyte globulin in renal transplantation using a variable dose according to the absolute number of CD3+ T cells. Transplantation Proceedings1995;27(5):2676‐8. [MEDLINE: 7482872] AbounaGM , al‐AbdullahIH , Kelly‐SullivanD , KumarMS , LooseJ , PhillipsK , et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation1995;59(11):1564‐8. [MEDLINE: 7778170] ">Abouna 1995</a> (45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 2 years</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss (all cause) 2 years</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.85</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.84</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leucopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.36</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral infection (all cause)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bacterial infection (all cause)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> ATG: adjusted by CD3 count versus adjusted by total lymphocytes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004759-bbs2-0005" title="AtaP , KaraM , OzdemirE , CanbakanM , GokceAM , BayraktarFA , et al. Monitoring of CD3(+) T‐cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation. Transplantation Proceedings2013;45(3):929‐31. [MEDLINE: 23622590] ">Ata 2013</a> (21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>**</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ATG: standard (3.75 mg/kg total) versus low dose (2.25 mg/kg total)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p><a href="./references#CD004759-bbs2-0035" title="GrafalsM , SimpsonM , GilliganH , PomposelliJ , AkoadM , KwajaK , et al. Prospective randomized study of low dose antithymocyte globulin as induction in non sensitized adult renal transplant recipients [abstract no: C1351]. American Journal of Transplantation2013;13(Suppl 5):430. [EMBASE: 71057927] GrafalsM , SmithB , MurakamiN , TrabuccoA , HamillK , MarangosE , et al. Immunophenotyping and efficacy of low dose ATG in non‐sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS ONE [Electronic Resource]2014;9(8):e104408. [MEDLINE: 25111080] SmithB , GrafalsM , MurakamiN , TrabuccoA , HamillK , MarangosE , et al. Immune phenotyping and efficacy of low dose ATG in non‐sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study [abstract]. Transplantation2014;98(Suppl 1):580. [EMBASE: 71545491] ">Grafals 2014</a> (43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.12</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.81</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leucopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.77</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BKV infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.00</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.44</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.07</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malignancy at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.30</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PTLD at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 events</p> </td> <td align="right" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft function at 1 year (SCr, µmol/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.00*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> OKT3: standard dose (5 mg) versus low dose (2 mg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><a href="./references#CD004759-bbs2-0067" title="NormanDJ , KimballJA , BarryJM . Cytokine‐release syndrome: differences between high and low doses of OKT3. Transplantation Proceedings1993;25(2 Suppl 1):35‐8. [MEDLINE: 8465420] NormanDJ , KimballJA , BennettWM , ShihabF , BatiukTD , MeyerMM , et al. A prospective, double‐blind, randomized study of high‐versus low‐dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transplant International1994;7(5):356‐61. [MEDLINE: 7993573] ">Norman 1993a</a> (26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 events</p> </td> <td align="right" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.51</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Herpes Simplex virus</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bacterial</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fungal</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malignancy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> OKT3: standard dose (5 mg) versus high dose (10 mg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD004759-bbs2-0003" title="AbramowiczD , GoldmanM , MatO , EstermansG , CrusiauxA , VanherweghemJL , et al. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transplant International1994;7(4):258‐63. [MEDLINE: 7916925] ">Abramowicz 1994</a> (29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 3 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 events</p> </td> <td align="right" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss at 3 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection to 3 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.47</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ALG: low versus high dose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD004759-bbs2-0074" title="SakhraniL , AswadS , ObispoE , MendezRG , KhetanU , AsaiP , et al. Optimal dose of Minnesota antilymphocyte globulin for induction immunosuppression in cadaveric renal transplants. Transplantation Proceedings1992;24(5):1730‐1. [MEDLINE: 1412814] ">Sakhrani 1992</a> (83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.86</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leucopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> ALG: 14 days versus 7 days</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD004759-bbs2-0039" title="GrundmannR , HesseU , WienandP , BaldamusC , ArnsW . Graft survival and long‐term renal function after sequential conventional cyclosporin A therapy in cadaver kidney transplantation‐‐a prospective randomized trial. Klinische Wochenschrift1987;65(18):879‐84. [MEDLINE: 3312789] GrundmannR , WienandP , HesseU . Sequential conventional and cyclosporine therapy in cadaver renal transplantation‐‐a prospective randomized trial. Transplantation Proceedings1987;19(5):4033‐4. [MEDLINE: 3313993] ">Grundmann 1987</a> (100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 events</p> </td> <td align="right" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss (all cause) 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pneumonia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wound infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 events</p> </td> <td align="right" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment stopped due to side effects</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.96</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1002.01</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft function at 1 year (SCr, µmol/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐35.4*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐78.72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ALG: high versus low potency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD004759-bbs2-0088" title="ThomasF , Mendez‐PiconG , ThomasJ , PeaceK , FloraR , LeeHM . Effect of antilyphocyte‐globulin potency on survival of cadaver renal transplants. Prospective randomised double‐blind trial. Lancet1977;2(8040):671‐4. [MEDLINE: 71492] ">Thomas 1977</a> (71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection at 3 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.14</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.55</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>11.00</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.53</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.30</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.90</b> </p> </td> </tr> </tbody> </table> </div> </p> <p><sup>* MD and SD for continuous variables (not RR and 95% CI).</sup> </p> <p><sup>** Results not converted to RR for extremely small studies with 10 or fewer participants in each group.</sup> </p> <p><sup>Significant results shown in <b>bold.</b> </sup> </p> </section> </section> <section id="CD004759-sec-0061"> <h5 class="title">Other antibody preparations</h5> <p>Anti‐CD2 rat monoclonal antibody was compared with no induction treatment in <a href="./references#CD004759-bbs2-0083" title="SquiffletJP , BesseT , MalaiseJ , MouradM , DelcordeC , HopeJA , et al. BTI‐322 for induction therapy after renal transplantation: a randomized study. Transplantation Proceedings1997;29(1‐2):317‐9. [MEDLINE: 9123018] SquiffletJP , BesseT , MouradM , MalaiseJ , DelcordeC , PirsonY , et al. A randomized study of BTI‐322 for the prevention of renal allograft rejection: one year follow up [abstract]. 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10‐14; Chicago (ILL). 1997:258. [CENTRAL: CN‐00509490] ">Squifflet 1997</a>. This small study (40 participants) showed acute rejection was decreased by anti‐CD2 (RR 0.42, 95% CI 0.18 to 0.96) but no difference in any other outcomes. Another small study compared anti CD7 with OKT3 (<a href="./references#CD004759-bbs2-0055" title="LazarovitsAI , RochonJ , BanksL , HollombyDJ , MuirheadN , JevnikarAM , et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. Journal of Immunology1993;150(11):5163‐74. [MEDLINE: 7684422] LazarovitsAI , RochonJ , BanksL , HollombyDJ , MuirheadN , JevnikarAM , et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. Transplantation Proceedings1993;25(1 Pt 1):820‐2. [MEDLINE: 7679844] SharmaL , MuirheadN , LazarovitsAI . Human mouse chimeric Cd7 monoclonal antibody (SCZCHH380) for the prophylaxis of kidney transplant rejection: no transplant losses and absence of chronic rejection at 4 years [abstract]. 15th Annual Meeting American Society of Transplant Physicians (ASTP); 1996 May 10‐14; Chicago Ill. 1996. ">Lazarovits 1993</a>) and there were no differences. Two studies assessed anti‐LFA‐1 monoclonal antibody: one in comparison with no induction agent (<a href="./references#CD004759-bbs2-0082" title="SpillnerJ , KohnleM , AlbrechtKH , HeemannU . Anti‐LFA‐1 monoclonal antibody in renal transplantation: renal function, infections, and other complications. Transplantation Proceedings1998;30(5):2163. [MEDLINE: 9723427] ">Spillner 1998</a>) and the other in comparison with ATG (<a href="./references#CD004759-bbs2-0046" title="HourmantM . Multicenter comparative study of an anti‐lfa1 adhesion molecule monoclonal antibody and thymoglobulin in prophylaxis of acute rejection in kidney transplantation. [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:336. [CENTRAL: CN‐00509239] HourmantM , BedrossianJ , DurandD , KesslerM , LeBranchuY , CaudrelierP , et al. Multicenter comparative study of an anti‐LFA‐1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Transplantation Proceedings1995;27(1):864. [MEDLINE: 7879209] HourmantM , BedrossianJ , DurandD , KesslerM , LebranchuY , CaudrelierP , et al. Multicenter study of an anti‐LFA1 adhesion molecule monoclonal antibody (Moab) and anti‐thymocyte globulin (ATG) in prophylaxis of acute rejection (AR) in kidney transplantation (KT) [abstract]. 14th Annual Meeting. American Society of Transplant Physicians (ASTP); 1995 May 14‐17; Chicago (ILL). 1995. HourmantM , BedrossianJ , DurandD , LebranchuY , RenoultE , CaudrelierP , et al. A randomized multicenter trial comparing leukocyte function‐associated antigen‐1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation1996;62(11):1565‐70. [MEDLINE: 8970608] ">Hourmant 1996</a>). Other than decreased fever with anti‐LFA‐1 compared to ATG, differences were not significant in either of these studies. One small pilot study (<a href="./references#CD004759-bbs2-0028" title="EjazN , ShieldsA , AllowayR , SadakaB , GirnitaA , MogilishettyG , et al. A prospective, randomized pilot study of B‐cell targeted induction therapy in sensitized kidney transplant recipients: final report [abstract no: 175]. American Journal of Transplantation2013;13(Suppl S5):84. [EMBASE: 71056751] EjazNS , ShieldsAR , AllowayRR , SadakaB , GirnitaAL , MogilishettyG , et al. Randomized controlled pilot study of B cell‐targeted induction therapy in HLA sensitized kidney transplant recipients. American Journal of Transplantation2013;13(12):3142‐54. [MEDLINE: 24266968] SchmidtN , ShieldsAR , AllowayRR , SadakaB , MogilishettyG , KremerJ , et al. Randomized controlled trial of B‐cell targeted induction therapy in HLA sensitized kidney transplant recipients: preliminary results [abstract no: 100]. American Journal of Transplantation2012;12(Suppl S3):56. [EMBASE: 70746047] ">Ejaz 2013</a>) comparing four different interventions (ATG versus ATG + rituximab versus ATG + bortezomib versus ATG + rituximab + bortezomib) did not show any significant differences in outcomes other than an increase in new‐onset peripheral neuropathy in the bortezomib groups. There were only 10 participants in each group and follow‐up only reported to one year at the time of this review. One final study compared anti‐ICAM‐1 monoclonal antibody with placebo (<a href="./references#CD004759-bbs2-0027" title="SalmelaK , WramnerL , EkbergH , HauserI , BentdalO , LinsLE , et al. A randomized multicenter trial of the anti‐ICAM‐1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti‐ICAM‐1 Renal Transplant Study Group. Transplantation1999;67(5):729‐36. [MEDLINE: 10096530] ">EARTS Study 1999</a>) but again there were no differences in outcomes. </p> <p><a href="./references#CD004759-bbs2-0068" title="NorrbyJ , OlaussonM . A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplantation Proceedings1997;29(7):3135‐6. [MEDLINE: 9365697] ">Norrby 1997</a> compared two rabbit ATG preparations made by different manufacturers. There was no difference for the only reported outcomes of acute rejection and CMV infection. One small (51 participants) study by <a href="./references#CD004759-bbs2-0084" title="SteinmullerDR , HayesJ , NovickAC , StreemSB , HodgeE , SlavisS , et al. Comparison of OKT3 to ALG for prophylaxis for patients with acute renal failure after cadaver renal transplantation [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:512A. [CENTRAL: CN‐00716029] SteinmullerDR , HayesJM , NovickAC , StreemSB , HodgeE , SlavisS , et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation1991;52(1):67‐71. [MEDLINE: 1677502] ">Steinmuller 1991</a> compared OKT3 with ALG but antibody therapy was only given for patients with delayed graft function. For this reason it was considered separately from the other studies comparing OKT3 and ALG. Side effects were reduced with ALG compared to OKT3 (RR 0.41, 95% CI 0.24 to 0.72) but there were no other significant differences in outcomes. Finally <a href="./references#CD004759-bbs2-0090" title="Toledo‐PereyraLH , BergrenC , MittalVK , WhittenJI , BaskinS , McNicholL . A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaver kidney transplantation. Transplantation1985;40(4):448‐50. [MEDLINE: 3901446] Toledo‐PereyraLH , BergrenC , WhittenJ . Comparison of ALG and ATG for renal transplantation [abstract]. Kidney International1985;28(2):388. [CENTRAL: CN‐00583280] ">Toledo‐Pereyra 1985</a> compared ATG with ALG also showed no significant differences in outcomes. </p> <section id="CD004759-sec-0062"> <h6 class="title">Table summarising single studies of other antibody preparations</h6> <p> <div class="table" id="CD004759-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Comparison / Study ID (number of participants)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> RR </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> 95% CI</b> </p> <p><b> lower limit</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> 95% CI</b> </p> <p><b> upper limit</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> Rabbit ATG Fresenius versus rabbit ATG Merieux</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD004759-bbs2-0068" title="NorrbyJ , OlaussonM . A randomized clinical trial using ATG Fresenius or ATG Merieux as induction therapy in kidney transplantation. Transplantation Proceedings1997;29(7):3135‐6. [MEDLINE: 9365697] ">Norrby 1997</a> (90) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.87</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.56</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.29</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> ALG versus ATG</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD004759-bbs2-0090" title="Toledo‐PereyraLH , BergrenC , MittalVK , WhittenJI , BaskinS , McNicholL . A prospective randomized comparison of antilymphoblast globulin versus antithymocyte globulin for cadaver kidney transplantation. Transplantation1985;40(4):448‐50. [MEDLINE: 3901446] Toledo‐PereyraLH , BergrenC , WhittenJ . Comparison of ALG and ATG for renal transplantation [abstract]. Kidney International1985;28(2):388. [CENTRAL: CN‐00583280] ">Toledo‐Pereyra 1985</a> (50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.10</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.92</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.95</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.73</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leucopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HSV infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.19</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.67</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> ALG vs OKT3 (given only if delayed graft functionpost‐operatively)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD004759-bbs2-0084" title="SteinmullerDR , HayesJ , NovickAC , StreemSB , HodgeE , SlavisS , et al. Comparison of OKT3 to ALG for prophylaxis for patients with acute renal failure after cadaver renal transplantation [abstract]. 11th International Congress of Nephrology; 1990 Jul 15‐20; Tokyo, Japan. 1990:512A. [CENTRAL: CN‐00716029] SteinmullerDR , HayesJM , NovickAC , StreemSB , HodgeE , SlavisS , et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation1991;52(1):67‐71. [MEDLINE: 1677502] ">Steinmuller 1991</a> (51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 6 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.48</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.98</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss (all cause) at 6 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.61</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects (any reported)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.41</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.24</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.72</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> Anti‐CD7 versus OKT3</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><a href="./references#CD004759-bbs2-0055" title="LazarovitsAI , RochonJ , BanksL , HollombyDJ , MuirheadN , JevnikarAM , et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. Journal of Immunology1993;150(11):5163‐74. [MEDLINE: 7684422] LazarovitsAI , RochonJ , BanksL , HollombyDJ , MuirheadN , JevnikarAM , et al. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. Transplantation Proceedings1993;25(1 Pt 1):820‐2. [MEDLINE: 7679844] SharmaL , MuirheadN , LazarovitsAI . Human mouse chimeric Cd7 monoclonal antibody (SCZCHH380) for the prophylaxis of kidney transplant rejection: no transplant losses and absence of chronic rejection at 4 years [abstract]. 15th Annual Meeting American Society of Transplant Physicians (ASTP); 1996 May 10‐14; Chicago Ill. 1996. ">Lazarovits 1993</a> (20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death 5 years</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss 5 years</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> Anti‐CD2 rat monoclonal antibody versus no induction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign=""> <p><a href="./references#CD004759-bbs2-0083" title="SquiffletJP , BesseT , MalaiseJ , MouradM , DelcordeC , HopeJA , et al. BTI‐322 for induction therapy after renal transplantation: a randomized study. Transplantation Proceedings1997;29(1‐2):317‐9. [MEDLINE: 9123018] SquiffletJP , BesseT , MouradM , MalaiseJ , DelcordeC , PirsonY , et al. A randomized study of BTI‐322 for the prevention of renal allograft rejection: one year follow up [abstract]. 16th Annual Meeting. American Society of Transplant Physicians (ASTP); 1997 May 10‐14; Chicago (ILL). 1997:258. [CENTRAL: CN‐00509490] ">Squifflet 1997</a> (40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 6 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss (death censored) at 6 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 events</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.42</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.18</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.96</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bacterial infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EB virus</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Herpes Simplex virus</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.49</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other viral infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.33</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.01</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malignancy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft function at 6 months (SCr, µmol/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐20.99</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> Anti‐LFA‐1 monoclonal antibody versus no induction<sup>1</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><a href="./references#CD004759-bbs2-0082" title="SpillnerJ , KohnleM , AlbrechtKH , HeemannU . Anti‐LFA‐1 monoclonal antibody in renal transplantation: renal function, infections, and other complications. Transplantation Proceedings1998;30(5):2163. [MEDLINE: 9723427] ">Spillner 1998</a> (22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss (all cause) at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.31</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft function at 1 year (SCr, µmol/L)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐17.6*</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐62.69</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> Anti‐LFA‐1 monoclonal antibody versus ATG</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign=""> <p><a href="./references#CD004759-bbs2-0046" title="HourmantM . Multicenter comparative study of an anti‐lfa1 adhesion molecule monoclonal antibody and thymoglobulin in prophylaxis of acute rejection in kidney transplantation. [abstract]. ISN XIII International Congress of Nephrology; 1995 Jul 2‐6; Madrid, Spain. 1995:336. [CENTRAL: CN‐00509239] HourmantM , BedrossianJ , DurandD , KesslerM , LeBranchuY , CaudrelierP , et al. Multicenter comparative study of an anti‐LFA‐1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation. Transplantation Proceedings1995;27(1):864. [MEDLINE: 7879209] HourmantM , BedrossianJ , DurandD , KesslerM , LebranchuY , CaudrelierP , et al. Multicenter study of an anti‐LFA1 adhesion molecule monoclonal antibody (Moab) and anti‐thymocyte globulin (ATG) in prophylaxis of acute rejection (AR) in kidney transplantation (KT) [abstract]. 14th Annual Meeting. American Society of Transplant Physicians (ASTP); 1995 May 14‐17; Chicago (ILL). 1995. HourmantM , BedrossianJ , DurandD , LebranchuY , RenoultE , CaudrelierP , et al. A randomized multicenter trial comparing leukocyte function‐associated antigen‐1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation1996;62(11):1565‐70. [MEDLINE: 8970608] ">Hourmant 1996</a> (101) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.72</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss (death censored) at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.08</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.62</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.09</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any episode of infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.74</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CMV disease</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.94</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment stopped due to side effects</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leucopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.57</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever (1st 10 days)</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.58</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.36</b> </p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.94</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> Anti‐ICAM‐1 monoclonal antibody versus placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign=""> <p><a href="./references#CD004759-bbs2-0027" title="SalmelaK , WramnerL , EkbergH , HauserI , BentdalO , LinsLE , et al. A randomized multicenter trial of the anti‐ICAM‐1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation: a report of the European Anti‐ICAM‐1 Renal Transplant Study Group. Transplantation1999;67(5):729‐36. [MEDLINE: 10096530] ">EARTS Study 1999</a> (266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Graft loss at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.76</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection at 3 months</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.18</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute rejection at 1 year</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Primary non function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed graft function</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any infection</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sepsis</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.59</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malignancy</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05</p> </td> <td align="right" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b> ATG versus ATG + rituximab vs ATG + bortezomib versus ATG + rituximab + bortezomib</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD004759-bbs2-0028" title="EjazN , ShieldsA , AllowayR , SadakaB , GirnitaA , MogilishettyG , et al. A prospective, randomized pilot study of B‐cell targeted induction therapy in sensitized kidney transplant recipients: final report [abstract no: 175]. American Journal of Transplantation2013;13(Suppl S5):84. [EMBASE: 71056751] EjazNS , ShieldsAR , AllowayRR , SadakaB , GirnitaAL , MogilishettyG , et al. Randomized controlled pilot study of B cell‐targeted induction therapy in HLA sensitized kidney transplant recipients. American Journal of Transplantation2013;13(12):3142‐54. [MEDLINE: 24266968] SchmidtN , ShieldsAR , AllowayRR , SadakaB , MogilishettyG , KremerJ , et al. Randomized controlled trial of B‐cell targeted induction therapy in HLA sensitized kidney transplant recipients: preliminary results [abstract no: 100]. American Journal of Transplantation2012;12(Suppl S3):56. [EMBASE: 70746047] ">Ejaz 2013</a> (40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>**</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> </div> </p> <p><sup>* MD and SD for continuous variables (not RR and 95% CI).</sup> </p> <p><sup>** Results not converted to RR for extremely small studies with 10 or fewer participants in each group</sup> </p> <p><sup>Significant results shown in <b>bold.</b> </sup> </p> <p><sup>1. Acute rejection was reported for anti‐LFA 1 versus no induction but was reported as total number of episodes rather than total number of patients with any episode (results were 5 episodes with anti‐LFA 1 versus 12 episodes with no induction)</sup> </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004759-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004759-sec-0063"></div> <section id="CD004759-sec-0064"> <h3 class="title" id="CD004759-sec-0064">Summary of main results</h3> <p>Many antibody preparations are now available for induction immunosuppression in kidney transplantation and we sought to summarise the evidence in this review to help inform clinical decision making and policy. Our inclusion criteria were deliberately broad resulting in 28 different pairwise comparisons and studies spanning over many decades. This review provides the best summary available of all RCTs (excluding IL2Ra) and highlights several issues. </p> <p>Firstly, the evidence basis for decision making is poorly informed by studies in this area. The effects of polyclonal antibody induction remain uncertain for many important outcomes including graft loss and death. Many relevant, well recognised potential harms are not reported frequently in RCTs and more well designed studies reporting patient‐centred outcomes (benefits and harms) are required. Some effects of antibody induction could be quantified. </p> <p>ATG reduced acute rejection rates by roughly one third when compared to placebo or no treatment, at the cost of approximately 50% increase in the risk of CMV complications and an uncertain impact on future malignancy risk. rATG reduces acute rejection compared to hATG but data supporting this is weak as all events were only reported in a single study. The only significant difference seen in comparisons between alemtuzumab and ATG in steroid avoidance studies was that alemtuzumab reduces rejection at one year; in comparison alemtuzumab increased CMV infection but had similar rejection rates when compared to no induction and triple maintenance. NODAT was not reduced with alemtuzumab plus ESW compared to triple maintenance. OKT3 decreases acute rejection compared to placebo or no treatment but has been withdrawn from clinical use due to a poor side effect profile. ALG prevented acute rejection and led to better kidney function at one year post‐transplant compared with placebo or no treatment but increased the rates of all viral infections. </p> <p>See <a href="./full#CD004759-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD004759-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD004759-sec-0065"> <h3 class="title" id="CD004759-sec-0065">Overall completeness and applicability of evidence</h3> <p>A decision was made to include any co‐intervention immunosuppression regimens to ensure all relevant studies were included. As a result, a large number of studies from the pre‐CNI era were included which may not be relevant to clinical practice today. Where possible, results were separated into CNI or non‐CNI maintenance as combining these groups was not felt to be clinically useful. As a result, there were multiple subgroups for outcomes of death and graft loss for most comparisons as studies frequently reported these outcomes at a variety of time points. There were no benefits seen for improved patient or graft survival with ATG despite decreased rejection rates when CNI and non‐CNI studies were separated. This lack of benefit may be due to small numbers of studies in each subgroup. When CNI and non‐CNI studies were combined, a reduction in both all‐cause graft loss and death‐censored graft loss was seen at one to two years post‐transplant. This benefit was not sustained however in the studies that assessed longer term graft survival at five years. Results for acute rejection were generally more robust as this was reported in nearly all studies and time points were more standardised resulting in larger subgroups and greater statistical power. New studies are required to see if the absence of benefit is due to a lack of power or whether there really is no effect of one antibody compared to another antibody or placebo on patient and graft survival. </p> <p>The main aim of using alemtuzumab has been to try to reduce the doses of maintenance immunosuppression required to prevent rejection, especially steroids. It is hoped that this will reduce some of the long term side effects of steroids, including NODAT. However, NODAT was not reduced with alemtuzumab plus ESW compared to ATG and triple maintenance or with alemtuzumab plus ESW compared to triple maintenance alone. This may be partly due to small numbers in these studies or may be due to the role of CNI, especially tacrolimus also causing increased rates of NODAT. Other steroid side effects have generally not been well reported in these studies. In the absence of any data to confirm a reduction in side effects, it is difficult to support the use of alemtuzumab and ESW currently compared to another antibody with triple maintenance. </p> <p>The applicability of the results of this meta‐analysis to the general transplant population may be limited by the individual studies. The majority of studies included patient groups with mixed immunological risk and a small number studied higher risk groups. Benefits and harms of individual treatments generally seemed homogenous across studies despite these apparent differences in risk. Harms are frequently under‐reported in clinical studies compared to benefits and this review may therefore underestimate some of the potential harms of treatments due to possible under‐reporting in the individual studies. </p> </section> <section id="CD004759-sec-0066"> <h3 class="title" id="CD004759-sec-0066">Quality of the evidence</h3> <p>Overall, the quality of the evidence was generally low to only moderately good by GRADE criteria. <a href="#CD004759-fig-0002">Figure 2</a> shows the individual biases for each study. The most common problem was potential selection bias due to unclear methods of both randomisation and allocation concealment. Only 20% to 27% of included studies were low risk of bias for either random sequence generation or allocation concealment (see <a href="#CD004759-fig-0003">Figure 3</a>). </p> <p>For the main comparison of ATG versus placebo, quality of evidence according to GRADE criteria was moderate for outcomes of acute rejection and CMV infection but low for all other outcomes. The evidence for acute rejection and CMV was graded as moderate rather than high as more than 50% of studies rated methods of allocation concealment and/or random sequence generation as ‘unclear’ or ‘high risk’ as a potential source of bias. For the comparison of alemtuzumab plus ESW versus ATG with and without ESW, the evidence for acute rejection was rated as moderate quality but evidence for all other outcomes was either low or very low quality by GRADE criteria. Again the main reason for acute rejection evidence being graded as moderate rather than high was a significant risk of selection bias due to poor reporting of randomisation and allocation concealment. </p> </section> <section id="CD004759-sec-0067"> <h3 class="title" id="CD004759-sec-0067">Potential biases in the review process</h3> <p>The review was conducted with standard Cochrane methodology and there were no changes from the original protocol. </p> </section> <section id="CD004759-sec-0068"> <h3 class="title" id="CD004759-sec-0068">Agreements and disagreements with other studies or reviews</h3> <p>One study of registry data of transplant recipients in the US also failed to show any improvement in all‐cause graft survival despite decreasing rates of acute rejection (<a href="./references#CD004759-bbs2-0123" title="Meier‐KriescheHU , ScholdJD , SrinivasTR , KaplanB . Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American Journal of Transplantation2004;4(3):378‐83. [MEDLINE: 14961990] ">Meier‐Kriesche 2004</a>). More alarmingly, this study showed a trend towards worsening death censored graft survival, despite more potent maintenance immunosuppression. However, given these trends are taken from registry data, it is hard to interpret what this really means, especially with older and more co‐morbid patients being transplanted in recent years. </p> <p>Many antibody therapies have now shown a reduction in acute rejection but it remains uncertain as to whether this translates into increased patient or graft survival for any of the antibodies in this review. In comparison, there was a reduction in graft loss at one year (but not after) for IL2Ra compared to placebo (24 studies, 4672 participants: RR 0.75, 95% CI 0.62 to 0.90) in a systematic review by <a href="./references#CD004759-bbs2-0133" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a>. However, there was no difference for graft loss when IL2Ra and ATG were compared in the same review and clinically diagnosed acute rejection rates were also similar for IL2Ra and ATG. However, ATG increased early malignancy at one year compared to IL2Ra (7 studies, 1067 participants: RR 0.25, 95% CI 0.07 to 0.87) but had no effect on malignancy at other time points (<a href="./references#CD004759-bbs2-0133" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a>). It is possible that malignancy is influenced more by maintenance immunosuppression than induction agents given it is a relatively late complication after transplantation. However, under‐reporting of late harms is common in RCTs and malignancy rates may therefore be grossly underestimated in existing studies of induction agents leading to insufficient power to determine true cancer risk. </p> <p>In steroid avoidance studies, alemtuzumab reduced acute rejection compared to ATG when ESW was used in both arms. These results would support using alemtuzumab over ATG in patients deemed to be at particularly high risk of steroid side effects and where maintenance with ESW is planned. Further studies of alemtuzumab and ESW compared to no induction and triple maintenance showed similar rates of acute rejection but an increased risk of CMV infection with alemtuzumab. There was no other difference in harms but this may need larger studies to show potential benefits of alemtuzumab relating to steroid avoidance. Reduction of maintenance immunosuppression certainly has theoretical benefits, including reduction in antihypertensives, antihyperlipidaemics, cholesterol, cataracts and NODAT requiring treatment as well as possible reduction of late complications such as malignancy. However, none of the studies to date have been long enough duration or large enough to confirm any of these suggested benefits. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004759-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of included and excluded studies." data-id="CD004759-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of included and excluded studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004759-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004759-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 1 Death." data-id="CD004759-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 1 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 2 Graft loss (all cause)." data-id="CD004759-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 2 Graft loss (all cause).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 3 Graft loss (death censored)." data-id="CD004759-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 3 Graft loss (death censored).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 4 Acute rejection." data-id="CD004759-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 4 Acute rejection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 5 Delayed graft function." data-id="CD004759-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 5 Delayed graft function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 6 Infection." data-id="CD004759-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 6 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 7 Leucopenia." data-id="CD004759-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 7 Leucopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 8 Thrombocytopenia." data-id="CD004759-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 8 Thrombocytopenia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 9 Malignancy or PTLD." data-id="CD004759-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 9 Malignancy or PTLD.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 10 Other adverse outcomes." data-id="CD004759-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 10 Other adverse outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 ATG versus placebo/no treatment, Outcome 11 Serum creatinine." data-id="CD004759-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 ATG versus placebo/no treatment, Outcome 11 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rabbit ATG versus horse ATG, Outcome 1 Main outcomes." data-id="CD004759-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Rabbit ATG versus horse ATG, Outcome 1 Main outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rabbit ATG versus horse ATG, Outcome 2 Other adverse outcomes." data-id="CD004759-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Rabbit ATG versus horse ATG, Outcome 2 Other adverse outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rabbit ATG versus horse ATG, Outcome 3 Serum creatinine." data-id="CD004759-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Rabbit ATG versus horse ATG, Outcome 3 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 1 Death and graft loss." data-id="CD004759-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 1 Death and graft loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 2 Rejection." data-id="CD004759-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 2 Rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 3 Infection." data-id="CD004759-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 3 Infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 4 Other adverse effects." data-id="CD004759-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 4 Other adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 5 Creatinine clearance." data-id="CD004759-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW, Outcome 5 Creatinine clearance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Alemtuzumab + early steroid withdrawal (ESW) versus no induction, Outcome 1 Main outcomes." data-id="CD004759-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Alemtuzumab + early steroid withdrawal (ESW) versus no induction, Outcome 1 Main outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Alemtuzumab + early steroid withdrawal (ESW) versus no induction, Outcome 2 Other adverse outcomes." data-id="CD004759-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Alemtuzumab + early steroid withdrawal (ESW) versus no induction, Outcome 2 Other adverse outcomes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Alemtuzumab + early steroid withdrawal (ESW) versus no induction, Outcome 3 Serum creatinine." data-id="CD004759-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Alemtuzumab + early steroid withdrawal (ESW) versus no induction, Outcome 3 Serum creatinine. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rituximab versus placebo, Outcome 1 Main outcomes." data-id="CD004759-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Rituximab versus placebo, Outcome 1 Main outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rituximab versus placebo, Outcome 2 Other adverse outcomes." data-id="CD004759-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Rituximab versus placebo, Outcome 2 Other adverse outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rituximab versus placebo, Outcome 3 Graft function at 6 months (eGFR)." data-id="CD004759-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Rituximab versus placebo, Outcome 3 Graft function at 6 months (eGFR).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 ATG versus OKT3, Outcome 1 Main outcomes." data-id="CD004759-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 ATG versus OKT3, Outcome 1 Main outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 ATG versus OKT3, Outcome 2 Other adverse outcomes." data-id="CD004759-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 ATG versus OKT3, Outcome 2 Other adverse outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 ATG versus OKT3, Outcome 3 Serum creatinine at 1 year." data-id="CD004759-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 ATG versus OKT3, Outcome 3 Serum creatinine at 1 year.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 OKT3 versus placebo/no induction, Outcome 1 Main outcomes." data-id="CD004759-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 OKT3 versus placebo/no induction, Outcome 1 Main outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 OKT3 versus placebo/no induction, Outcome 2 Other adverse effects." data-id="CD004759-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 OKT3 versus placebo/no induction, Outcome 2 Other adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 OKT3 versus placebo/no induction, Outcome 3 Serum creatinine." data-id="CD004759-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 OKT3 versus placebo/no induction, Outcome 3 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 ALG versus OKT3, Outcome 1 Main outcomes." data-id="CD004759-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 ALG versus OKT3, Outcome 1 Main outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 ALG versus OKT3, Outcome 2 Other adverse outcomes." data-id="CD004759-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 ALG versus OKT3, Outcome 2 Other adverse outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 ALG versus OKT3, Outcome 3 Serum creatinine." data-id="CD004759-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 ALG versus OKT3, Outcome 3 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 ALG versus placebo/no induction, Outcome 1 Main outcomes." data-id="CD004759-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 ALG versus placebo/no induction, Outcome 1 Main outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 ALG versus placebo/no induction, Outcome 2 Other adverse outcomes." data-id="CD004759-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 ALG versus placebo/no induction, Outcome 2 Other adverse outcomes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004759-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/urn:x-wiley:14651858:media:CD004759:CD004759-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_t/tCD004759-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 ALG versus placebo/no induction, Outcome 3 Serum creatinine." data-id="CD004759-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 ALG versus placebo/no induction, Outcome 3 Serum creatinine.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/media/CDSR/CD004759/image_n/nCD004759-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004759-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>ATG compared with placebo or no induction for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: kidney transplant recipients</b> </p> <p><b>Settings:</b> </p> <p><b>Intervention: ATG</b> </p> <p><b>Comparison: placebo/no treatment</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo/no treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ATG</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (including CNI)</b> </p> <p>Follow‐up: median 24 months (IQR 12‐24)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.75</b> </p> <p>(0.27 to 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>632 (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> <br/> (8 to 64) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause graft loss (including CNI)</b> </p> <p>Follow‐up: median 1 year (IQR 12‐24)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.65</b> </p> <p>(0.36 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>549 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> <br/> (39 to 129) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Delayed graft function</b> </p> <p>Follow‐up: N/A (immediate)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.93</b> (0.78 to 1.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1304 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>283 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> <br/> (221 to 311) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute rejection (including CNI)</b> </p> <p>Follow‐up: median 1 year (IQR 6‐24)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.61</b> </p> <p>(0.49 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1491 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> <br/> (179 to 277) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Infection: CMV infection</b> </p> <p>Follow‐up: median 1 year (IQR 4.5‐13.5)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.55</b> </p> <p>(1.24 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1072 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>273 per 1000</b> <br/> (218 to 343) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Malignancy</b> </p> <p>Follow‐up: median 18 months (IQR 12‐60)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b> </p> <p>(0.30 to 2.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>891 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> <br/> (5 to 44) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval: RR<b>:</b> Risk Ratio; <b>IQR:</b> interquartile range. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> At risk of selection bias as more than 50% of studies rated as allocation concealment and/or random sequence generation unclear or high risk of causing bias. </p> <p><sup>2</sup> Confidence interval includes range of plausible values below clinical significance or including harm. </p> <p><sup>3</sup>Based on few events across all studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004759-tbl-0002"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Alemtuzumab plus ESW or steroid minimisation versus ATG for induction therapy for kidney transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: kidney transplant recipients</b> </p> <p><b>Settings:</b> </p> <p><b>Intervention: alemtuzumab plus ESW or steroid minimisation</b> </p> <p><b>Comparison: ATG</b> ± <b>ESW or steroid minimisation</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>ATG</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Alemtuzumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Death (ESW both arms)</b> </p> <p>Follow‐up: median 1 year (IQR 12‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.27</b> (0.07 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>180 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>102 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> <br/> (7 to 108) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>All‐cause graft loss (ESW both arms)</b> </p> <p>Follow‐up: median 18 months (IQR 12‐30)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.60</b> </p> <p>(0.34 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> <br/> (50 to 160) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute rejection (ESW both arms)</b> </p> <p>Follow‐up: median 18 months (IQR 12‐30)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.57</b> </p> <p>(0.35 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>208 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b> <br/> (73 to 193) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Biopsy‐proven CAN (ESW with alemtuzumab only)</b> </p> <p>Follow‐up: median 30 months (IQR 24‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.45</b> </p> <p>(1.02 to 5.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>86 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>284 per 1000</b> <br/> (118 to 689) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>CMV infection (all studies)</b> </p> <p>Follow‐up: median 30 months</p> <p>(IQR 24‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.08</b> </p> <p>(0.46 to 2.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> <br/> (37 to 205) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>NODAT (ESW alemtuzumab only)</b> </p> <p>Follow‐up: median 30 months (IQR 24‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.41</b> </p> <p>(0.12 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>69 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>97 per 1000</b> <br/> (28 to 332) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Malignancy (all studies)</b> </p> <p>Follow‐up: median 36 months (IQR 12‐36)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 4.93</b> </p> <p>(0.59 to 41.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All reported events from single study (other 2 studies reported 0 events)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>54 per 1000</b> <br/> (6 to 452) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval: RR<b>:</b> Risk Ratio; <b>IQR:</b> interquartile range. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> At risk of selection bias as more than 50% of studies rated as allocation concealment and/or random sequence generation unclear or high risk of causing bias. </p> <p><sup>2</sup> Confidence interval includes range of plausible values below clinical significance or including harm. </p> <p><sup>3</sup>Based on few events across all studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/full#CD004759-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ATG versus placebo/no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 3 to 6 months (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.13, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 1 to 2 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.27, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 1 to 2 years (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.86, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 At 5 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.11, 7.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Graft loss (all cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 3 to 6 months (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>638</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.34, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 1 to 2 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 1 to 2 years (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.49, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 At 5 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.62, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 At 1 to 2 years (all studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.53, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Graft loss (death censored) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 1 to 2 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.19, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 1 to 2 years (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.38, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 at 5 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.20, 13.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 At 1 to 2 years (all studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.39, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2044</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.51, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 1 to 2 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.49, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 At 1 to 2 years (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.43, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Delayed graft function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Any infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1072</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.24, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Other viral infection (not CMV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.43, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Viral infection (all cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.56, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Bacterial infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.96, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Leucopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.86 [2.79, 5.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.41 [1.61, 3.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Malignancy or PTLD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Malignancy at 1 to 2 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.22, 3.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Malignancy at 5 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.14, 6.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Malignancy at 1 to 2 years (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 PTLD at 1 to 2 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Other adverse outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 NODAT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.56, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Serum sickness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>60.67 [3.74, 984.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.46, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 At 6 months (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>503</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.34 [‐13.44, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 At 1 year (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.56 [‐21.81, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 At 1 year: LD recipients (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.70 [‐67.32, 47.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 At 1 year: DD recipients (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.0 [‐62.70, 16.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 At 5 years (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.70 [‐68.98, 3.58]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ATG versus placebo/no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rabbit ATG versus horse ATG</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Main outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.07, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Death at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.35, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Graft loss (all cause) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.08, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Graft loss (all cause) at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.58, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Acute rejection at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Acute rejection at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.04, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.06, 4.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other adverse outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Infection (all cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 CMV disease at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Leucopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Malignancy at 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rabbit ATG versus horse ATG</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death and graft loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.06, 2.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Death at 2 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.15, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Graft loss (all cause) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.12, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Graft loss (all cause) at 2 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.47, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Graft loss (death censored) at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.08, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Graft loss (death censored) at 2 to 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [0.67, 8.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.13, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Acute rejection at 3 to 6 months (ESW both arms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.17, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Acute rejection ≥ 1 year (all studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.44, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Acute rejection ≥ 1 year (ESW both arms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.35, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Acute rejection ≥ 1 year (ESW with alemtuzumab only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.50, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 CAN (biopsy proven) (ESW with alemtuzumab only)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.02, 5.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 All cause (moderate‐severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.63, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>225</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.46, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 BK virus infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Other adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Leucopenia at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.0 [1.29, 342.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Leucopenia at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.35, 28.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 NODAT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.12, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Malignancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.93 [0.59, 41.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 PTLD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Cytokine release syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 3.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Any serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.59, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Creatinine clearance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐13.35 [‐23.91, ‐2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.86 [‐23.73, ‐2.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Alemtuzumab + early steroid withdrawal (ESW) or minimisation versus ATG ± ESW</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Alemtuzumab + early steroid withdrawal (ESW) versus no induction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Main outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 6 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.60, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Graft loss (all cause) at 6 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.47, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Acute rejection at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.48, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Acute rejection ≥ 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.42, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.26, 15.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other adverse outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.18, 4.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Infection (all cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.46, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 NODAT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.13, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.45, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Malignancy or PTLD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐28.90, 18.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.89 [‐43.29, 37.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Alemtuzumab + early steroid withdrawal (ESW) versus no induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rituximab versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Main outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.18, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Death at 3 to 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.27, 15.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Graft loss (all cause) at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.26, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Graft loss (death censored) at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.21, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Acute rejection at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.48, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.65, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other adverse outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.75, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 BK virus infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Fungal infection at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.50, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Leucopenia at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.15 [2.00, 33.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Malignancy at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.40, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Graft function at 6 months (eGFR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [‐3.34, 3.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rituximab versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">ATG versus OKT3</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Main outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 6 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>451</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.64, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Graft loss (death censored) at 6 to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.64, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Acute rejection at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.53, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.52, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other adverse outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.88, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Bacterial infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.20, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Leucopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.78, 4.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.81 [0.24, 97.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Malignancy at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Unable to complete induction due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.10, 39.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum creatinine at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">ATG versus OKT3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">OKT3 versus placebo/no induction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Main outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 1 to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.18, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Death at 3 to 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.37, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Graft loss (all cause) at 1 to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.30, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Graft loss (all cause) at 3 to 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.47, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Acute rejection, any episode (+ CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.43, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Acute rejection at 3 months (no CNI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.33, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.70, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Infection (all cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.04, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Bacterial infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.76, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Viral infection (all cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.72, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.82, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 HSV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.89, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Fungal infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.33, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Malignancy or PTLD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.52, 3.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐15.78, 13.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.22 [‐18.21, 5.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 3 to 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐21.10 [‐49.81, 7.61]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">OKT3 versus placebo/no induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">ALG versus OKT3</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Main outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 1 to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.62, 6.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Death at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.13, 8.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Graft loss (all cause) at 1 to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.57, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Graft loss (all cause) at 3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.68, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Acute rejection (any episode)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.83, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.61, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other adverse outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.82, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Viral infection (not CMV)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.34, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Serious infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.8 [0.19, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Viral infection (all cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.69, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 PCP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 PTLD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.85 [‐28.55, ‐3.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.50 [‐13.52, 38.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">ALG versus OKT3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004759-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">ALG versus placebo/no induction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Main outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Death at 1 to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.96, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Death at 3 to 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.67, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Death at 15 to 20 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.40, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Graft loss (all cause) at 1 to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.75, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Graft loss (all cause) at 3 to 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.47, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Graft loss (all cause) at 15 to 20 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.67, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Acute rejection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.53, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Delayed graft function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.31, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Other adverse outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 CMV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [1.23, 4.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Any viral infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [1.86, 3.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Bacterial infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.92, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Fungal infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.63, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Thrombocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.19 [3.10, 47.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Leucopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.31 [0.61, 676.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Malignancy or PTLD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.27, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 NODAT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.22, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum creatinine <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 1 to 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.94 [‐50.86, 16.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 10 to 20 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.77 [‐41.06, 33.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">ALG versus placebo/no induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004759.pub2/references#CD004759-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004759.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004759-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004759-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD004759-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004759\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004759\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004759\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004759\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004759\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004759.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004759.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004759.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004759.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004759.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728254381"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004759.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728254385"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004759.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebff48a00f46e',t:'MTc0MDcyODI1NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 